Document:

EX-4.27

			
	Exhibit 4.27 as filed with 20-F	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as [**]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 EXHIBIT 4.27 
 CROSS-LICENSE AGREEMENT 
 By and Among 

ALNYLAM PHARMACEUTICALS, INC. 
 TEKMIRA PHARMACEUTICALS CORPORATION 
 And 

PROTIVA BIOTHERAPEUTICS INC. 
 Dated: November 12, 2012 

 TABLE OF CONTENTS 

 

							
	 ARTICLE I - DEFINITIONS
	  	 	2	  
		
	 ARTICLE II - LICENSE GRANTS AND RELATED RIGHTS
	  	 	12	  
			
	 2.1
	  	License Grants to Tekmira	  	 	12	  
			
	 2.2
	  	License Grants to Alnylam	  	 	12	  
			
	 2.3
	  	Sublicensing	  	 	13	  
			
	 2.4
	  	Coordination with Supplemental Agreement	  	 	14	  
			
	 2.5
	  	Covenants Not to Sue	  	 	15	  
			
	 2.6
	  	Retained Rights	  	 	15	  
			
	 2.7
	  	Rights in Bankruptcy	  	 	15	  
		
	 ARTICLE III - SELECTION OF ADDITIONAL TARGETS
	  	 	15	  
			
	 3.1
	  	Tekmira Additional Targets	  	 	15	  
			
	 3.2
	  	Alnylam Additional Exclusive Targets	  	 	16	  
			
	 3.3
	  	Selection Process	  	 	16	  
		
	 ARTICLE IV - FINANCIAL PROVISIONS
	  	 	17	  
			
	 4.1
	  	Manufacturing Opt-Out Payment	  	 	17	  
			
	 4.2
	  	Restructuring Payment	  	 	17	  
			
	 4.3
	  	Milestones with Respect to Tekmira Milestone Products	  	 	17	  
			
	 4.4
	  	Milestones with Respect to Biodefense Targets	  	 	18	  
			
	 4.5
	  	Milestones with Respect to Alnylam Products	  	 	19	  
			
	 4.6
	  	Milestones for Certain Alnylam Existing Exclusive Targets	  	 	20	  
			
	 4.7
	  	Royalty Term	  	 	21	  
			
	 4.8
	  	Royalties Payable by Tekmira	  	 	21	  
			
	 4.9
	  	Royalties on Alnylam Products	  	 	21	  
			
	 4.10
	  	Royalty Reduction	  	 	23	  
			
	 4.11
	  	Third Party License Payments	  	 	23	  
			
	 4.12
	  	Reports	  	 	24	  
			
	 4.13
	  	Tax Withholding	  	 	24	  
			
	 4.14
	  	Payments	  	 	24	  
			
	 4.15
	  	Audits	  	 	24	  
		
	 ARTICLE V - INTELLECTUAL PROPERTY
	  	 	25	  
			
	 5.1
	  	Category 1, 2 and 3 Patents	  	 	25	  

  
 i 

							
			
	 5.2
	  	Prosecution and Maintenance of Other Patents	  	 	25	  
			
	 5.3
	  	Third Party Infringement of Alnylam’s Patents	  	 	25	  
			
	 5.4
	  	Competitive Infringement of Category 1 Patents	  	 	26	  
			
	 5.5
	  	Third Party Infringement of Tekmira’s Patents	  	 	27	  
			
	 5.6
	  	Patent Certification	  	 	27	  
		
	 ARTICLE VI - CONFIDENTIAL INFORMATION AND PUBLICITY
	  	 	27	  
			
	 6.1
	  	Non-Disclosure of Confidential Information	  	 	27	  
			
	 6.2
	  	Limitation on Disclosures	  	 	29	  
			
	 6.3
	  	Publicity	  	 	29	  
		
	 ARTICLE VII - INDEMNIFICATION AND INSURANCE
	  	 	30	  
			
	 7.1
	  	Tekmira Indemnification	  	 	30	  
			
	 7.2
	  	Alnylam Indemnification	  	 	30	  
			
	 7.3
	  	Tender of Defense; Counsel	  	 	31	  
			
	 7.4
	  	Tekmira Insurance	  	 	31	  
			
	 7.5
	  	Alnylam Insurance	  	 	32	  
		
	 ARTICLE VIII - EXPORT
	  	 	32	  
			
	 8.1
	  	General	  	 	32	  
			
	 8.2
	  	Delays	  	 	32	  
			
	 8.3
	  	Assistance	  	 	32	  
		
	 ARTICLE IX - TERM AND TERMINATION
	  	 	33	  
			
	 9.1
	  	Term; Expiration	  	 	33	  
			
	 9.2
	  	Material Breach	  	 	33	  
			
	 9.3
	  	Challenges of Alnylam’s Patents	  	 	33	  
			
	 9.4
	  	Challenges of Tekmira Patents	  	 	34	  
			
	 9.5
	  	Consequences of Termination; Survival	  	 	34	  
			
	 9.6
	  	Licenses upon Termination	  	 	35	  
		
	 ARTICLE X - MISCELLANEOUS
	  	 	35	  
			
	 10.1
	  	Representations and Warranties	  	 	35	  
			
	 10.2
	  	Dispute Resolution; Arbitration Procedures	  	 	37	  
			
	 10.3
	  	Force Majeure	  	 	37	  
			
	 10.4
	  	Consequential Damages	  	 	37	  
			
	 10.5
	  	Assignment	  	 	38	  

  
 ii 

							
			
	 10.6
	  	Notices	  	 	38	  
			
	 10.7
	  	Independent Contractors	  	 	39	  
			
	 10.8
	  	Governing Law; Jurisdiction	  	 	39	  
			
	 10.9
	  	Severability	  	 	39	  
			
	 10.10
	  	No Implied Waivers	  	 	39	  
			
	 10.11
	  	Headings	  	 	39	  
			
	 10.12
	  	Entire Agreement	  	 	39	  
			
	 10.13
	  	Waiver of Rule of Construction	  	 	40	  
			
	 10.14
	  	No Third Party Beneficiaries	  	 	40	  
			
	 10.15
	  	Further Assurances	  	 	40	  
			
	 10.16
	  	Performance by Affiliates	  	 	40	  
			
	 10.17
	  	Counterparts	  	 	40	  
		
	 EXHIBIT A - IP MANAGEMENT TERMS
	  	 	42	  
		
	 SCHEDULE 1.9 - ALNYLAM EXISTING IN-LICENSES
	  	 	47	  
		
	 SCHEDULE 1.10 - ALNYLAM EXISTING SUBLICENSES
	  	 	48	  
		
	 SCHEDULE 1.15 - CERTAIN ALNYLAM PATENTS
	  	 	49	  
		
	 SCHEDULE 1.19 - CERTAIN BIODEFENSE TARGETS
	  	 	50	  
		
	 SCHEDULE 1.22 - CATEGORY 1 PATENTS
	  	 	51	  
		
	 SCHEDULE 1.23 - CATEGORY 2 PATENTS
	  	 	52	  
		
	 SCHEDULE 1.24 - CATEGORY 3 PATENTS
	  	 	53	  
		
	 SCHEDULE 1.70 - TEKMIRA MANUFACTURING DOCUMENTS
	  	 	54	  

  
 iii

 CROSS-LICENSE AGREEMENT 

This Cross-License Agreement (this “Agreement”) is entered into as of November 12, 2012 (the “Effective Date”),
by and among ALNYLAM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware having a principal office at 300 Third Street, Cambridge, MA 02142, U.S.A. (“Alnylam”), TEKMIRA PHARMACEUTICALS CORPORATION, a
Canadian corporation having a principal office at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Tekmira”), and, solely with respect to Section 10.12, PROTIVA BIOTHERAPEUTICS INC., a wholly-owned subsidiary of Tekmira and
a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”). 
 RECITALS 
 WHEREAS, Tekmira owns or controls certain intellectual
property covering certain nucleic acid delivery technology known as Lipid Nanoparticle or SNALP (“LNP”) technology (the “LNP/SNALP Technology”) that is useful for the delivery of a variety of therapeutic products, including those
that function through RNA interference (“RNAi”) or the modulation of microRNAs (“miRNAs”), and is also engaged in the business of discovering, developing, manufacturing and commercializing human therapeutic products; 

WHEREAS, Alnylam owns or controls certain intellectual property covering fundamental aspects of the structure and uses of
therapeutic products that function through RNAi or the modulation of miRNA and certain intellectual property covering LNP/SNALP Technology; and Alnylam is developing capabilities to develop and commercialize such therapeutic products; 

WHEREAS, Alnylam and Tekmira are parties to several existing agreements relating to RNAi, miRNA and SNALP/LNP Technology,
including an Amended and Restated License and Collaboration Agreement dated May 30, 2008 (the “Alnylam-Tekmira LCA”); an Amended and Restated Cross-License Agreement dated May 30, 2008, between Alnylam and Protiva, now a wholly
owned subsidiary of Tekmira (as amended, the “Alnylam-Protiva CLA” and collectively with the Alnylam-Tekmira LCA, the “Prior Cross-License Agreements”); a Development, Manufacturing and Supply Agreement dated January 2,
2009, as amended, and a Quality Assurance Agreement dated January 29, 2009 (collectively, the “Manufacturing Agreements”); a Supplemental Agreement dated July 27, 2009, among Tekmira, Protiva, Alnylam, AlCana Technologies, Inc.
(“AlCana”) and the University of British Columbia (“UBC”) (the “Supplemental Agreement”) and a related Sponsored Research Agreement dated July 26, 2009, among Alnylam, UBC and AlCana (the “Sponsored Research
Agreement”); and a Sublicense Agreement dated January 8, 2007, between Alnylam and Inex Pharmaceuticals Corporation (to which Tekmira is the successor in interest) (the “UBC Sublicense”); 

WHEREAS, the Parties have entered into a Settlement Agreement concurrently with the execution of this Agreement (the
“Settlement Agreement”) pursuant to which they have agreed to settle certain disputes between them; 

  
 - 1 -

 WHEREAS, in connection with the Settlement Agreement, the Parties have agreed to
replace the Prior Cross-License Agreements with this Agreement, supersede rights and obligations under the Supplemental Agreement as between themselves with the rights and obligations set forth in this Agreement, and terminate the Manufacturing
Agreements; and 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable
consideration, the receipt of which is hereby acknowledged, Alnylam and Tekmira enter into this Agreement effective as of the Effective Date: 
 ARTICLE I- DEFINITIONS 
 General. When used in this Agreement, each
of the following terms, whether used in the singular or plural, will have the meanings set forth in this Article I. 
 1.1
Act means the United States Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. §§321 et seq., as such may be amended from time to time, and its implementing regulations. 

1.2 Active Internal Development Program means, with respect to a particular siRNA Product or miRNA Product, that, as of the time
of Target selection under Section 3.3(a), there is an active program of Research, Development or Commercialization with respect to such siRNA Product or miRNA Product at such Party or any of its Affiliates. 

1.3 Affiliate means, with respect to a Person, any corporation, company, partnership, joint venture and/or firm which controls, is
controlled by, or is under common control with such Person. For purposes of the foregoing sentence, “control” means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock
or shares having the right to vote for the election of directors, or (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and
policies of such non-corporate entities. 
 1.4 Aggregate Annual Net Sales means, for each calendar year starting with
the calendar year in which the First Commercial Sale occurs for a Product, the total Net Sales of such Product during such calendar year. 
 1.5 ALN-TTR means Alnylam’s siRNA Product in an LNP Formulation that is designed to target the human TTR gene product. 
 1.6 ALN-VSP means Alnylam’s siRNA Product in an LNP Formulation that is designed to target the human VEGF and KSP gene products. 

1.7 Alnylam Exclusive Target means any of the Alnylam Existing Exclusive Targets or any of the Alnylam Additional Exclusive
Targets. 
 1.8 Alnylam Existing Exclusive Target means any of the following Targets: VSP (VEGF and KSP used in
combination), TTR and PCSK9. 

  
 - 2 -

 1.9 Alnylam Existing In-License means any of the agreements set forth on
Schedule 1.9, pursuant to which Alnylam has a license from any Third Party under any Alnylam Licensed Technology. 
 1.10
Alnylam Existing Sublicense means any of the agreements set forth on Schedule 1.10, pursuant to which Alnylam has granted a sublicense to any Third Party under any Tekmira Combined Licensed Technology and/or Category 1 Patent. 

1.11 Alnylam Field means the use of siRNA Products or miRNA Products directed to an Alnylam Target for the prevention, treatment
or palliation of human disease, and related Research, Development and Commercialization activities. 
 1.12 Alnylam
Know-How means all Know-How Controlled by Alnylam as of the Effective Date and that, prior to the Effective Date, was (a) disclosed by Alnylam to Tekmira or (b) otherwise learned by Tekmira; provided, that Alnylam
Know-How shall not include Know-How learned by Tekmira solely as a result of the litigation settled pursuant to the Settlement Agreement. 
 1.13 Alnylam Licensed Technology means, collectively, the Alnylam Patents and the Alnylam Know-How. 
 1.14 Alnylam Non-Exclusive Target means any Target that is not an Alnylam Exclusive Target or a Tekmira Exclusive Target. 
 1.15 Alnylam Patent means any Patent Controlled by Alnylam as of the Effective Date that was filed, or claims priority to a Patent that was filed, before April 15, 2010, or any foreign
counterpart of any of the foregoing Patents, and that either: 
 (a) is listed on Schedule 1.15; or 

(b) is related to general siRNA structures or modifications (excluding conjugated siRNAs); or 

(c) has claims relating to a lipid or an LNP Formulation or its manufacture; or 

(d) has claims relating to non-conjugated siRNAs directed to a Tekmira Target. 

Alnylam Patents shall not include any Patent that (i) is a UBC Patent; or (ii) is Controlled by Alnylam pursuant to an
in-license that is not an Alnylam Existing In-License. 
 Notwithstanding the foregoing, the licenses granted to Tekmira under
Section 2.1 with respect to the Patents in Section 1.15(c) above will only include Researching, Developing and Commercializing Tekmira Products in an LNP Formulation. 

1.16 Alnylam Product means an siRNA Product or miRNA Product Researched, Developed or Commercialized by Alnylam, its Affiliates or
Sublicensees that is directed to an Alnylam Target. 

  
 - 3 -

 1.17 Alnylam Sublicensable Product means an Alnylam Product that has been developed
by Alnylam or its Affiliates [**]. Any such Alnylam Product described in clause (a) may also include existing or future back up or improvement oligonucleotide products directed to the same Target as such Product in LNP Formulations or other
lipid-based formulations. 
 1.18 Alnylam Target means any of the Alnylam Exclusive Targets or Alnylam Non-Exclusive
Targets. 
 1.19 Biodefense Target means (a) a Target within the genome of one or more Category A, B and C
pathogens, as defined by the National Institute of Allergy and Infectious Diseases, including without limitation, pathogens set forth on Schedule 1.19, but specifically excluding influenza virus, or (b) an endogenous cellular Target against
which Alnylam Develops and/or Commercializes an Alnylam Product for commercial supply to one or more Funding Authorities. 

1.20 Bona Fide Collaboration means a collaboration between Alnylam and one or more Third Parties involving Research, Development,
Manufacture and/or Commercialization of one or more Alnylam Products and established under a written agreement in which (a) the scope of the licenses granted, and financial or other commitments of value, are of material value to Alnylam, and
(b) Alnylam undertakes and performs substantial, mutual research, development and/or commercialization activity with the Third Party. For purposes of clarity, it is understood and agreed that no collaboration in which all or substantially all
of Alnylam’s contributions or anticipated contributions are or will be in the form of the grant by Alnylam of licenses or sublicenses to one or more intellectual property rights will be considered a Bona Fide Collaboration. 

1.21 Business Day means a day on which banking institutions in Boston, Massachusetts and Vancouver, British Columbia, Canada, are
open for business. 
 1.22 Category 1 Patent means any Patent set forth on Schedule 1.22, any Patent Controlled by
Tekmira after the Effective Date that claims priority to any of the Patents set forth on Schedule 1.22, or any foreign counterpart of any of the foregoing Patents. 
 1.23 Category 2 Patent means any Patent set forth on Schedule 1.23, any Patent Controlled by Alnylam after the Effective Date that claims priority to any of the Patents set forth on Schedule 1.23,
or any foreign counterpart of any of the foregoing Patents. 
 1.24 Category 3 Patent means any Patent set forth on
Schedule 1.24, any Patent Controlled by Alnylam after the Effective Date that claims priority to any of the Patents set forth on Schedule 1.24, or any foreign counterpart of any of the foregoing Patents. 

1.25 Combination Product means a product that incorporates in a combination one or more pharmacologically active ingredients in
addition to the active pharmaceutical ingredient in the Alnylam Product or Tekmira Product, as applicable. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 4 - 

 1.26 Commercialize or Commercialization means any and all activities directed
to Manufacturing (including, without limitation, by means of contract manufacturers), marketing, promoting, distributing, importing, exporting and selling a Product, in each case for commercial purposes, and activities directed to obtaining pricing
and reimbursement approvals, as applicable. 
 1.27 Confidential Information means all proprietary or confidential
information and materials, patentable or otherwise, of a Party disclosed by or on behalf of such Party to the other Party before, on or after the Effective Date, including, without limitation, chemical substances, formulations, techniques,
methodology, equipment, data, reports, Know-How, sources of supply, patent positioning, business plans, and also including without limitation proprietary and confidential information of Third Parties in possession of such Party under an obligation
of confidentiality, whether or not related to making, using or selling Products. 
 1.28 Control, Controls or
Controlled by means, with respect to any Know-How or Patent, the possession of (whether by ownership or license, other than pursuant to this Agreement), or the ability of a Party or any of its Existing Affiliates to grant access to, or a
license or sublicense of, such Know-How or Patent as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such
access or license or sublicense. 
 1.29 Cover, Covers or Covered by means, with respect to a product and a
Patent, that, but for ownership of or a license or sublicense under such Patent, the making, using, selling, offering for sale or importing of, or other stated action with respect to, such product would infringe such Patent (or, if such Patent is a
patent application, would infringe a patent issued from such patent application). 
 1.30 Develop, Developing or
Development means with respect to a Product, preclinical and clinical drug development activities, including without limitation: test method development and stability testing, toxicology, formulations, manufacturing scale-up, preclinical and
clinical Manufacture, quality assurance/quality control development, statistical analysis and report writing; clinical studies and regulatory affairs; Regulatory Approval and registration. 

1.31 Existing Affiliate means, with respect to a Party, an Affiliate of such Party as of the Effective Date. 

1.32 FDA means the United States Food and Drug Administration or any successor agency thereto. 

1.33 First Commercial Sale means, with respect to each Product, the first commercial sale in a country as part of a nationwide
introduction after receipt by a Product Seller of Regulatory Approval in such country, excluding de minimis named patient and compassionate use sales. 
 1.34 Follow-On Product means a Product directed towards a Target that is the same Target that is targeted by a Successful Tekmira Milestone Product, a Successful Alnylam Product or a Successful
Biodefense Product, as applicable, but that contains a different chemical structure for the siRNA and/or a different cationic lipid component for the LNP Formulation. 

  
 - 5 -

 1.35 Funding Authority means the United States Department of Health and Human
Services or other United States or foreign government or international agencies responsible for requesting, approving and/or funding the development and manufacture of products for biodefense purposes. 

1.36 GAAP means United States generally accepted accounting principles applied on a consistent basis. 

1.37 IND means a United States investigational new drug application or its equivalent or any corresponding foreign application.

 1.38 Institutional Collaborator means any academic or non-profit institution or Person employed by or otherwise
affiliated with such an institution that does not meet the definition of Permitted Contractor. 
 1.39 Know-How means
biological materials and other tangible materials, information, data, inventions, practices, methods, protocols, formulas, formulations, knowledge, know-how, trade secrets, processes, assays, skills, experience, techniques and results of
experimentation and testing, including without limitation pharmacological, toxicological and preclinical and clinical test data and analytical and quality control data, patentable or otherwise. 

1.40 LNP Formulation means an LNP formulation, characterized by its components and its unique ratios among components. 

1.41 Major Market means, individually and collectively, the United States, the European Union, Canada, the United Kingdom, France,
Germany, Italy, Spain, China and Japan. 
 1.42 Manufacturing or Manufacture means, with respect to a Product, all
activities associated with the production, manufacture and processing of such Product, and the filling, finishing, packaging, labeling, shipping, and storage of such Product, including without limitation formulation process scale-up for toxicology
and clinical study use, aseptic fill and finish, stability testing, analytical development, quality assurance and quality control, and the production of the bulk finished dosage form of such Product from the siRNA and miRNA. 

1.43 miRNA Product means a product containing, comprised of or based on native or chemically modified RNA oligomers designed to
either (a) modulate, inhibit or interfere with a particular miRNA transcript; or (b) provide the function and/or mimic the activity of an miRNA. 
 1.44 Necessary Third Party IP means, with respect to any country in the Territory, on a country-by-country basis, any Patent in such country owned or controlled by a Third Party that Covers Alnylam
Products and/or Tekmira Products. 
 1.45 Net Sales means the gross amount invoiced by Alnylam, its Affiliates or
Sublicensees for Alnylam Products, or by Tekmira, its Affiliates or Sublicensees for Tekmira Products (in each case, such invoicing entity, a “Product Seller”), on sales or other dispositions in the Territory of such Products during the
applicable Royalty Term to Third Parties which are not Affiliates or Sublicensees of the Product Seller, less (a) to the extent allowed and taken, sales returns and allowances, granted or accrued, including trade, quantity and cash discounts
and any 

  
 - 6 -

 
other adjustments, including those granted on account of price adjustments, billing errors, rejected goods, damaged or defective goods, recalls, returns, rebates, chargebacks, reimbursements or
similar payments granted or given to wholesalers or other distributors, buying groups, health care insurance carriers or other institutions; (b) adjustments arising from consumer discount programs or similar programs; (c) customs or excise
duties, sales tax, consumption tax, value added tax, and other similar taxes (except income taxes) measured by the production, sale, or delivery of goods; (d) duties relating to sales and any payments in respect of sales to the United States
government, any State government or any foreign government, or to any governmental authority, or with respect to any government subsidized program or managed care organization; and (e) charges for freight and insurance related to the return of
Products and not otherwise paid by the customer. 
 In the event that a Product is sold in any country in the form of a Combination Product in
any year, Net Sales of such Combination Product will be adjusted by multiplying actual Net Sales of such Combination Product in such country by the fraction A/(A+B), where A is the average Net Sales price per daily dose during such year of the
Product in such country, if sold separately in such country, and B is the average Net Sales price per daily dose of any product containing the other pharmacologically active ingredients in the Combination Product in such country, if sold separately
in such country. If, in a specific country, the product containing the other pharmacologically active ingredients in the Combination Product are not sold separately in such country, Net Sales will be calculated by multiplying actual Net Sales of
such Combination Product by the fraction A/C, where A is the average Net Sales price per daily dose of the Product in such country and C is the average Net Sales price per daily dose of the Combination Product in such country. If, in a specific
country, the Product is not sold separately in such country, Net Sales will be calculated by multiplying actual Net Sales of such Combination Product by the fraction (C-B)/C, where B is the average Net Sales price per daily dose of the product
containing the other pharmacologically active ingredients in the Combination Product in such country and C is the average Net Sales price per daily dose of the Combination Product in such country. If, in a specific country, both the Product and the
product containing the other pharmacologically active ingredients in the Combination Product are not sold separately in such country, the Net Sales price for the Product and the product containing the other pharmacologically active ingredients in
the Combination Product will be negotiated by the Parties in good faith based upon the costs, overhead and profit as are then incurred for the Product and all similar substances then being made and marketed by the selling Party and having an
ascertainable market price. 
 Net Sales shall be determined from books and records maintained in accordance with GAAP, consistently applied
throughout the organization and across all products of the entity whose sales of Product are giving rise to Net Sales. 
 1.46
Party means either Alnylam or Tekmira or, solely with respect to Section 10.12, Protiva; Parties means Alnylam and Tekmira and, solely with respect to Section 10.12, Protiva. 

1.47 Patent means any patent (including any reissue, extension, substitution, confirmation, re-registrations, re-examination,
invalidation, supplementary protection certificate or patents of addition) or patent application (including any provisional application, continuation, continuation-in-part or divisional). 

  
 - 7 -

 1.48 Permitted Contractor means a Third Party that performs activities (e.g.,
as a contractor or consultant) under a bona fide contract services arrangement on behalf of a Party or its Affiliates. 

1.49 Person means any person or entity. 
 1.50 Phase I Clinical Trial means the first study of a Product in humans the primary purpose of which is the determination of safety and which may include the determination of pharmacokinetic
and/or pharmacodynamic profiles in healthy individuals or patients. 
 1.51 Phase II Clinical Trial means (a) a
study of dose exploration, dose response, duration of effect, kinetics or preliminary efficacy and safety study of a Product in the target patient population, (b) a controlled dose-ranging clinical trial to evaluate further the efficacy and
safety of such Product in the target population and to define the optimal dosing regimen or (c) a clinical trial that the sponsoring Party or its Affiliate refers to in a press release as a Phase II Clinical Trial or Study. 

1.52 Phase III Clinical Trial or Pivotal Trial means (a) a controlled study of a Product in patients of the efficacy and
safety of such Product which is prospectively designed to demonstrate statistically whether such Product is effective and safe for use in a particular indication in a manner sufficient to obtain Regulatory Approval to market such Product or
(b) a clinical trial that the sponsoring Party or its Affiliate refers to in a press release as a Phase III Clinical Trial or Study. 
 1.53 Product means a Tekmira Product or an Alnylam Product. 
 1.54
Protiva Patent means any Patent Controlled by Protiva on or after the Effective Date that was filed, or that claims priority to a Patent that was filed before April 15, 2010, but excluding Patent claims that Cover Tekmira Products, which
excluded Patent claims are solely directed to PLK1, APOB, Ebola, WEE1, ALDH2 or CSN5. 
 1.55 Protiva Know-How
means all Know-How Controlled by Protiva as of the Effective Date and that, prior to the Effective Date, was (a) disclosed to Alnylam by Protiva or (b) otherwise learned by Alnylam; provided, that Protiva Know-How shall not
include Know-How learned by Alnylam solely as a result of the litigation settled pursuant to the Settlement Agreement. 
 1.56
Qualifying Patent means an Alnylam Patent or, if there is no Valid Claim of an Alnylam Patent remaining in the applicable sublicensed territory, any Patent Controlled by Alnylam that claims the composition of matter or method of use of a
product. 
 1.57 Regulatory Approval means, with respect to each Product Developed and Commercialized, the receipt of
sufficient authorization from the appropriate regulatory authority on a country-by-country basis to market and sell such Product in a country, including (where necessary in a particular country prior to marketing a Product) all separate pricing
and/or reimbursement approvals that may be required for marketing. 

  
 - 8 -

 1.58 Research or Researching means identifying, evaluating, validating and
optimizing Products prior to pre-IND GLP toxicology studies. 
 1.59 Royalty Quarter means each of the four
(4) calendar quarters that begin January 1, April 1, July 1 and October 1 of each year. 

1.60 siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference
mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified
RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin. 
 1.61 siRNA Product means a product containing, comprised of or based on siRNAs or other double-stranded moieties effective in gene function modulation and designed to modulate the function of
particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or other double-stranded moieties are complementary. 
 1.62 Sublicensee means (a) a Third Party to whom Alnylam has granted (or to whom another permitted sublicensee under an Alnylam Existing Sublicense grants) a sublicense pursuant to any of the
Alnylam Existing Sublicenses, or (b) a Third Party to whom a Party (or another permitted sublicensee of such Party under this Agreement) grants a sublicense of all or a portion of the rights licensed to it hereunder as permitted herein.

 1.63 Sublicensable Product means an Alnylam Sublicensable Product or a Tekmira Sublicensable Product. 

1.64 Target means (a) a nucleic acid that encodes or is required for expression of a polypeptide (including without
limitation messenger RNA and miRNA), together with all variants of such polypeptide; (b) the set of nucleic acids that encode a defined non-peptide entity, including a microorganism, virus, bacterium or single cell parasite; provided
that the entire genome of a microorganism, virus, bacterium, or single cell parasite shall be regarded as a single Target; or (c) a naturally occurring interfering RNA or miRNA or precursor thereof. 

1.65 Tekmira Additional Target means a Tekmira Additional Exclusive Target or a Tekmira Additional Non-Exclusive Target.

 1.66 Tekmira Combined Licensed Technology means, collectively, the Protiva Patents, the Protiva Know-How, the Tekmira
Patents and the Tekmira Know-How. 
 1.67 Tekmira Exclusive Target means ALDH2 or any of the Tekmira Additional Exclusive
Targets. 
 1.68 Tekmira Field means the use of siRNA Products directed to a Tekmira Target for the prevention, treatment
or palliation of human disease, and related Research, Development and Commercialization activities. 

  
 - 9 -

 1.69 Tekmira Know-How means all Know-How, other than Protiva Know-How, Controlled by
Tekmira as of the Effective Date and that, prior to the Effective Date, was (a) disclosed by Tekmira to Alnylam or (b) otherwise learned by Alnylam; provided, that Tekmira Know-How shall not include Know-How learned by
Alnylam solely as a result of the litigation settled pursuant to the Settlement Agreement. 
 1.70 Tekmira Manufacturing
Documents means the documents identified in Schedule 1.70. 
 1.71 Tekmira Milestone Product means any Tekmira
Product Covered by a Valid Claim within the Alnylam Patents and that is directed to a Tekmira Non-Exclusive Target other than Ebola. 
 1.72 Tekmira Non-Exclusive Target means any of the following Targets: PLK1, APOB, Ebola, WEE1, CSN5, or any of the Tekmira Additional Non-Exclusive Targets. 

1.73 Tekmira Patent means any Patent, other than a Protiva Patent, UBC Patent or Category 1 Patent, that is Controlled by Tekmira
on or after the Effective Date and that was filed, or that claims priority to a Patent that was filed, before April 15, 2010. 
 1.74 Tekmira Product means an siRNA Product Researched, Developed or Commercialized by Tekmira, its Affiliates or Sublicensees that is directed to a Tekmira Target. 

1.75 Tekmira Royalty-Bearing Patent means any Patent within the Tekmira Combined Licensed Technology, any Category 1 Patent, any
Category 2 Patent as to which a Tekmira employee is listed as an inventor, any Category 3 Patent as to which a Tekmira employee is listed as an inventor, and any UBC Patent. 
 1.76 Tekmira Sublicensable Product means a Product that has been developed by Tekmira or its Affiliates for which (a) a Target has been identified, and a potential therapeutic intervention
described, and (b) one (1) or more oligonucleotide(s) have been screened in in vitro studies and (c) non-GLP rodent pharmacology data has been generated. 
 1.77 Tekmira Target means a Tekmira Exclusive Target or a Tekmira Non-Exclusive Target. 
 1.78 Tekmira-UBC License Agreement means that certain license agreement between Tekmira and UBC, dated effective July 1, 1998, as amended by Amendment Agreement between Tekmira and UBC dated
effective July 11, 2006, and Second Amendment Agreement dated effective August 14, 2007. 
 1.79 Territory
means worldwide. 
 1.80 Third Party means any Person other than Tekmira, Alnylam or any of their respective Affiliates.

  
 - 10 -

 1.81 UBC Patent means a Patent sublicensed to Alnylam pursuant to the UBC Sublicense
and that was filed, or that claims priority to a Patent that was filed, before April 15, 2010. 
 1.82 Valid Claim
means (a) any claim in an issued and unexpired patent within the Alnylam Patents or the Tekmira Royalty-Bearing Patents, as applicable, that has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental
agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal, and which has not been admitted by the holder of the patent to be invalid or unenforceable through reissue, re-examination, or
disclaimer or otherwise and (b) a patent application within the Alnylam Patents or the Tekmira Royalty-Bearing Patents, as applicable, a claim of which has been pending less than [**] years and which claim has not been cancelled, withdrawn or
abandoned or finally rejected by an administrative agency action from which no appeal can be taken. 
  

					
	 Additional Defined Terms
	  	Section Reference	 
	 AAA
	  	 	10.2	  
	 Agreement
	  	 	PREAMBLE	  
	 AlCana
	  	 	RECITALS	  
	 Alnylam
	  	 	PREAMBLE	  
	 Alnylam Additional Exclusive Target
	  	 	3.2	  
	 Alnylam Indemnitee
	  	 	7.1	  
	 Alnylam-Protiva CLA
	  	 	RECITALS	  
	 Alnylam-Tekmira LCA
	  	 	RECITALS	  
	 Ascletis
	  	 	4.6	  
	 Code
	  	 	2.7	  
	 Competitive Infringement
	  	 	5.4(a)	  
	 Effective Date
	  	 	PREAMBLE	  
	 IP Management Terms
	  	 	5.1	  
	 Lead Development Candidate
	  	 	1.17	  
	 LNP
	  	 	RECITALS	  
	 LNP Improvements
	  	 	2.2(d)	  
	 LNP/SNALP Technology
	  	 	RECITALS	  
	 Losses
	  	 	7.1	  
	 miRNA
	  	 	RECITALS	  
	 Manufacturing Agreements
	  	 	RECITALS	  
	 Prior Cross-License Agreements
	  	 	RECITALS	  
	 Product Seller
	  	 	1.45	  
	 Protiva
	  	 	PREAMBLE	  
	 RNAi
	  	 	RECITALS	  
	 Royalty Term
	  	 	4.7	  
	 Settlement Agreement
	  	 	RECITALS	  
	 Sponsored Research Agreement
	  	 	RECITALS	  

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 11 - 

					
	 Additional Defined Terms
	  	Section Reference	 
	 Successful Alnylam Product
	  	 	4.5	  
	 Successful Biodefense Product
	  	 	4.4	  
	 Successful Tekmira Milestone Product
	  	 	4.1	  
	 Supplemental Agreement
	  	 	RECITALS	  
	 Tekmira
	  	 	PREAMBLE	  
	 Tekmira Additional Exclusive Target
	  	 	3.1	  
	 Tekmira Additional Non-Exclusive Target
	  	 	3.1	  
	 Tekmira Indemnitee
	  	 	7.2	  
	 UBC
	  	 	RECITALS	  
	 UBC Sublicense
	  	 	RECITALS	  

 ARTICLE II- LICENSE GRANTS AND RELATED RIGHTS 

2.1 License Grants to Tekmira. 
 (a) Subject to the terms and conditions of this Agreement and the Alnylam Existing In-Licenses, Alnylam hereby grants to Tekmira and its Affiliates an exclusive right and license under the Alnylam
Licensed Technology to Research, Develop and Commercialize Tekmira Products directed to any Tekmira Exclusive Target in the Tekmira Field in the Territory. 
 (b) Subject to the terms and conditions of this Agreement and the Alnylam Existing In-Licenses, Alnylam hereby grants to Tekmira and its Affiliates a non-exclusive right and license under the Alnylam
Licensed Technology to Research, Develop and Commercialize Tekmira Products directed to any Tekmira Non-Exclusive Target in the Tekmira Field in the Territory. 
 (c) The licenses set forth in this Section 2.1 include the right to grant sublicenses as provided in, and subject to, Section 2.3 below. 

2.2 License Grants to Alnylam. 
 (a) Subject to the terms and conditions of this Agreement, Tekmira hereby grants to Alnylam and its Affiliates an exclusive right and license under the Tekmira Combined Licensed Technology and the
Category 1 Patents to Research, Develop and Commercialize Alnylam Products directed to any Alnylam Exclusive Target in the Alnylam Field in the Territory. 
 (b) Subject to the terms and conditions of this Agreement, Tekmira grants to Alnylam and its Affiliates a non-exclusive right and license under the Tekmira Combined Licensed Technology and the Category 1
Patents to Research, Develop and Commercialize Alnylam Products directed to any Alnylam Non-Exclusive Target in the Alnylam Field in the Territory. 
 (c) Subject to the terms and conditions of this Agreement, Tekmira grants to Alnylam and its Affiliates a non-exclusive right and license (without the right to grant sublicenses outside of the Alnylam
Field) under the Category 1 Patents for any and all purposes, both in the Alnylam Field and outside of the Alnylam Field, in the Territory. The license granted pursuant to this Section 2.2(c) shall be fully paid-up and royalty-free outside the
Alnylam Field. 

  
 - 12 -

 (d) Subject to the terms and conditions of this Agreement, Tekmira grants to Alnylam and its
Affiliates a non-exclusive, non-sublicensable, fully paid-up, royalty-free right and license under the Tekmira Combined Licensed Technology and the Category 1 Patents to research, develop, make, have made and use improvements to such technology and
inventions claimed or covered by such Patents (“LNP Improvements”) and to research, develop, make, have made, use and commercialize LNP Improvements. As between the Parties, Alnylam shall own all LNP Improvements made by Alnylam and its
Affiliates pursuant to the license granted under this Section 2.2(d); provided, however, that such ownership of LNP Improvements shall not extinguish or alter any of Alnylam’s obligations to Tekmira for any products that are
Alnylam Products. 
 (e) The licenses set forth in subsections (a), (b) and (c) of this Section 2.2 include the
right to grant sublicenses as provided in, and subject to, Section 2.3 below. 
 2.3 Sublicensing. 

(a) The licenses granted to Tekmira in Section 2.1 include the right for Tekmira to grant sublicenses, but only on a Tekmira
Sublicensable Product-by-Tekmira Sublicensable Product basis, to Third Parties to Research, Develop and/or Commercialize Tekmira Products that are Tekmira Sublicensable Products. Tekmira shall require that the terms of any sublicense under its
rights in this Agreement are fully in compliance with the terms and conditions of this Agreement and of the Alnylam Existing In-Licenses governing Alnylam’s rights under the Alnylam Licensed Technology. 

(b) The licenses granted to Alnylam in Section 2.2(a), Section 2.2(b) and Section 2.2(c) include the right for Alnylam to
grant sublicenses in the Alnylam Field, but only on a Alnylam Sublicensable Product-by-Alnylam Sublicensable Product basis, to Third Parties to Research, Develop and/or Commercialize Alnylam Products that are Alnylam Sublicensable Products. Alnylam
shall require that the terms of any sublicense under its rights in this Agreement are fully in compliance with the terms and conditions of this Agreement. 
 (c) Any sublicense granted by a Party hereunder shall be subject and subordinate to the terms and conditions of this Agreement and shall contain terms and conditions consistent with those in this
Agreement. The sublicensing Party shall assume full responsibility for the performance of all obligations and observance of all terms herein under the licenses granted to it and will itself pay and account to the other Party for all payments due
under such licenses by reason of any such sublicense. If a sublicensing Party becomes aware of a material breach of any sublicense by a Sublicensee, the sublicensing Party shall promptly notify the other Party of the particulars of same and take all
reasonable efforts to enforce the terms of such sublicense. 
 (d) Unless otherwise provided in this Agreement, the sublicensing
Party will notify the other Party within [**] days after execution of a sublicense entered into hereunder and provide a copy of the fully executed sublicense agreement to the other Party within the same time frame (with such reasonable redactions as
the sublicensing Party may make, provided that 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 13 - 

 
such redactions do not include provisions necessary to demonstrate compliance with the requirements of this Agreement), which shall be treated as Confidential Information of the sublicensing
Party under Article VI; and provided further that the other Party may disclose such agreement(s) to Third Parties under confidence if and to the extent required in order to comply with such other Party’s contractual obligations
under both this Agreement and Third Party agreements. 
 (e) Tekmira hereby waives the foregoing sublicensing restrictions and
requirements of Section 2.2(c), Section 2.2(d) and this Section 2.3 with respect to the Alnylam Existing Sublicenses. In addition, to the extent that Alnylam as of the Effective Date has licensed or sublicensed any Patent or Know-How
Controlled by Tekmira as of the Effective Date to any Third Party pursuant to any Alnylam Existing Sublicense, or granted any Third Party pursuant to any Alnylam Existing Sublicense any option to obtain a license or sublicense under any Patent or
Know-How Controlled by Tekmira, the rights of the applicable Third Party shall not be affected by this Agreement, and if such Third Party Develops or Commercializes Alnylam Products, then Tekmira will be entitled to milestone payments and royalties
with respect thereto as set forth in this Agreement. Alnylam agrees that it will not grant any additional options, licenses or sublicenses under Alnylam Patents, Tekmira Combined Licensed Technology, UBC Patents or Category 1 Patents to AlCana to
Research, Develop or Commercialize siRNA Products without the prior written consent of Tekmira or enter into any additional contractual obligations to indemnify AlCana as to AlCana’s practice of the Alnylam Patents, Tekmira Combined Licensed
Technology, UBC Patents or Category 1 Patents to Research, Develop or Commercialize siRNA Products. 
 (f) Notwithstanding
Sections 2.3(a) and 2.3(b), either Party may utilize Permitted Contractors and Institutional Collaborators to Research and/or Develop their respective Products, whether or not such Products have become Sublicensable Products; provided
that (i) such Party does not grant any such Permitted Contractor or Institutional Collaborator any license to Commercialize Products that are not Sublicensable Products and (ii) no Party shall share any of the other Party’s
Confidential Information with such Permitted Contractor or Institutional Collaborator unless such Third Party shall have executed a binding confidentiality agreement containing reasonably customary terms and conditions. 

2.4 Coordination with Supplemental Agreement. Tekmira and Alnylam hereby agree that the terms of this Agreement and the Settlement
Agreement (and the Binding Term Sheet attached thereto) extinguish, supersede, and replace the rights and obligations of Tekmira, Alnylam, and AlCana under the Supplemental Agreement solely as between and among Tekmira, Alnylam, and AlCana;
provided, however, Alnylam’s payment obligations to UBC and AlCana under the Supplemental Agreement and Sponsored Research Agreement shall survive the execution of this Agreement and the Settlement Agreement (and the Binding Term
Sheet attached thereto), and shall also survive any termination of the Supplemental Agreement or Sponsored Research Agreement, in each case for the duration of the applicable Royalty Term (as defined in the Sponsored Research Agreement). Subject to
the terms and conditions of the Settlement Agreement and any subsequent agreement(s) among Alnylam, Tekmira, UBC and AlCana, the rights and obligations of UBC under the Supplemental Agreement and Sponsored Research Agreement shall be maintained.
Notwithstanding any of the foregoing, nothing in this section 2.4 shall operate to relieve Alnylam of its obligation to comply with its payment or royalty obligations to UBC or AlCana, either directly or indirectly, under the Supplemental Agreement
or Sponsored Research Agreement. 

  
 - 14 -

 2.5 Covenants Not to Sue. Alnylam hereby covenants that it and its Existing
Affiliates will not initiate any legal suit against Tekmira or any of its Existing Affiliates asserting that: 
 (a) any
internal Research performed solely by Tekmira or its Existing Affiliates (and not with any Third Party) and solely for the purpose of identifying a Target for selection as a Tekmira Additional Target hereunder during the period starting on the
Effective Date and continuing until the earlier of (i) the [**] anniversary of the Effective Date and (ii) such date that Tekmira completes its selection of the Tekmira Additional Targets pursuant to Article III; or 

(b) the formulating in LNP Formulations by Tekmira or any of its Existing Affiliates of oligonucleotides controlled by any bona
fide Third Party pharmaceutical collaborator on behalf of such Third Party and solely for Research (but not Development or Commercialization); 
 constitutes infringement and/or misappropriation of the Alnylam Licensed Technology. For clarity, the Parties agree that the covenants set forth in this Section 2.5 do not extend to any Third Party.

 2.6 Retained Rights. Each Party expressly retains any rights not expressly granted to the other Party under this
Article II (or otherwise under this Agreement). 
 2.7 Rights in Bankruptcy. All licenses and rights to licenses granted
under or pursuant to this Agreement by a Party to other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the “Code”), licenses of rights to “intellectual
property” as defined under Section 101(35A) of the Code. The Parties agree that each Party, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code, and that
upon commencement of a bankruptcy proceeding by or against the other Party under the Code, such Party shall be entitled to a complete duplicate of, or complete access to (as such Party deems appropriate), any such intellectual property and all
embodiments of such intellectual property. Such intellectual property and all embodiments thereof shall be promptly delivered to such Party (a) upon any such commencement of a bankruptcy proceeding upon written request therefor by such Party,
unless such other Party elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of such other Party upon written request
therefor by such Party. The foregoing provisions are without prejudice to any rights such Party may have arising under the Code or other applicable law. 
 ARTICLE III- SELECTION OF ADDITIONAL TARGETS 
 3.1 Tekmira Additional
Targets. Subject to Section 3.3, during the period beginning on the Effective Date and ending on the [**] anniversary thereof, Tekmira may select (i) up to 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 15 - 

 
two (2) Targets (other than the Alnylam Exclusive Targets) that shall each become a “Tekmira Additional Exclusive Target” and (ii) up to five (5) Targets (other than the
Alnylam Exclusive Targets) that shall each become a “Tekmira Additional Non-Exclusive Target”. For clarity, the Parties acknowledge that such seven (7) Tekmira Additional Targets shall be in addition to the one (1) Tekmira
Exclusive Target and the five (5) Tekmira Non-Exclusive Targets selected as of the Effective Date. 
 3.2 Alnylam
Additional Exclusive Targets. Subject to Section 3.3, during the period beginning on the Effective Date and ending on the [**] anniversary thereof, Alnylam may select up to five (5) Targets (other than the Tekmira Targets) that shall
each become an “Alnylam Additional Exclusive Target”. For clarity, the Parties acknowledge that the five (5) Alnylam Exclusive Additional Targets shall be in addition to the Alnylam Existing Exclusive Targets. 

3.3 Selection Process. The following process shall apply to the selection of Tekmira Additional Targets and Alnylam Additional
Exclusive Targets. 
 (a) As to Targets that are peptide entities, the selecting Party shall initially notify the other Party in
writing of the NCBI Gene ID number (or, if a NCBI Gene ID number is not available, the specific sequence of the proposed Target) of each Target nominated by the selecting Party for selection as an additional Target. As to Targets that are
non-peptide entities, the selecting Party shall initially notify the other Party in writing of the non-peptide entity. Within [**] Business Days following the other Party’s receipt of a notice nominating a Target, such other Party shall notify
the selecting Party in writing whether such Target is either: (i) subject to a binding contractual obligation to a Third Party that would be breached by the inclusion of such Target as an additional Target under these terms, or (ii) the
subject of an Active Internal Development Program at such other Party and such Active Internal Development Program was in existence as such prior to the receipt of such notice from the selecting Party and such other Party determines in good faith
that it intends to continue such Active Internal Development Program, and so notifies the selecting Party. If neither of these criteria applies, the Target shall be considered to have been successfully nominated as a Tekmira Additional Non-Exclusive
Target, Tekmira Additional Exclusive Target, or Alnylam Additional Exclusive Target, as applicable. 
 (b) If a Target submitted
to Alnylam is not available for license as a Tekmira Additional Target pursuant to subsection (a) above, then Tekmira may nominate an additional Target as a Tekmira Additional Target, until two (2) Tekmira Additional Exclusive Targets and
five (5) Tekmira Additional Non-Exclusive Targets have been identified and successfully nominated pursuant to the foregoing procedure. Any Target successfully nominated pursuant to the foregoing procedure shall be a Tekmira Additional Target.

 (c) If a Target submitted to Tekmira is not available for license as an Alnylam Additional Exclusive Target pursuant to
subsection (a) above, then Alnylam may nominate an additional Target as an Alnylam Additional Exclusive Target, until five (5) Alnylam Additional Exclusive Targets have been identified and successfully nominated pursuant to the foregoing
procedure. Any Target successfully nominated pursuant to the foregoing procedure shall be an Alnylam Exclusive Additional Target. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 16 - 

 ARTICLE IV- FINANCIAL PROVISIONS 

4.1 Manufacturing Opt-Out Payment. Within ten (10) Business Days after the Effective Date, Alnylam shall pay Tekmira a fee of
thirty million U.S. dollars ($30,000,000), which amount shall constitute full consideration for the termination of and release of Alnylam from all of Alnylam’s obligations under the Manufacturing Agreements, including without limitation the
obligations to obtain materials and/or services from Tekmira, and the rights to Manufacture and have Manufactured Alnylam Products included in the Development and Commercialization rights granted to Alnylam pursuant to Sections 2.2(a) and 2.2(b).
Based on Tekmira’s provision to Alnylam of a completed Form W-8BEN, Alnylam agrees that it will not withhold taxes from the payment under this Section 4.1. 
 4.2 Restructuring Payment. Within ten (10) Business Days after the Effective Date, Alnylam shall pay Tekmira a fee of thirty-five million U.S. dollars ($35,000,000), which amount shall
constitute payment for the termination of the Prior Cross-License Agreements and the Parties’ rights and obligations thereunder, as well as the restructuring of certain milestone payments and royalty rates for certain Alnylam Products as set
forth in Sections 4.6 and 4.9(d). Based on Tekmira’s provision to Alnylam of a completed Form W-8BEN, Alnylam agrees that it will not withhold taxes from the payment under this Section 4.2. 

4.3 Milestones with Respect to Tekmira Milestone Products. On a Tekmira Milestone Product-by-Tekmira Milestone Product basis,
payments will be payable by Tekmira to Alnylam based upon the achievement of certain milestone events as set forth in the table below (all references are to U.S. dollars). Tekmira will provide written notice to Alnylam of the occurrence of a
milestone event within [**] Business Days, and pay the indicated milestone fee to Alnylam within [**] days, after the occurrence of the relevant event. 
 Capitalized terms in the chart below shall be read in context to apply to Tekmira Milestone Products; provided, however, that each milestone payment will be payable no more than once in
respect of any given Tekmira Milestone Product. 
  

					
	 Milestone Event
	  	Milestone Fee	 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 17 - 

 If one or more milestone events set out above are skipped for any reason, the payment for such skipped
milestone event(s) will be due at the same time as the payment for the next achieved milestone event. The milestone payments described above shall be payable only once in relation to each Tekmira Milestone Product that achieves Regulatory Approval
in a Major Market (each, a “Successful Tekmira Milestone Product”). Therefore, unless and until there is a Successful Tekmira Milestone Product directed to a particular Target, any of the milestone payments made by Tekmira under this
Section in connection with a Tekmira Milestone Product directed to such Target shall be fully creditable against the repeated achievement of such milestone event by any other Tekmira Milestone Product directed to such Target. However, in the event
that there is a Successful Tekmira Milestone Product directed to a Target and Tekmira subsequently begins to Develop or continues to develop a Follow-On Product then, if and when any of the milestone events set out above is thereafter achieved for
such Follow-On Product, in addition to the milestone payment for such milestone event, there will also be due and payable all of the milestone payment(s) for any such milestones that were achieved but not paid for such Follow-On Product prior to the
achievement of Regulatory Approval in a Major Market of a Successful Tekmira Milestone Product with respect to such Target. 

4.4 Milestones with Respect to Biodefense Targets. The milestone fees payable by Alnylam to Tekmira with respect to Alnylam
Products directed to Biodefense Targets that are not intended for sale, directly or indirectly, to a Funding Authority shall be as set forth in Section 4.4. The milestone fees payable by Alnylam to Tekmira with respect to Alnylam Products
Covered by a Valid Claim within the Tekmira Royalty-Bearing Patents that are directed to Biodefense Targets which are intended for sale, directly or indirectly, to a Funding Authority shall be payable on an Alnylam Product-by-Alnylam Product basis
as follows, subject to Section 4.6: 
  

					
	 Milestone Event
	  	Milestone Fee	 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 

 In the event one or more milestone events set out above are skipped for any reason, the payment for such skipped
milestone event(s) will be due at the same time as the payment for the next achieved milestone event. The milestone payments described above shall be payable only once 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 18 - 

 
in relation to each Alnylam Royalty Product directed to a Biodefense Target that achieves First Commercial Sale in a Major Market (each, a “Successful Biodefense Product”). Therefore,
unless and until there is a Successful Biodefense Product directed to a particular Biodefense Target, any of the milestone payments made by Alnylam under this Section in connection with an Alnylam Product directed to such Biodefense Target shall be
fully creditable against the repeated achievement of such milestone event by any other Alnylam Product directed to such Biodefense Target. However, in the event that there is a Successful Biodefense Product directed to a Biodefense Target and
Alnylam subsequently begins to Develop or continues to Develop a Follow-On Product, then, if and when any of the milestone events set out above is thereafter achieved for such Follow-On Product directed to such Biodefense Target, in addition to the
milestone payment for such milestone event, there will also be due and payable all of the milestone payment(s) for any such milestones that were achieved but not paid for such Follow-On Product prior to the achievement of Approval in a Major Market
of a Successful Biodefense Product with respect to such Biodefense Target. 
 4.5 Milestones with Respect to Alnylam
Products. On an Alnylam Product-by-Alnylam Product basis, and except as otherwise set forth in Sections 4.4 and 4.6, payments will be payable by Alnylam to Tekmira based on the achievement of certain milestone events as set forth in the table
below (all references are to U.S. dollars) with respect to any Alnylam Product that is Covered by a Valid Claim within the Tekmira Royalty-Bearing Patents. Alnylam will provide written notice to Tekmira of the occurrence of a milestone event within
[**] Business Days, and pay the indicated milestone fee to Tekmira within [**] days, after the occurrence of the relevant event. 
 Capitalized
terms in the chart below shall be read in context to apply to Alnylam Products; provided, however, that each milestone payment will be payable no more than once in respect of any given Alnylam Product. 

 

					
	 Milestone Event
	  	Milestone Fee	 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 
	 [**]
	  	 	[	**] 

 If one or more milestone events set out above are skipped for any reason, the payment for such skipped milestone event(s)
will be due at the same time as the payment for the next achieved 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 19 - 

 
milestone event. The milestone payments described above shall be payable only once in relation to each Alnylam Product that achieves Regulatory Approval in a Major Market (each, a
“Successful Alnylam Product”). Therefore, unless and until there is a Successful Alnylam Product directed to a particular Target, any of the milestone payments made by Alnylam under this Section in connection with an Alnylam Product
directed to such Target shall be fully creditable against the repeated achievement of such milestone event by any other Alnylam Product directed to such Target. However, in the event that there is a Successful Alnylam Product directed to a Target
and Alnylam subsequently begins to Develop or continues to Develop a Follow-On Product, if and when any of the milestone events set out above is thereafter achieved for such Follow-On Product directed to such Target, in addition to the milestone
payment for such milestone event, there will also be due and payable all of the milestone payment(s) for any such milestones that were achieved but not paid for such Follow-On Product prior to the achievement of Regulatory Approval in a Major Market
of a Successful Alnylam Product directed to such Target. 
 4.6 Milestones for Certain Alnylam Existing Exclusive
Targets. In lieu of any milestone payments under Sections 4.4 and 4.5 with respect to all Alnylam Products that are directed to any of the Alnylam Existing Exclusive Targets, a milestone payment will be due by Alnylam to Tekmira solely for the
first achievement of each of the corresponding milestone events set forth in the table below (all references are to U.S. dollars) by the applicable Alnylam Product identified below. Alnylam will provide written notice to Tekmira of the occurrence of
a milestone event within [**] Business Days, and pay the indicated milestone fee to Tekmira within [**] days, after the occurrence of the relevant milestone event. For the avoidance of doubt, each milestone fee set forth below will be payable no
more than once. 
  

					
	 Milestone Event
	  	Milestone Fee	 
	Dosing of first patient in a Phase III Clinical Trial for ALN-TTR; provided that such ALN-TTR is Covered by a Valid Claim within the Tekmira Royalty-Bearing
Patents	  	$	5,000,000	  
		
	Tekmira has [**] for clinical development of ALN-VSP in China either by (i) provision of direct Manufacturing services, including but not limited to the clinical trial drug
product material and associated manufacturing and regulatory information necessary and sufficient for the initiation of a clinical trial in China or Korea, or (ii) the transfer of necessary Manufacturing process technology used to produce batch
[**] of ALN-VSP for Alnylam clinical trials and sufficient to produce at least one (1) batch of ALN-VSP suitable for clinical trials in China or Korea.	  	$	5,000,000	  

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 20 - 

 In addition to the corresponding milestone fee, all expenses actually incurred by Tekmira for the activities
set forth in clauses (i) and (ii) in the second milestone listed in the above table shall be paid by [**]. 
 4.7
Royalty Term. Royalties shall be payable hereunder on a Product-by-Product and country-by-country basis commencing on the First Commercial Sale of a Product in a country and continuing during any period in which (a) in the case of
Alnylam Products, a Valid Claim within the Tekmira Royalty-Bearing Patents Covers the applicable Alnylam Product in such country of sale, or (b) in the case of Tekmira Products, a Valid Claim within the Alnylam Patents Covers the applicable
Tekmira Product in such country of sale (such period, as applicable, the “Royalty Term”). Upon the expiration of the Royalty Term applicable to a given Product and country, the license granted under Section 2.1(a),
Section 2.1(b), Section 2.2(a) or Section 2.2(b), as applicable, shall become fully paid-up, royalty-free, non-exclusive, perpetual and irrevocable with respect to such Product in such country. 

4.8 Royalties Payable by Tekmira. During the applicable Royalty Term, Tekmira shall pay running royalties on Net Sales of Tekmira
Products Covered by one or more Valid Claims of any Alnylam Patent in the applicable country of sale in accordance with the applicable running royalty rates set out in the table below (all references are to U.S. dollars): 

 

					
	 Aggregate Annual Net Sales
	  	Royalty Rate	 
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  

 No royalties will be payable more than once by Tekmira with respect to any single unit of Tekmira Product. 

4.9 Royalties on Alnylam Products. During the applicable Royalty Term, Alnylam shall pay running royalties on Net Sales of Alnylam
Products Covered by one or more Valid 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 21 - 

 
Claims of the Tekmira Royalty-Bearing Patents in the applicable country of sale, as follows (all references are to U.S. dollars), whether or not such Alnylam Products are directed to Biodefense
Targets, subject to Section 4.9(d): 
 (a) Where the Net Sales are those of, and are invoiced by, any one of the following:

 (i) Alnylam or its Affiliate; 
 (ii) Roche; 
 (iii) Regulus Therapeutics under a sub-license granted by Alnylam;
or 
 (iv) another sub-licensee under a sub-license granted by Alnylam in connection with, and solely for the purpose of, a Bona
Fide Collaboration; 
 the applicable running royalty rates shall be as set out in the table below: 

 

					
	 Aggregate Annual Net Sales
	  	Royalty Rate	 
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  

 (b) In all other cases, the applicable running royalty rates shall be set out in the table below:

  

					
	 Aggregate Annual Net Sales
	  	Royalty Rate	 
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  

 (c) No royalties will be payable more than once by Alnylam with respect to any single unit of Alnylam
Product. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 22 - 

 (d) The royalty rate payable on Net Sales of Alnylam Products Covered by one or more Valid
Claims of the Tekmira Royalty-Bearing Patents in the applicable country of sale that are directed to any of the Alnylam Existing Exclusive Targets shall be reduced by [**] of Aggregate Annual Net Sales at all tiers set forth in the tables in
subsections (a) and (b) above (e.g., where such a table indicates a royalty rate of [**]%, the royalty rate that would apply instead with respect to Net Sales of Alnylam Products directed to any of the Alnylam Existing Exclusive
Targets shall be [**]%). 
 4.10 Royalty Reduction. The royalties due under Section 4.8 or 4.9 above, as applicable,
may be reduced on a country-by-country basis in the Territory by the amount of royalties paid or payable with respect to Necessary Third Party IP; provided, however, that royalties due under Section 4.8 or 4.9 above, as
applicable, may not be reduced by more than [**] of the royalties otherwise due (and will not in any case be reduced below [**] of the amount of royalties that would otherwise be due, e.g., for Net Sales of a Tekmira Product up to and
including [**], the minimum effective royalty rate would be [**]%). For purposes of illustration only, if Aggregate Annual Net Sales of a Tekmira Product are [**] and royalties due to Third Parties in respect of the sale of such product total [**]
of Net Sales (or [**]), royalties due to Alnylam may be reduced only by [**] which is determined as follows: maximum reduction is [**] of the royalty due on Net Sales of [**], calculated by [**]. For the avoidance of doubt, royalties paid or payable
by Alnylam pursuant to the Supplemental Agreement or the Sponsored Research Agreement shall constitute royalties paid or payable to Third Parties with respect to Necessary Third Party IP for purposes of this Section 4.10, notwithstanding any
assignment or transfer of the rights to receive such payments to Tekmira or any of its Affiliates; provided, however, that royalties paid or payable pursuant to the Supplemental Agreement or the Sponsored Research Agreement on
Aggregate Annual Net Sales greater than [**] of any Alnylam Product, where such royalties are paid or payable only because such Alnylam Product is Covered by a Valid Claim within the Category 1 Patents (i.e., where such royalties would not be
paid or payable based on other patent rights in the absence of such Category 1 Patents), shall not result in a reduction to royalties under this Agreement pursuant to this Section 4.10 of more than [**]% of such Aggregate Annual Net Sales
greater than [**] in respect of any such Alnylam Product. 
 4.11 Third Party License Payments. Tekmira shall pay 100% of
all royalties, license fees, milestones and similar payments (if any) payable to any Third Party under its existing in-licenses, if any, for the rights to Tekmira Combined Licensed Technology licensed to Alnylam under this Agreement. In addition,
notwithstanding the differences between the milestones and royalties payable by Alnylam under this Agreement and the milestones and royalties that were payable under the Alnylam-Tekmira LCA, Tekmira remains solely responsible for, and agrees to pay
to UBC, any and all amounts payable to UBC pursuant to the Tekmira-UBC License Agreement, including, without limitation, any and all amounts payable to UBC in connection with Alnylam’s exercise of its rights under the UBC Sublicense and any and
all amounts paid by Alnylam to Tekmira under this Agreement or the UBC Sublicense. Alnylam shall pay 100% of all royalties, license fees, milestones and similar payments (if any) payable to any Third Party under any Alnylam Existing In-License for
the rights to Alnylam Licensed Technology licensed to Tekmira under this Agreement. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 23 - 

 4.12 Reports. As to each Royalty Quarter commencing with the Royalty Quarter during
which the First Commercial Sale occurs with respect to a Tekmira Product, in the case of Tekmira as the reporting Party, or with respect to an Alnylam Product, in the case of Alnylam as the reporting Party, within [**] days after the end of such
Royalty Quarter (if the reporting Party has not entered into an agreement with a Sublicensee) and within [**] days after the receipt by the reporting Party from a Sublicensee of such Sublicensee’s report, as required by such Sublicensee’s
sublicense for each Royalty Quarter (if the applicable Party has entered into an agreement with a Sublicensee), each reporting Party will deliver to the other Party to this Agreement a written report showing, on a country-by-country basis, the Net
Sales of Products calculated under GAAP and its royalty obligation for such quarter with respect to such Net Sales under this Agreement together with wire transfer of an amount equal to such royalty obligation. All Net Sales will be segmented in
each such report according to sales by the selling Party and each of its Affiliates and Sublicensees, as well as on a product-by-product basis, including the rates of exchange used to convert Net Sales to United States Dollars from the currency in
which such sales were made. For the purposes of this Agreement, the rates of exchange to be used for converting Net Sales to United States Dollars will be the simple average of the selling and buying rates of U.S. dollars published in The Wall
Street Journal East Coast Edition for the last Business Day of the Royalty Quarter covered by the report. 
 4.13 Tax
Withholding. Each paying Party will use all reasonable and legal efforts to reduce tax withholding with respect to payments to be made to the other Party under this Agreement. Notwithstanding such efforts, subject to Sections 4.1 and 4.2, if the
paying Party concludes that tax withholdings under the laws of any country are required with respect to payments, the paying Party will make the full amount of the required payment to such other Party after any tax withholding. In any such case, the
paying Party shall provide such other Party with a written explanation of such withholding and original receipts or other evidence reasonably desirable and sufficient to allow it to document such tax withholdings for purposes of claiming foreign tax
credits and similar benefits. 
 4.14 Payments. Unless otherwise agreed by the Parties, all payments required to be made
under this Agreement will be made in United States Dollars via wire transfer to an account designated in advance by the receiving Party. 
 4.15 Audits. At any given point in time, each Party will have on file and will require its Affiliates and Sublicensees to have on file complete and accurate records for the last [**] years of all
Net Sales of Products for which it is the paying Party. The other Party to this Agreement will have the right, [**] during each twelve (12) month period, to retain at its own expense an independent qualified certified public accountant
reasonably acceptable to such Party to review such records solely for accuracy and for no other purpose upon reasonable notice and under a written obligation of confidentiality, during regular business hours. If the audit demonstrates that the
payments owed under this Agreement have been understated, the audited Party will pay the balance to such other Party together with interest on such amounts from the 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 24 - 

 
date on which such payment obligation accrued at a rate equal to the then current [**] United States dollar LIBOR rate plus [**] percent per annum. If the underpayment is greater than five
percent of the amount owed, then the audited Party will reimburse such other Party for its reasonable out-of-pocket costs of the audit. If the audit demonstrates that the payments owed under this Agreement have been overstated, such other Party to
this Agreement will credit the balance against the next payment due from the audited Party (without interest). 
 ARTICLE V-
INTELLECTUAL PROPERTY 
 5.1 Category 1, 2 and 3 Patents. Subject to the terms and conditions set forth in the
Exhibit A attached hereto (the “IP Management Terms”): 
 (a) Alnylam hereby assigns to Tekmira all of Alnylam’s
right, title and interest in and to the Category 1 Patents, subject to any existing rights granted by Alnylam to Third Parties under the Category 1 Patents, including but not limited to such rights granted by Alnylam to UBC and AlCana under the
Supplemental Agreement and rights granted under the Alnylam Existing Sublicenses; provided, however, that such assignment shall exclude any right to enforce the Category 1 Patents with respect to any alleged infringing activities by
Alnylam and/or any of its licensees that occurred prior to the Effective Date. 
 (b) In the event that Tekmira obtains any
ownership interest in any Category 2 Patent or Category 3 Patent pursuant to the inventorship determination made under Sections 5 and 6 of the IP Management Terms, Tekmira shall and hereby does assign to Alnylam all of Tekmira’s right, title
and interest in and to such Category 2 Patent or Category 3 Patent, as applicable. 
 (c) Each Party agrees to execute such
further documents and take such further actions as the other Party may reasonably request in order to give effect to the assignments contemplated under subsections (a) and (b) above. 

(d) The filing, prosecution and maintenance of Category 1 Patents, Category 2 Patents and Category 3 Patents shall be governed by the
applicable provisions of the IP Management Terms. 
 5.2 Prosecution and Maintenance of Other Patents. Subject to the IP
Management Terms, Alnylam will have the sole right and responsibility, at Alnylam’s discretion and at its expense, to file, prosecute and maintain patent protection in the Territory for all Patents (other than Category 2 Patents, and Category 3
Patents) within the Alnylam Licensed Technology. Tekmira will have the sole right and responsibility, at Tekmira’s discretion and at its expense, to file, prosecute and maintain patent protection in the Territory for all Patents (other than
Category 1 Patents) within the Tekmira Combined Licensed Technology. 
 5.3 Third Party Infringement of Alnylam’s
Patents. 
 (a) Each Party will promptly report in writing to the other Party during the Term any known or suspected
infringement by a Third Party of any of the Alnylam Patents of which such 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 25 - 

 
Party becomes aware, as such infringement relates to Research, Development or Commercialization of Products directed at any Tekmira Target, or any Tekmira Product, and will provide the other
Party with all available evidence supporting such infringement. 
 (b) Alnylam will have the sole and exclusive right to
initiate an infringement or other appropriate suit in the Territory with respect to infringements or suspected infringements of any of the Alnylam Patents and to any and all recoveries obtained in connection therewith. 

(c) Alnylam will have the sole and exclusive right to select counsel for any suit referred to in subsection 5.3(b) above initiated by it
and will pay all expenses of the suit, including without limitation attorneys’ fees and court costs. 
 5.4 Competitive
Infringement of Category 1 Patents. 
 (a) Each Party will promptly report in writing to the other Party during the Term any
known or suspected infringement by a Third Party of any of the Category 1 Patents of which such Party becomes aware. If any such infringement relates to the development, making, using, selling, offering for sale or importing of a product that is
directed against an Alnylam Exclusive Target (“Competitive Infringement”), then Alnylam will have the first right to initiate an infringement or other appropriate suit in the Territory with respect to such Competitive Infringement;
provided, that if Alnylam fails to initiate a suit or take other appropriate action with respect to such Competitive Infringement within [**] days after becoming aware of the basis for such suit or action, then Tekmira may, in its
discretion, provide Alnylam with written notice of Tekmira’s intent to initiate a suit or take other appropriate action with respect to such Competitive Infringement. If Tekmira provides such notice and Alnylam fails to initiate a suit or take
such other appropriate action within [**] days after receipt of such notice from Tekmira, then Tekmira shall have the right to initiate a suit or take other appropriate action that it believes is reasonably required to protect its interests with
respect to such Competitive Infringement. 
 (b) The Party bringing the enforcement action with respect to such Competitive
Infringement shall have the right to defend against any claim arising during such action asserting that the Category 1 Patent that is subject of such Competitive Infringement is invalid or unenforceable. 

(c) Regardless of which Party brings such the enforcement action with respect to such Competitive Infringement, the Party not bringing
the enforcement action shall (i) provide all reasonable assistance to the Party bringing the action, at the expense of the Party bringing the action, and (ii) have the right to join and participate in such action at its own expense with
its own counsel and to share equally all expenses of such suit if it so elects. If required under applicable law in order for the initiating Party to initiate and/or maintain such suit, or if the initiating Party is unable to initiate or prosecute
such suit solely in its own name or it is otherwise advisable to obtain an effective legal remedy, in each case, the other Party shall, at the expense of the initiating Party, join as a party to the suit and will execute all documents necessary for
the initiating Party to initiate litigation to prosecute and maintain such action. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 26 - 

 (d) Any damages or other recovery, whether by settlement or otherwise, from an action under
this Section 5.4 to enforce the Category 1 Patent against Competitive Infringement shall first be applied pro rata to reimburse the Parties for the costs and expenses of litigation in such action, and [**] of any remaining amount shall
be paid to or retained by the Party conducting the litigation and [**] of such remaining amount shall be paid to or retained by the other Party. 
 5.5 Third Party Infringement of Tekmira’s Patents. 
 (a) Each Party
will promptly report in writing to the other Party during the Term any known or suspected infringement by a Third Party of any Patents within the Tekmira Combined Licensed Technology of which such Party becomes aware, as such infringement relates to
the Research, Development or Commercialization of Products directed at any Alnylam Target, or any Alnylam Product, and will provide the other Party with all available evidence supporting such infringement. 

(b) Tekmira will have the sole and exclusive right to initiate an infringement or other appropriate suit in the Territory with respect to
infringements or suspected infringements of any of the Patents within the Tekmira Combined Licensed Technology, and of any of the Category 1 Patents that does not constitute Competitive Infringement and to any and all recoveries obtained in
connection therewith. 
 (c) Tekmira will have the sole and exclusive right to select counsel for any suit referred to in
subsection 5.5(b) above initiated by it and will pay all expenses of the suit, including without limitation attorneys’ fees and court costs. 
 5.6 Patent Certification. To the extent required by law or permitted by law, the Parties shall use reasonable efforts to maintain with the applicable regulatory authorities during the Term correct
and complete listings of applicable Patents for Alnylam Products or Tekmira Products, as the case may be, being Commercialized, including but not limited to all so-called “Orange Book” listings required under the Hatch-Waxman Act.

 ARTICLE VI- CONFIDENTIAL INFORMATION AND PUBLICITY 

6.1 Non-Disclosure of Confidential Information. Each Party agrees that all Confidential Information of a Party that is disclosed
by a Party to the other Party (a) will not be used by the receiving Party except in connection with the activities contemplated by this Agreement, (b) will be maintained in confidence by the receiving Party, and (c) will not be
disclosed by the receiving Party to any Third Party without the prior written consent of the disclosing Party. Notwithstanding the foregoing, the receiving Party will be entitled to use and disclose Confidential Information of the disclosing Party
that (i) was known by the receiving Party or its Affiliates prior to its date of disclosure by the disclosing Party to the receiving Party as demonstrated by legally admissible evidence available to the receiving Party, (ii) either before
or after the date of the disclosure such Confidential Information is lawfully disclosed to the receiving Party or its Affiliates by sources other than the disclosing Party, (iii) either before or 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 27 - 

 
after the date of the disclosure by the disclosing Party or its Affiliates to the receiving Party such Confidential Information becomes published or otherwise part of the public domain through no
fault, act or omission on the part of the receiving Party or its Affiliates, (iv) is independently developed by or for the receiving Party or its Affiliates without reference to or in reliance upon the Confidential Information as demonstrated
by legally admissible evidence available to the receiving Party or its Affiliates, (v) is reasonably necessary to conduct clinical trials or to obtain regulatory approval of Products, or for the prosecution and maintenance of Patents, and such
Patents shall include without limitation claims to the nucleic acid component of the Products, the Products as formulated with an LNP including excipients, as well as methods of use and manufacture of the foregoing, along with any other claims that
are usual and customary to obtain maximum protection for a pharmaceutical, (vi) is reasonably required in order for a Party to obtain financing or conduct discussions with existing or potential Development and/or Commercialization partners so
long as such Third Party recipients are bound by an obligation of confidentiality, or (vii) in the reasonable judgment of the receiving Party is required to be disclosed by the receiving Party to comply with applicable laws or regulations or
legal process, including without limitation by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or NASDAQ,
provided that the receiving Party provides prior written notice of such disclosure to the disclosing Party and takes reasonable and lawful actions to avoid or minimize the extent of such disclosure, or (viii) solely with respect
to Confidential Information comprising Alnylam Know-How, Tekmira Know-How or Protiva Know-How, is otherwise reasonably necessary to disclose in connection with the Research, Development or Commercialization of Products hereunder. 

Alnylam and its Affiliates shall not provide the Tekmira Manufacturing Documents or copies thereof to any Third Party, and shall not reproduce such
Tekmira Manufacturing Documents in any patent application, publication or other public disclosure; provided, however, that Alnylam and its Affiliates shall be permitted to provide such Tekmira Manufacturing Documents to (1) on a
need-to-know basis, Third Party contract manufacturers and other Permitted Contractors that are engaged to manufacture Alnylam Products or to provide services in connection with Development, Manufacturing or regulatory matters for Alnylam Products
and/or (2) Sublicensees (who shall also be permitted to provide such Tekmira Manufacturing Documents on a need-to-know basis to Third Party contract manufacturers and other Permitted Contractors that are engaged to manufacture Alnylam Products
or to provide services in connection with Development, Manufacturing or regulatory matters for Alnylam Products), in each of the foregoing clauses (1) or (2), that are subject to binding confidentiality agreements containing reasonably
customary terms and conditions and, in the case of Third Party contract manufacturers and other Permitted Contractors, restricting such Third Parties from providing the Tekmira Manufacturing Documents to further Third Parties other than in
accordance with clause (3) below, and/or (3) regulatory authorities to the extent reasonably necessary to obtain Regulatory Approval for, or comply with regulatory requirements applicable to the Development or Commercialization of, any
Alnylam Product. 
 Notwithstanding anything to the contrary in this Agreement, the confidentiality and non-use obligations under this Agreement
and the restrictions set forth in the immediately preceding paragraph shall not apply to Confidential Information consisting of Alnylam Know-How, Tekmira Know-How or Protiva Know-How, including such Confidential Information comprised by the Tekmira
Manufacturing Documents, that is mentally retained in the unaided memories of the receiving Party’s and its Affiliates’ employees, consultants and advisors. 

  
 - 28 -

 For the avoidance of doubt, information received by a Party solely as a result of the litigation settled
pursuant to the Settlement Agreement shall not be governed by this Agreement and therefore shall not be subject to the exceptions set forth in the immediately preceding paragraphs permitting the use and disclosure of Confidential Information
hereunder (i.e., nothing in this Agreement shall lessen any restrictions on the use and disclosure of such information imposed in such litigation proceedings). 
 If a Party is required by judicial or administrative process to disclose Confidential Information that is subject to the non-disclosure provisions of this Section 6.1, such Party shall promptly
inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall
remain otherwise subject to the confidentiality and non-use provisions of this Section 6.1, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably practical, including without limitation
seeking an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information. In addition to the foregoing restrictions on public disclosure, if either Party concludes that a copy of this Agreement must be
filed with the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States, such Party shall seek the maximum confidential treatment available under applicable law, provide the other Party
with a copy of this Agreement showing any sections as to which the Party proposes to request confidential treatment, provide the other Party with an opportunity to comment on any such proposal and to suggest additional portions of this Agreement for
confidential treatment, and take such Party’s reasonable comments into consideration before filing this Agreement. 
 6.2
Limitation on Disclosures. Each Party agrees that it will provide Confidential Information received from the other Party solely to its employees, consultants and advisors, and the employees, consultants and advisors of its or its Affiliates
or existing or potential Sublicensees, as applicable, who have a legitimate business need to know and an obligation to maintain in confidence the Confidential Information of the disclosing Party. The receiving Party is liable for any breach of the
non-disclosure obligation of, as applicable, (a) its and its Affiliates’ employees, consultants and advisors, (b) existing or potential Sublicensees and (c) the employees, consultants and advisors of any existing or potential
Sublicensees. 
 6.3 Publicity. 
 (a) No disclosure of the existence of, or the terms of, this Agreement may be made by either Party or its Affiliates, and no Party or its Affiliates shall use the name, trademark, trade name or logo of
the other Party or its employees in any publicity, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by law or as set forth in this
Section 6.3. Either Party may issue press releases or otherwise make public statements or disclosures (such as in annual reports to stockholders or filings with the Securities and Exchange Commission) as it determines, based on advice of
counsel, are reasonably necessary to comply with applicable laws and 

  
 - 29 -

 
regulations. In addition, following any press release(s) announcing this Agreement or any other public disclosure by the Parties, either Party shall be free to disclose, without the other
Party’s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of the Agreement which have already been publicly disclosed in accordance herewith. 

Any reference made by Alnylam in a press release to LNP technology shall include the following statement: 

“About LNP Technology 
 Alnylam has licenses to Tekmira LNP intellectual property for use in RNAi therapeutic products.” 
 Any reference made by Tekmira in a press release to siRNA programs shall include the following statement: 
 “About Alnylam RNAi Technology 
 Tekmira has licenses to Alnylam RNAi
intellectual property for certain RNAi programs.” 
 ARTICLE VII- INDEMNIFICATION AND INSURANCE 

7.1 Tekmira Indemnification. Tekmira agrees to indemnify and hold harmless Alnylam and its Affiliates, and their respective
agents, directors, officers and employees and their respective successors and permitted assigns (the “Alnylam Indemnitees”) from and against any and all losses, costs, damages, fees or expenses (“Losses”) incurred by an Alnylam
Indemnitee arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by a Third Party based on (a) any claim made against Alnylam by Third Parties regardless of the form or forum in which any such claim
is made alleging (i) infringement or misappropriation of Third Party intellectual property, or (ii) personal injury, or death occurring to any person claimed to result, directly or indirectly, from the possession, use or consumption of, or
treatment with, any Tekmira Product Covered by an Alnylam Patent, whether claimed by reason of breach of warranty, negligence or product defect, and (b) any breach of any representation, warranty or covenant of Tekmira in this Agreement.

 The above indemnification shall not apply to the extent that any Losses are due to a breach of any of Alnylam’s representations,
warranties, covenants and/or obligations under this Agreement. 
 7.2 Alnylam Indemnification. Alnylam agrees to
indemnify and hold harmless Tekmira, its Affiliates, and their respective agents, directors, officers and employees and their respective successors and permitted assigns (the “Tekmira Indemnitees”) from and against any and all Losses
incurred by a Tekmira Indemnitee arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by a Third Party based on (a) any claim made against Tekmira by Third Parties regardless of the form or forum in
which any such claim is made alleging (i) infringement or misappropriation of Third Party intellectual property, or (ii) personal injury, or death occurring to any person claimed to result, directly or indirectly, from the possession, use
or consumption of, or treatment with, any Alnylam Product Covered by a Tekmira Patent, whether claimed by reason of breach of warranty, negligence or product defect, and (b) any breach of any representation, warranty or covenant of Alnylam in
this Agreement. 

  
 - 30 -

 The above indemnification shall not apply to the extent that any Losses are due to a breach of any of
Tekmira’s representations, warranties, covenants and/or obligations under this Agreement. 
 7.3 Tender of Defense;
Counsel. The obligation to indemnify pursuant to this Article shall be contingent upon timely notification by the indemnitee to the indemnitor of any claims, suits or service of process; the tender by the indemnitee to the indemnitor of full
control over the conduct and disposition of any claim, demand or suit; and reasonable cooperation by the indemnitee in the defense of the claim, demand or suit. No indemnitor will be bound by or liable with respect to any settlement or admission
entered or made by any indemnitee without the prior written consent of the indemnitor. The indemnitee will have the right to retain its own counsel to participate in its defense in any proceeding hereunder. The indemnitee shall pay for its own
counsel except to the extent it is determined that (a) one or more legal defenses may be available to it which are different from or additional to those available to the indemnitor, or (b) representation of both Parties by the same counsel
would be inappropriate due to actual or potential differing interests between them. In any such case and to such extent, the indemnitor shall be responsible to pay for the reasonable costs and expenses of one separate counsel retained to participate
in the defense of the indemnitee, provided that such expenses are otherwise among those covered by the indemnitor’s indemnity obligations under this Article VII. Notwithstanding the foregoing, if the indemnitor reasonably believes that any of
the exceptions to its obligation of indemnification of the indemnitee set forth in Sections 7.1 or 7.2 may apply, the indemnitor shall promptly notify the indemnitee, which shall then have the right to be represented in any such action or proceeding
by separate counsel at the indemnitee’s expense; provided, that the indemnitor shall be responsible for payment of such expenses if the indemnitee is ultimately determined to be entitled to indemnification from the indemnitor.

 7.4 Tekmira Insurance. With respect to its activities under this Agreement, Tekmira will secure and maintain in full
force and effect throughout the term of the licenses set out in Section 2.1 (and for at least [**] years thereafter for claims-made coverage), the following types and amounts of insurance coverage with carriers having a minimum AM Best rating
of A, with per claim deductibles that do not exceed [**]: 
 Comprehensive General Liability and Personal Injury, including coverage for
contractual liability assumed by Tekmira and coverage for Tekmira independent contractor(s), with limits of at least [**] per occurrence and a general aggregate limit of [**]. 
 Prior to, at, and following the dosing of the first patient in a Phase I Clinical Trial of any Tekmira Product by Tekmira, its Affiliates or Sublicensees, Umbrella Liability, exclusive of the coverage
provided by the policies listed above, with a limit of at least [**]. 
 Prior to, at, and following the First Commercial Sale of any Tekmira
Product by Tekmira, its Affiliates or Sublicensees, Products/Clinical/Professional Liability, exclusive of the coverage 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 31 - 

 
provided by the Comprehensive General Liability policy, with limits of at least [**] per occurrence and an aggregate limit of at least [**], with Alnylam to be named as an additional insured
party with respect to each Tekmira Product under such coverage. 
 7.5 Alnylam Insurance. With respect to its activities
under this Agreement, Alnylam will secure and maintain in full force and effect throughout the term of the licenses set out in Sections 2.2(a) and 2.2(b) (and for at least [**] years thereafter for claims-made coverage), the following types and
amounts of insurance coverage with carriers having a minimum AM Best rating of A, with per claim deductibles that do not exceed [**]: 

Comprehensive General Liability and Personal Injury, including coverage for contractual liability assumed by Alnylam and coverage for Alnylam independent
contractor(s), with limits of at least [**] per occurrence and a general aggregate limit of [**]. 
 Prior to, at, and following the dosing of
the first patient in a Phase I Clinical Trial of any Alnylam Product by Alnylam, its Affiliates or Sublicensees, Umbrella Liability, exclusive of the coverage provided by the policies listed above, with a limit of at least [**]. 

Prior to, at, and following the First Commercial Sale of any Alnylam Product by Alnylam, its Affiliates or Sublicensees, Products/Clinical Liability,
exclusive of the coverage provided by the Comprehensive General Liability policy, with limits of at least [**] per occurrence and an aggregate limit of at least [**], with Tekmira to be named as an additional insured party with respect to each
Alnylam Product under such coverage. 
 ARTICLE VIII- EXPORT 

8.1 General. The Parties acknowledge that the exportation from the United States of materials, products and related technical data
(and the re-export from elsewhere of United States origin items) may be subject to compliance with United States export laws, including without limitation the United States Bureau of Export Administration’s Export Administration Regulations,
the Act and regulations of the FDA issued thereunder, and the United States Department of State’s International Traffic and Arms Regulations which restrict export, re-export, and release of materials, products and their related technical data,
and the direct products of such technical data. The Parties agree, under this Agreement, to comply with all applicable exports laws and to commit no act that, directly or indirectly, would violate any United States law, regulation, or treaty, or any
other international treaty or agreement, relating to the export, re-export, or release of any materials, products or their related technical data to which the United States adheres or with which the United States complies. 

8.2 Delays. The Parties acknowledge that they cannot be responsible for any delays attributable to export controls which are
beyond the reasonable control of either Party. 
 8.3 Assistance. The Parties agree to provide reasonable assistance to
one another in connection with each Party’s efforts to fulfill its obligations under this Article VIII. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 32 - 

 ARTICLE IX- TERM AND TERMINATION 

9.1 Term; Expiration. The term of this Agreement shall begin on the Effective Date and, unless terminated earlier as provided
herein, the licenses granted under Sections 2.1(a), 2.1(b), 2.2(a), 2.2(b) and 2.2(c) of this Agreement will become fully paid-up, perpetual, non-exclusive and irrevocable at the end of the period set forth in Section 4.7, as applicable to each
of such licenses. The term of this Agreement shall expire upon the expiration of the last-to-expire Royalty Term. 
 9.2
Material Breach. 
 (a) Alnylam, as the licensor under Section 2.1, will have the right to terminate the licenses
granted thereunder, upon written notice to Tekmira, on a Tekmira Product-by-Tekmira Product basis in the event Tekmira materially breaches its obligations under this Agreement related to the licenses granted under Section 2.1 with respect to a
particular Tekmira Product(s), or such licenses in their entirety if such breach is not specific to particular Tekmira Product(s), and Tekmira does not remedy such breach within ninety (90) days after receipt of written notice from Alnylam
specifically identifying the breach and stating that Alnylam intends to terminate such licenses if Tekmira fails to remedy the breach within the ninety (90)-day time period; provided, however, that if Tekmira disputes in good
faith that the claimed breach exists, such 90-day period will not start to run until such dispute has been resolved or can no longer be maintained in good faith. 
 (b) Tekmira, as the licensor under Section 2.2, will have the right to terminate the licenses granted thereunder, upon written notice to Alnylam, on an Alnylam Product-by-Alnylam Product or
technology-by-technology basis in the event Alnylam materially breaches its obligations under this Agreement related to the licenses granted under Section 2.2 with respect to a particular Alnylam Product(s) or technology(-ies), or such licenses
in their entirety if such breach is not specific to particular Alnylam Product(s) or technology(-ies), and does not remedy such breach within ninety (90) after receipt of written notice from Tekmira specifically identifying the breach and
stating that Tekmira intends to terminate such licenses if Alnylam fails to remedy the breach within the ninety (90) time period; provided, however, that if Alnylam disputes in good faith that the claimed breach exists, such
90-day period will not start to run until such dispute has been resolved or can no longer be maintained in good faith. 
 9.3
Challenges of Alnylam’s Patents. In the event that Tekmira or any of its Affiliates shall (a) commence or participate in any action or proceeding (including, without limitation, any patent opposition or re-examination proceeding),
or otherwise assert in writing any claim, challenging or denying the validity of any of the Alnylam Patents or any claim thereof or (b) actively assist any other Person in bringing or prosecuting any action or proceeding (including, without
limitation, any patent opposition or re-examination proceeding) challenging or denying the validity of the Alnylam Patents or any claim thereof, Alnylam will have the right to give notice to Tekmira (which notice must be given, if at all, within
sixty (60) after Alnylam first learns of the foregoing) that the licenses granted by Alnylam to such Patent will terminate in thirty (30) following such notice, and, unless Tekmira withdraws or causes to be withdrawn all such challenge(s)
within such thirty-day period, such licenses will so terminate. 

  
 - 33 -

 9.4 Challenges of Tekmira Patents. In the event that Alnylam or any of its Affiliates
shall (a) commence or participate in any action or proceeding (including, without limitation, any patent opposition or re-examination proceeding), or otherwise assert in writing any claim, challenging or denying the validity of any of the
Category 1 Patents or Patents within the Tekmira Combined Licensed Technology, or any claim thereof or (b) actively assist any other Person in bringing or prosecuting any action or proceeding (including, without limitation, any patent
opposition or re-examination proceeding) challenging or denying the validity of any of the Category 1 Patents or Patents within the Tekmira Combined Licensed Technology, or any claim thereof, Tekmira will have the right to give notice to Alnylam
(which notice must be given, if at all, within sixty (60) after Tekmira first learns of the foregoing) that Alnylam’s license under such Patent will terminate in thirty (30) following such notice, and, unless Alnylam withdraws or
causes to be withdrawn all such challenge(s) within such thirty-day period, such licenses will so terminate. 
 9.5
Consequences of Termination; Survival. 
 (a) In the event of termination by Alnylam under Section 9.2(a) above, all
licenses and rights granted by Alnylam to Tekmira under Section 2.1 of this Agreement will terminate with respect to the particular Tekmira Product(s), or in their entirety, as provided in Section 9.2(a); provided, however,
that to the extent such licenses and rights are required in respect of clinical trials that are ongoing and cannot reasonably be terminated promptly due to health or safety reasons or the requirements of applicable law, such licenses and rights will
continue in effect until such clinical trials are properly terminated; provided, further, that any license that has become fully paid-up and perpetual pursuant to Section 9.1 shall survive. 

(b) In the event of termination by Tekmira under Section 9.2(b) above, all licenses and rights granted by Tekmira to Alnylam under
Section 2.2 of this Agreement will terminate with respect to the particular Alnylam Product(s) and/or technology(-ies), or in their entirety, as provided in Section 9.2(b); provided, however, that to the extent such licenses
and rights are required in respect of clinical trials that are ongoing and cannot reasonably be terminated promptly due to health or safety reasons or the requirements of applicable law, such licenses and rights will continue in effect until such
clinical trials are properly terminated; provided, further, that any license that has become fully paid-up and perpetual pursuant to Section 9.1 shall survive. 

(c) Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or
termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including without limitation the
obligation to pay royalties for Products sold prior to such expiration or termination. The provisions of Sections 6.1, 6.2 and 6.3(a) shall survive the expiration or termination of this Agreement for a period of five (5) years. In addition, the
provisions of Sections 2.2(c) (to the extent the license in such section extends outside of Alnylam Products in the Alnylam Field), 2.2(d), 2.4, 2.6, 2.7, 4.7, 4.11, 4.12, 4.13, 4.14, 4.15, 5.1(d), 5.4, Article VII, 9.1, 9.5, 9.6, 10.1(d), 10.2,
10.4, 10.6, 10.8 and 10.16, and any license that has become fully paid-up and perpetual pursuant to Section 9.1, shall survive any expiration or termination of this Agreement. 

  
 - 34 -

 9.6 Licenses upon Termination. 

(a) Upon any termination of this Agreement, Alnylam shall enter into an agreement containing substantially the same provisions as this
Agreement with any Sublicensees of Tekmira existing at the time of such termination, covering the Tekmira Products that had been licensed to such Sublicensee by Tekmira in compliance with this Agreement, provided that at the time of
any termination of this Agreement, such Sublicensees are in full compliance with the terms and conditions of the sublicense agreement. Alnylam acknowledges that such Sublicensees of Tekmira that are then in full compliance with the terms and
conditions of their respective sublicense agreement are third party beneficiaries of this Agreement, including this Section 9.6(a). 
 (b) Upon any termination of this Agreement, Tekmira shall enter into an agreement containing substantially the same provisions as this Agreement with any Sublicensees of Alnylam existing at the time of
such termination, covering the Alnylam Products that had been licensed to such Sublicensee by Alnylam in compliance with this Agreement, provided that at the time of any termination of this Agreement, such Sublicensees are in full
compliance with the terms and conditions of the sublicense agreement. Tekmira acknowledges that such Sublicensees of Alnylam that are then in full compliance with the terms and conditions of their respective sublicense agreement are third party
beneficiaries of this Agreement, including this Section 9.6(b). 
 ARTICLE X- MISCELLANEOUS 

10.1 Representations and Warranties. 
 (a) Mutual Representations and Warranties by Tekmira and Alnylam. 
 (i)
Each Party hereby represents and warrants to the other Party as of the Effective Date: 
 (a) It is duly organized and validly
existing under the laws of the jurisdiction of its incorporation or formation, and has all necessary power and authority to conduct its business in the manner in which it is currently being conducted, to own and use its assets in the manner in which
its assets are currently owned and used, and to enter into and perform its obligations under this Agreement. 
 (b) The
execution, delivery and performance of this Agreement has been duly authorized by all necessary action on the part of such Party and its Board of Directors and no consent, approval, order or authorization of, or registration, declaration or filing
with any Third Party or governmental authority is necessary for the execution, delivery or performance of this Agreement. 

(c) This Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against it in accordance with its
terms, subject to (A) laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (B) rules of law governing specific performance, injunctive relief and other equitable remedies. 

  
 - 35 -

 (d) It has never approved or commenced any proceeding, or made any election contemplating,
the winding up or cessation of its business or affairs or the assignment of material assets for the benefit of creditors. To such Party’s knowledge, no such proceeding is pending or threatened. 

(ii) Each Party acknowledges and agrees that the other Party has not made any representation or warranty that it has or can provide all
the rights that are necessary or useful to Research, Develop or Commercialize a Product. 
 (iii) Each Party represents and
warrants to the other Party that as of the Effective Date it has the right to grant to such other Party, its Affiliates and Sublicensees the licenses granted hereunder and has not granted any conflicting rights to any other Person. Each Party shall
maintain any applicable in-licenses in effect and shall not amend any such in-licenses in a manner that is detrimental to the rights of the other Party under this Agreement without the prior written consent of such other Party. 

(b) Alnylam Representations and Warranties. Alnylam hereby represents and warrants to Tekmira that: 

(i) to Alnylam’s knowledge, the conception, development and reduction to practice of the Alnylam Licensed Technology licensed to
Tekmira under this Agreement did not constitute or involve the misappropriation of trade secrets or other rights or property of any Person; 
 (ii) it has not assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the Alnylam Licensed Technology in a manner that conflicts with any rights granted to Tekmira
hereunder. 
 (c) Tekmira Representations and Warranties. Tekmira hereby represents and warrants to Tekmira that:

 (i) to Tekmira’s knowledge, the conception, development and reduction to practice of the Tekmira Combined Licensed
Technology licensed to Alnylam under this Agreement did not constitute or involve the misappropriation of trade secrets or other rights or property of any Person; and 
 (ii) it has not assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the Tekmira Combined Licensed Technology in a manner that conflicts with any rights granted to
Alnylam hereunder. 
 (d) Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY
MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY INTELLECTUAL PROPERTY, PRODUCTS, GOODS, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY
DISCLAIMS ALL IMPLIED CONDITIONS, REPRESENTATIONS, AND WARRANTIES, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND 

  
 - 36 -

 
NONINFRINGEMENT OR VALIDITY OF PATENT RIGHTS WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR
COMMERCIALIZATION OF ANY PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY SUCH PRODUCT WILL BE ACHIEVED. 
 10.2 Dispute Resolution; Arbitration Procedures. The Parties agree that any disputes that arise under this Agreement between them during the period starting on the Effective Date and ending on the
third anniversary of the Effective Date, including without limitation, claims relating to the enforcement of this Agreement, shall be resolved by binding arbitration conducted in accordance with the Commercial Arbitration Rules and Supplementary
Procedures for Large Complex Disputes of the American Arbitration Association (“AAA”). The arbitration shall be conducted by a panel of three persons experienced in large commercial disputes who are independent of the arbitrating Parties
and neutral with respect to the dispute presented for arbitration. Within [**] days after initiation of arbitration, each arbitrating Party shall select one person to act as an arbitrator and the Party-selected arbitrators shall select an additional
arbitrator within [**] days of their appointment. If the arbitrators selected by the Parties are unable or fail to agree on the third arbitrator, the additional arbitrator shall be appointed by the AAA. The place of the arbitration shall be in
Chicago, Illinois, USA, and all proceedings and communications shall be in English. Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an arbitrator may disclose the existence, content, or results of
an arbitration without the prior written consent of both Parties. 
 10.3 Force Majeure. No failure or omission by the
Parties in the performance of any obligation of this Agreement will be deemed a breach of this Agreement or create any liability if the same will arise from any cause or causes beyond the control of the Parties, including, but not limited to, the
following: acts of God; acts or omissions of any government; any rules, regulations or orders issued by any governmental authority or by any officer, department, agency or instrumentality thereof; fire; flood; storm; earthquake; accident; war;
rebellion; insurrection; riot; and invasion. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force
majeure circumstances. 
 10.4 Consequential Damages. NEITHER PARTY (INCLUDING ITS AFFILIATES AND SUBLICENSEES) SHALL BE
LIABLE UNDER THIS AGREEMENT FOR ANY SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES OR FOR LOSS OF PROFIT OR LOST REVENUE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION
10.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OF A PARTY OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE VI. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 37 - 

 10.5 Assignment. 

(a) This Agreement, and any of its rights and obligations, may not be assigned or otherwise transferred by either Party without the prior
written consent of the other Party, which consent shall not be unreasonably withheld, delayed or conditioned; provided, however, that either Party may assign this entire Agreement, without the consent of the other Party, in connection
with such Party’s merger, consolidation or transfer or sale of all or substantially all of the assets of such Party; and provided further that the successor, surviving entity, purchaser of assets, or transferee, as applicable,
expressly assumes in writing such Party’s obligations under this Agreement, if any. 
 (b) Any purported transfer or
assignment in contravention of this Section 10.5 shall, at the option of the non-assigning Party, be null and void and of no effect. 
 (c) This Agreement shall be binding upon and inure to the benefit of the Parties and their permitted successors and assigns. 
 10.6 Notices. 
  

			
	Notices to Alnylam will be addressed to:
	
	 Alnylam Pharmaceuticals, Inc.

	 300 Third Street

	 Cambridge, Massachusetts 02142

	 U.S.A.

	 Attention:
	  	Senior Vice President, Chief Business Officer
	 Facsimile No.:
	  	(617) 812-0353
	
	With copy to:
	
	 WilmerHale LLP

	 60 State Street

	 Boston, Massachusetts 02109

	 Attention:
	  	Steven D. Singer, Esq.
		  	Steven D. Barrett, Esq.
	 Facsimile No.:
	  	(617) 526-5000
	
	Notices to Tekmira will be addressed to:
	
	 Tekmira Pharmaceuticals Corporation

	 100-8900 Glenlyon Parkway

	 Burnaby, B.C.

	 Canada V5J 5J8

	 Attention:
	  	President & CEO
	 Facsimile No.:
	  	(604) 630-5103
	
	With copy to:
	
	 Orrick, Herrington & Sutcliffe LLP

	 1000 Marsh Road

	 Menlo Park, CA 94025-1015

	 Attention:
	  	Elizabeth A. Howard
		  	R. King Milling
	 Facsimile No.:
	  	(650) 614-7401

  
 - 38 -

 Either Party may change its address by giving notice to the other Party in the manner provided in this
Section 10.6. Any notice required or provided for by the terms of this Agreement will be in writing and will be (a) sent by certified mail, return receipt requested, postage prepaid, (b) sent via a reputable international express
courier service, or (c) sent by facsimile transmission, with a copy by regular mail. The effective date of the notice will be the actual date of receipt by the receiving Party. 

10.7 Independent Contractors. It is understood and agreed that the relationship between the Parties is that of independent
contractors and that nothing in this Agreement will be construed as authorization for either Party to act as the agent for the other Party. 
 10.8 Governing Law; Jurisdiction. This Agreement will be governed and interpreted in accordance with the substantive laws of the State of Delaware, U.S.A., notwithstanding the provisions governing
conflict of laws under such law of the State of Delaware to the contrary, provided that (a) matters of intellectual property law, if any, will be determined in accordance with the national intellectual property laws relevant to the
intellectual property in question, and (b) the application of the 1980 United Nations Convention on Contracts for the International Sale of Goods is expressly excluded from this Agreement. 

10.9 Severability. In the event that any provision of this Agreement is held by a court of competent jurisdiction to be
unenforceable because it is invalid or in conflict with any law of the relevant jurisdiction, the validity of the remaining provisions will not be affected and the rights and obligations of the Parties will be construed and enforced as if the
Agreement did not contain the particular provisions held to be unenforceable, provided that the Parties will negotiate in good faith a modification of this Agreement with a view to revising this Agreement in a manner which reflects, as
closely as is reasonably practicable, the commercial terms of this Agreement as originally signed. 
 10.10 No Implied
Waivers. The waiver by either Party of a breach or default of any provision of this Agreement by the other Party will not be construed as a waiver of any succeeding breach of the same or any other provision, nor will any delay or omission on the
part of either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party. 

10.11 Headings. The headings of articles and sections contained this Agreement are intended solely for convenience and ease of
reference and do not constitute any part of this Agreement, or have any effect on its interpretation or construction. 
 10.12
Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to its subject matter and supersedes all previous written or oral representations, agreements and understandings between the Parties including,
without limitation, the Prior Cross-License Agreements and the Manufacturing Agreements, but 

  
 - 39 -

 
excluding the Settlement Agreement, the Supplemental Agreement (subject to Section 2.4) and the UBC Sublicense. The Parties specifically agree that the corresponding provisions of this
Agreement shall supersede in their entirety any surviving provisions of the Prior Cross-License Agreements. This Agreement (including the attachments hereto) may be amended only by a writing signed by both Parties. 

10.13 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review,
drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

10.14 No Third Party Beneficiaries. Except as expressly contemplated herein, no Third Party, including any employee of any Party
to this Agreement, shall have or acquire any rights by reason of this Agreement. 
 10.15 Further Assurances. Each Party
will provide such further documents or instruments required by the other Party as may be reasonably necessary or desirable to give effect to the purpose of this Agreement and carry out its provisions. 

10.16 Performance by Affiliates. Either Party may use one or more of its Affiliates to perform its obligations and duties
hereunder and Affiliates of a Party are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding obligations of such Party and the relevant Party shall remain liable hereunder for
the prompt payment and performance of all their respective obligations hereunder. 
 10.17 Counterparts. This Agreement
may be executed in any number of counterparts, each of which will be deemed an original, and all of which together will constitute one and the same instrument. 
 [Signature Page Follows] 

  
 - 40 -

 IN WITNESS WHEREOF, Alnylam, Tekmira and Protiva have set their hands to this Cross-License Agreement as of
the date first written above. 
  

			
	ALNYLAM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Barry Greene

	Name:	 	Barry Greene
	Title:	 	President and Chief Operating Officer
	
	TEKMIRA PHARMACEUTICALS CORPORATION
		
	By:	 	 /s/ Mark J. Murray

	Name:	 	Mark J. Murray
	Title:	 	President & CEO
	
	 PROTIVA BIOTHERAPEUTICS INC.
 solely with respect to Section 10.12

		
	By:	 	 /s/ Mark J. Murray

	Name:	 	Mark J. Murray
	Title:	 	President & CEO

  
 - 41 -

 EXHIBIT A - IP MANAGEMENT TERMS 

Management of Category 1, 2, and 3 Patents 
 1. The Category 1 Patents shall be assigned to Tekmira pursuant to Section 5.1(a) of this Agreement. Within [**] days of the Effective Date, representative(s) of each Party shall meet in the offices
of Blank Rome in NY, NY to coordinate the transition of prosecution control from Alnylam to Tekmira. Within [**] business days of the Effective Date, Alnylam will determine which priority applications, in whole or in part, within the [**] family
will be assigned to Tekmira and shall record such assignments with the U.S. Patent and Trademark Office. For clarity, all priority applications, in whole or in part, to which [**] family members that have been assigned to Tekmira are entitled, or
are necessary to effect a valid priority claim shall be assigned to Tekmira according to the procedure set forth above. 
 2. The Category 2
Patents and the Category 3 Patents shall be owned by Alnylam. If Tekmira obtains any ownership interest in any Category 2 Patents or any Category 3 Patents as a result of any inventorship determination pursuant to this Agreement, Tekmira shall
assign such interest to Alnylam as set forth in Section 5.1(b) of this Agreement. 
 3. If it is determined that a novel lipid, or novel
lipid formulation is disclosed for the first time in a Category 2 Patent application or a Category 3 Patent application, then a divisional or continuation will be filed to isolate this subject matter. The division or continuation will be assigned to
Tekmira, and for the purposes of this Agreement will be treated as Category 1 IP. 
 4. Prosecution and Maintenance of Category 1 Patents.

 a. Within [**] days following the Effective Date, each Party shall provide to the other Party the name of the person responsible for
prosecution and maintenance of Category 1 Patents within such Party’s company. 
 b. The Parties agree that current outside US counsel
utilized by Alnylam prior to the Effective Date shall continue to handle US prosecution and coordinate rest of world prosecution of Category 1 Patents for a period of at least [**] month from the Effective Date. For [**]. 

c. If the outside counsel identified in 3.b above are not acceptable to Tekmira due to a bona fide conflict of interest, the Parties shall agree on
mutually acceptable outside counsel and the cost of transferring such cases shall be divided equally between Alnylam and Tekmira. If after [**] months from the effective date Tekmira wishes to transfer any of the above cases to an outside firm of
their choosing and is such firm is acceptable to Alnylam, Tekmira shall be free to do so but the cost of transferring such cases shall be borne by Tekmira 100%. 
 d. If the Parties cannot agree on choice of outside counsel, each Party shall provide the names of three (3) law firms they find acceptable, excluding those firms the other Party found unacceptable,
to the third party arbitrator as provided below and agree to abide by the decision of the arbitrator. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 42 

 e. Starting on the Effective Date Tekmira shall control prosecution with input and agreement from Alnylam
and shall diligently prosecute the Category 1 Patents claims in the broadest reasonable manner possible. Alnylam shall be copied on any correspondence with the respective patent offices related to the prosecution of the Category 1 Patents, and
Tekmira shall consult Alnylam prior to any proposed filing, response or claim additions, deletions or amendments with sufficient time to allow for review, comment and agreement by Alnylam. 
 f. Alnylam shall be consulted and must agree on any inventorship determinations or any changes to inventorship prior to filing such changes with any patent office. In the event, however, that there is a
disagreement between the Parties as to inventorship determinations, the Parties agree that they will be bound by the inventorship determinations made pursuant to the procedure outlined in paragraph 4.k below. 

g. Except as otherwise set forth in 3.c above or 3.h below, prosecution and maintenance costs shall be divided equally between Alnylam and Tekmira for
Category 1 Patents. 
 h. If for whatever reason Tekmira wishes to abandon an application for or cease to maintain any Category 1 Patents in a
jurisdiction, Tekmira will provide Alnylam with [**] days advance notice and, if Alnylam wishes to maintain such application or patent, it will be at Alnylam’s expense and such application or patent shall be assigned back to Alnylam, and
Tekmira shall have no further rights in such application or patent and such application or patent shall cease to constitute Category 1 Patents. 

i. Tekmira shall not have the right to utilize, refer to, incorporate or any way use to support claims, any subject matter that is explicitly disclosed
in a patent application to which any of the Category 1 Patents claims priority that is also not explicitly disclosed in the Category 1 IP application in question or that is also not explicitly disclosed in other Tekmira owned or controlled patents
or patent applications having an earlier filing date than the Category 1 Patent priority application containing such subject matter. For clarity, subject matter that is incorporated by reference or incorporated by virtue of a priority claim in the
Category 1 Patents in question shall not in any way be used by Tekmira unless that subject matter is also explicitly disclosed in the Category 1 Patent in question or was explicitly disclosed in other Tekmira owned or controlled patent or patent
applications having an earlier filing date than the Category 1 Patent or Category 1 Patent priority application in question. 
 j. Alnylam shall
not have the right in any patent or patent application that it owns or controls, to utilize, refer to, incorporate or any way use to support claims in such patent or patent application, any subject matter that was explicitly disclosed in any of the
Category 1 Patents by virtue of having a common priority document with any of the Category 1 Patents, unless it was explicitly disclosed in such Alnylam owned or controlled patent or patent application . 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 43 

 k. In the event there is a disagreement between the Parties on any prosecution matter (including new patent
application filings, claims, claim amendments, deletions or additions), or any inventorship determination or correction they agree to utilize the dispute resolution mechanism as set forth in paragraph 7 below. 

5. Prosecution and Maintenance of Category 2 Patents. 
 a. Prosecution and maintenance of Category 2 Patents shall be controlled by Alnylam and as to Category 2 Patents Alnylam shall have sole discretion in any decisions regarding patent prosecution and all
prosecution and maintenance costs shall be borne by Alnylam. 
 b. Within [**] days of Tekmira providing the names of Tekmira inventors to be
added to patent application [**] in Alnylam patent family [**] Alnylam shall add such inventors by filing with the US Patent and Trademark Office a corresponding correction, and the added inventors shall assign their rights in this application to
Alnylam upon their addition to the application. Alnylam will similarly correct the inventorship in related US and foreign applications or patents where a claim or claims of similar scope exist. 

c. Within [**] days of the Effective Date an inventorship determination shall be performed on all Category 2 Patents at Alnylam’s expense.

 d. If it is determined that Tekmira inventors should be added any application(s) or patent(s), Alnylam shall add such inventors by filing
with the respective patent office a corresponding correction, and the added inventors shall assign their rights in this application to Alnylam upon their addition to the application. 
 e. If Tekmira disagrees with the above inventorship determination the Parties agree to utilize the dispute resolution mechanism as set forth in paragraph 7 below. 

f. Tekmira shall be provided [**] days advance notice on any material claim amendments, additions or deletions in any Category 2 Patents that utilize or
relate to disputed subject matter or if it decides to abandon any patent or patent application. 
 g. Tekmira shall be copied on all
correspondence with the respective patent offices related to the prosecution of Category 2 Patents for which an inventorship determination referenced above results in the addition of a Tekmira inventor. 

6. Prosecution and Maintenance of Category 3 Patents. 
 a. Prosecution and maintenance of Category 3 Patents shall be controlled by Alnylam and as to Category 3 Patents Alnylam shall have sole discretion in any decisions regarding patent prosecution and all
prosecution and maintenance costs shall be borne by Alnylam. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 44 

 b. Upon claim allowance an independent inventorship determination shall be made by Alnylam at its cost and
inventorship shall be corrected if warranted. If Tekmira inventors are added to any applications, such inventors shall assign their rights to such patent applications to Alnylam. 
 c. In the event that Tekmira wishes to determine inventorship for any claim prior to allowance it may do so at its expense. If as a result of such determination Tekmira inventors are added to any
applications, such inventors shall assign their rights to such patent applications to Alnylam 
 d. If Tekmira disagrees with the above
inventorship determination, the Parties agree to utilize the dispute resolution mechanism as set forth in paragraph 7 below. 
 e. Tekmira shall
be provided [**] days advance notice on any material claim amendments, additions or deletions in any Category 3 Patents that utilize or relate to disputed subject matter or if it decides to abandon any patent or patent application. 

f. In addition to 6e above, Tekmira shall be copied on all correspondence with the respective patent offices related to the prosecution of such Tekmira
Category 3 Patents for which an inventorship determination referenced above results in the addition of a Tekmira inventor. 
 7. Dispute
Resolution Mechanism. 
 a. A third party gatekeeper/arbiter shall be identified along with a simple, speedy dispute resolution mechanism in the
event of any disagreement among the Parties regarding the matters set forth in this Exhibit A. 
 b. The arbiter shall be mutually agreed to by
the Parties. When a dispute arises among the Parties, the arbiter shall consider in good faith the position(s) of each Party in the dispute which the Parties shall have [**] business days to submit to such arbiter. The arbiter shall render his/her
decision in an unbiased manner in accordance with the patent laws of the jurisdiction of the patent application as to which such disagreement pertains within [**] business days of receiving all relevant documentation from the Parties and, at the
arbiter’s discretion, discussion with the Parties; provided, however, that the arbiter shall hold no ex parte meetings or substantive conversations with a Party without the consent of the other Party. 

c. In the event that the arbiter is no longer willing or capable of serving in this function a replacement shall be selected or if the Parties cannot
agree to a replacement arbiter, one will be selected as follows: 
 i. Each of the Parties shall nominate five (5) potential arbiters and
any potential arbiter appearing on both Parties’ lists shall be the arbiter and the Parties shall attempt in good faith to secure such arbiter’s services. In the event that there is more than one (1) arbiter that appears on both such
lists, the Parties shall agree in good faith which arbiter to approach first. In the event that there are no arbiters in common, the Parties shall repeat the process until an arbiter appears on both such lists or until the Parties can otherwise
agree on an arbiter. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 45 

	d.	The costs of the arbiter shall be divided equally between the Parties. 

 8. Cooperation. 
 a. The Parties hereby agree as to Category 1 Patents, Category 2 Patents,
Category 3 Patents: 
 i. to make its employees, agents and consultants reasonably available to the other Party (or the other Party’s
authorized attorneys, agents or representatives), to the extent reasonably necessary to enable such Party to undertake patent prosecution as contemplated by this Exhibit A; 
 ii. to cooperate, if necessary and appropriate, with the other Party in gaining patent term extensions wherever applicable to patent rights; 
 iii. to endeavor in good faith to coordinate its efforts wherever possible or reasonable with the other Party to minimize or avoid interference with the prosecution and maintenance of the other
Party’s patent applications; 
 iv. in the event one Party receives an obviousness-type double patenting rejection in an application such
Party controls over an application controlled by the other Party, the Parties will enter into good faith discussions to take steps necessary to allow both sets of claims to issue, such steps potentially including assigning an ownership interest in
the patent application in question to the other party so that common ownership is established allowing for the filing of a terminal disclaimer. In the event that such common ownership is established the Party receiving the ownership interest will
license all of its rights back in such application to the other Party; and 
 v. Unless otherwise explicitly provided in this Agreement the
Parties shall have rights with respect to the enforcement of Category 1 Patents, Category 2 Patents, Category 3 Patents according to their respective ownership interests in such patent rights as provided under applicable law. 

9. For the avoidance of doubt, the Parties agree that, despite Tekmira’s prior identification of the following patent families as being subject to
an inventorship challenge by Tekmira, Tekmira does not challenge Alnylam’s inventorship or sole ownership of the following patent families: [**]. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 46 

 SCHEDULE 1.9 - ALNYLAM EXISTING IN-LICENSES 

 

	1.	Co-Exclusive License Agreement between Max Planck Innovation GmbH (formerly Garching Innovation GmbH) and Alnylam Pharmaceuticals, Inc., dated December 20, 2002,
as amended by Amendment dated July 2, 2003, the Requirements Amendment effective June 15, 2005, the Waiver Amendment effective August 9, 2007 and the Amendment to the Alnylam Co-Exclusive License Agreement dated as of March 14,
2011, by and between Alnylam Pharmaceuticals, Inc., on the one hand, and Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology and Max-Planck-Innovation GmbH, on the other hand; and Co-Exclusive License Agreement between
Max Planck Innovation GmbH (formerly Garching Innovation GmbH) and Alnylam Europe AG (formerly Ribopharma AG), dated July 30, 2003 

  
 47 

 SCHEDULE 1.10 - ALNYLAM EXISTING SUBLICENSES 

 

	1.	InterfeRx Option Agreement between AlCana Technologies, Inc., and Alnylam Pharmaceuticals, Inc., dated December 9, 2009 

 

	2.	License and Collaboration Agreement between Alnylam Pharmaceuticals, Inc. and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd., dated June 29, 2012

  

	3.	License and Collaboration Agreement between Alnylam Pharmaceuticals, Inc. and Genzyme Corporation, dated October 18, 2012 

 

	4.	License and Collaboration Agreement between Monsanto Company and Alnylam Pharmaceuticals, Inc., dated August 27, 2012 

 

	5.	Research Collaboration and License Agreement between Novartis Institutes for BioMedical Research, Inc. and Alnylam Pharmaceuticals, Inc., dated October 12, 2005,
as amended by letter amendment dated May 1, 2011 

  

	6.	Amended and Restated License and Collaboration Agreement among Alnylam Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., and Regulus Therapeutics Inc. (formerly
Regulus Therapeutics LLC), dated January 1, 2009, as amended by amendments dated June 10, 2010 and October 25, 2011 

  

	7.	License and Collaboration Agreement among F. Hoffmann-La Roche Ltd, Hoffman-La Roche Inc., and Alnylam Pharmaceuticals, Inc., dated July 8, 2007, as amended by
letter amendment dated May 29, 2008 (assigned to Arrowhead Research Corporation in October 2011) 

  

	8.	Collaboration Agreement among Alnylam Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., and Hoffman-La Roche Inc., dated October 29, 2009 (assigned to Arrowhead
Research Corporation in October 2011) 

  

	9.	License and Collaboration Agreement between Takeda Pharmaceutical Company Limited and Alnylam Pharmaceuticals, Inc., dated May 27, 2008, as supplemented or amended
by letter agreements dated August 18, 2009 and March 16, 2011 

  

	10.	Supplemental Agreement among Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Protiva Biotherapeutics Inc., the University of British Columbia, and
AlCana Technologies, Inc., dated July 27, 2009 

  
 48 

 SCHEDULE 1.15 – CERTAIN ALNYLAM PATENTS 

 

															
	 Case Number
	  	 Country Name
	  	 Case

Type
	  	 Application
Status
	  	 Application
Number
	  	 Filing Date
	  	 Patent Number
	  	 Issue Date

[**] 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 49 

 SCHEDULE 1.19 - CERTAIN BIODEFENSE TARGETS 

Category A Pathogens: 
 BACTERIA: 

[**] 
 VIRUSES: 

[**] 
 Category B Pathogens: 

BACTERIA: 
 [**] 

VIRUSES: 
 [**] 

Category C Pathogens 
 BACTERIA: 

[**] 
 VIRUSES: 

[**] 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 50 

 SCHEDULE 1.22 - CATEGORY 1 PATENTS 

 

																	
	 Case Number
	  	 Country

Name
	  	 Law

Firm
	  	 Case

Type
	  	 Application
Status
	  	 Application
Number
	  	 Filing

Date
	  	 Patent

Number
	  	 Issue Date

[**] 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 51 

 SCHEDULE 1.23 - CATEGORY 2 PATENTS 

 

																	
	 Case Number
	  	 Country
Name
	  	 Law

Firm
	  	 Case

Type
	  	 Application
Status
	  	 Application
Number
	  	 Filing Date
	  	 Patent

Number
	  	 Issue Date

[**] 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 52 

 SCHEDULE 1.24 - CATEGORY 3 PATENTS 

 

																	
	 Case Number
	  	 Country
Name
	  	 Law

Firm
	  	 Case

Type
	  	 Application
Status
	  	 Application
Number
	  	 Filing

Date
	  	 Patent

Number
	  	 Issue Date

[**] 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 53 

 SCHEDULE 1.70 - TEKMIRA MANUFACTURING DOCUMENTS 

Tekmira Manufacturing Documents are limited to the following documents provided to Alnylam by Tekmira: 

 

	1.	Batch records or master batch records for [**] 

  

	2.	The following technical protocols and reports: [**] 

  

	3.	Specifications for raw materials, components and final products for [**] 

  

	4.	The following technical presentations: [**] 

  

	6.	Production Plans for [**] 

  

	7.	Technical transfer plans for [**] 

  

	8.	[**] 

  

	9.	Minutes of Production Meeting telecons [**] 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 54EX-4.28

			
	Exhibit 4.28 as filed with 20-F	 	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are
designated as [**]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 Exhibit 4.28 
 EXECUTION COPY 
  

 
 LICENSE
AGREEMENT 
 By and Between 
 PROTIVA BIOTHERAPEUTICS INC. 

And 

MARINA BIOTECH, Inc. 

 
  

 TABLE OF CONTENTS 

 

							
	 Article 1 DEFINITIONS AND INTERPRETATION
	  	 	1	  
			
	 1.1
	  	Definitions	  	 	1	  
			
	 1.2
	  	Interpretation	  	 	8	  
		
	 Article 2 LICENSES
	  	 	8	  
			
	 2.1
	  	License Grant	  	 	8	  
			
	 2.2
	  	Sublicense Rights	  	 	9	  
		
	 Article 3 DISCLOSURE AND TRANSFER OF MARINA KNOW-HOW AND COOPERATION
	  	 	9	  
			
	 3.1
	  	Disclosure and Transfer of MARINA Know-How	  	 	9	  
			
	 3.2
	  	Cooperation	  	 	9	  
		
	 Article 4 FINANCIAL PROVISIONS
	  	 	10	  
			
	 4.1
	  	Upfront Payment	  	 	10	  
			
	 4.2
	  	Milestone Payments	  	 	10	  
			
	 4.3
	  	Royalties	  	 	11	  
			
	 4.4
	  	Anti-Stacking Provisions	  	 	12	  
			
	 4.5
	  	Sublicense Fees	  	 	12	  
			
	 4.6
	  	Payment of Royalty and Sublicense Fee Obligations	  	 	12	  
			
	 4.7
	  	Currency Restrictions	  	 	13	  
			
	 4.8
	  	Taxes	  	 	13	  
			
	 4.9
	  	Late Payments	  	 	14	  
			
	 4.10
	  	Audit	  	 	14	  
		
	 Article 5 PAYMENT TERMS
	  	 	14	  
			
	 5.1
	  	Payment Terms	  	 	14	  
			
	 5.2
	  	Currency	  	 	14	  
		
	 Article 6 INTELLECTUAL PROPERTY
	  	 	15	  
			
	 6.1
	  	Ownership of Inventions	  	 	15	  
			
	 6.2
	  	Disclosure of Inventions During the Term	  	 	15	  
			
	 6.3
	  	Perfection of Ownership Rights	  	 	15	  
		
	 Article 7 PATENT PROSECUTION
	  	 	16	  
			
	 7.1
	  	Prosecution and Maintenance	  	 	16	  
			
	 7.2
	  	Updating of Patent Tables	  	 	16	  

							
	 7.3
	  	Consultation and Reporting	  	 	16	  
			
	 7.4
	  	Abandonment, Withdrawal and Discontinuance	  	 	18	  
			
	 7.5
	  	Prosecuting Infringement Proceedings	  	 	19	  
			
	 7.6
	  	Breach of Confidence Proceedings	  	 	20	  
			
	 7.7
	  	Defense of Infringement Proceedings	  	 	20	  
			
	 7.8
	  	Procedures	  	 	20	  
			
	 7.9
	  	Product Trademarks	  	 	21	  
		
	 Article 8 CONFIDENTIALITY
	  	 	21	  
			
	 8.1
	  	Duty of Confidence	  	 	21	  
			
	 8.2
	  	Exceptions	  	 	21	  
			
	 8.3
	  	Authorized Disclosures	  	 	22	  
		
	 Article 9 TERM AND TERMINATION
	  	 	23	  
			
	 9.1
	  	Term	  	 	23	  
			
	 9.2
	  	Termination	  	 	23	  
			
	 9.3
	  	Effect of Termination	  	 	26	  
			
	 9.4
	  	Survival	  	 	26	  
		
	 Article 10 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	27	  
			
	 10.1
	  	Representations and Warranties by Each Party	  	 	27	  
			
	 10.2
	  	Representations and Warranties by MARINA	  	 	27	  
			
	 10.3
	  	Acknowledgements of PROTIVA	  	 	29	  
			
	 10.4
	  	Covenants of MARINA	  	 	29	  
			
	 10.5
	  	No Other Warranties	  	 	30	  
		
	 Article 11 INDEMNIFICATION; LIABILITY
	  	 	30	  
			
	 11.1
	  	Indemnification by MARINA	  	 	30	  
			
	 11.2
	  	Indemnification by PROTIVA	  	 	30	  
			
	 11.3
	  	Indemnification Procedure	  	 	31	  
			
	 11.4
	  	Mitigation of Loss	  	 	33	  
			
	 11.5
	  	Insurance	  	 	33	  
			
	 11.6
	  	Special, Indirect and Other Losses	  	 	33	  
			
	 11.7
	  	No Exclusion	  	 	33	  
		
	 Article 12 PUBLICATIONS AND PUBLICITY
	  	 	33	  
			
	 12.1
	  	Publications	  	 	33	  
			
	 12.2
	  	Publicity	  	 	34	  

  
 ii 

							
		
	 Article 13 GENERAL PROVISIONS
	  	 	34	  
			
	 13.1
	  	Assignment	  	 	34	  
			
	 13.2
	  	Extension to Affiliates; Subcontractors	  	 	35	  
			
	 13.3
	  	Severability	  	 	35	  
			
	 13.4
	  	Governing Law and Jurisdiction	  	 	35	  
			
	 13.5
	  	Force Majeure	  	 	35	  
			
	 13.6
	  	Waivers and Amendments	  	 	36	  
			
	 13.7
	  	Relationship of the Parties	  	 	36	  
			
	 13.8
	  	Notices	  	 	36	  
			
	 13.9
	  	Further Assurances	  	 	36	  
			
	 13.10
	  	Compliance with Law	  	 	36	  
			
	 13.11
	  	No Third Party Beneficiary Rights	  	 	37	  
			
	 13.12
	  	English Language	  	 	37	  
			
	 13.13
	  	Expenses	  	 	37	  
			
	 13.14
	  	Entire Agreement	  	 	37	  
			
	 13.15
	  	Cumulative Remedies	  	 	37	  
			
	 13.16
	  	Counterparts	  	 	38	  
		
	 EXHIBIT A – MARINA PATENTS
	  			
		
	 EXHIBIT B – PRESS RELEASES
	  			

  
 iii

 LICENSE AGREEMENT 

This LICENSE AGREEMENT (“Agreement”) is made as of this
28th day of November, 2012 (“Effective
Date”), by and between PROTIVA BIOTHERAPEUTICS INC., a British Columbia corporation (“PROTIVA”), and MARINA
BIOTECH, INC., a Delaware corporation (“MARINA”). PROTIVA and MARINA are each referred to individually as a “Party” and
together as the “Parties.” 
 RECITALS 
 WHEREAS, MARINA has developed a proprietary platform for creating novel oligonucleotide therapeutics and owns or Controls (as defined below) certain intellectual property relating thereto;
and 
 WHEREAS, PROTIVA wishes to obtain, and MARINA wishes to grant, a license to such intellectual property on
the terms and conditions set forth herein; 
 NOW THEREFORE, in consideration of the mutual covenants and agreements herein contained, the
Parties agree as follows. 
 Article 1 DEFINITIONS AND INTERPRETATION 

 

	1.1	Definitions. 

 Unless the context
otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. 

 

	(a)	“Affiliate” means, with respect to a Person, any other Person that controls, is controlled by, or is under common control with that Person. For the
purpose of this definition, “control” shall mean direct or indirect ownership of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent
(50%) or more of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby the entity or person controls or has the right to control the board of
directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity. In the case of entities organized under the laws of certain countries, the
maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and in such case such lower percentage shall be substituted in the preceding sentence, provided, that such foreign investor has the
power to direct the management and policies of such entity. 

  

	(b)	“Agreement” shall have the meaning set forth in the preamble. 

 

	(c)	“Applicable Law” means all applicable laws, rules, ordinances, and regulations, including any rules, regulations, guidelines or other requirements of
relevant government agencies, that may be in effect from time to time in the applicable country or jurisdiction, applicable to the specific activities being undertaken pursuant to this Agreement. 

	(d)	“Business Day” means any day that is not a Saturday, a Sunday, or other day which is a statutory holiday in the Province of British Columbia, Canada or
a Federal holiday in the State of Washington, U.S.A. 

  

	(e)	“Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30
and December 31. 

  

	(f)	“Calendar Year” means each successive period of twelve (12) months commencing on January 1 and ending on December 31.

  

	(g)	“Claims” means all Third Party demands, claims, actions, proceedings and liabilities (whether criminal or civil, in contract, tort or otherwise) for
losses, damages, reasonable legal costs and other reasonable expenses of any nature whatsoever. 

  

	(h)	“Combination Product” means a single Product or a co-packaged Product in dosage form that includes one or more UNAs and one or more Other APIs. All
reference to Product in this Agreement shall be deemed to include Combination Products, to the extent applicable. 

  

	(i)	“Commercialize” or “Commercialization” means those activities comprising or relating to the manufacturing, promotion, marketing,
advertising, distribution and sale of PROTIVA Products, including Phase IV trials or equivalent clinical trials conducted following Regulatory Approval as needed or useful to promote and market the Licensed Product and/or maintain
such Regulatory Approval. 

  

	(j)	“Commercially Reasonable Efforts” means, with respect to particular tasks or activities hereunder in developing or Commercializing a
PROTIVA Product, a level of efforts applied to such tasks or activities reasonably consistent with the efforts commonly used by similarly-situated companies in the pharmaceutical industry (taking into account, among other things, the
size, available resources, available funding, product lines and other relevant characteristics of such companies) to conduct such activities on products at a similar (as compared to the PROTIVA Product at the applicable time) stage in
its product life and of similar market potential, profit potential and strategic value resulting from its own research efforts, based on information and conditions then-prevailing, including, without limitation, efficacy of the product, the
competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood of regulatory approval given the regulatory structure involved and the likelihood of adequate reimbursement.
Commercially Reasonable Efforts shall be determined on a country by country or market-by-market basis (as most applicable) for a particular PROTIVA Product, and it is anticipated that the level of effort will change over time
reflecting changes in the status of the PROTIVA Product and the country (or markets) involved. 

  

	(k)	 “Confidential Information” means all Know-How and other confidential and/or proprietary information and data of a financial,
commercial, scientific or technical nature owned or Controlled by a disclosing Party or entrusted to a disclosing Party by a Third Party with the right to disclose, and which the disclosing Party or any of its Affiliates has supplied or otherwise
made available to the other Party or its Affiliates, whether made available orally, in writing or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae in relation to this

  
 2 

	 	
Agreement. For purposes hereof, this Agreement and the terms hereof shall be deemed to be the Confidential Information of both Parties, subject to the rights of disclosure set forth in Article 8
and Subsections 12.2(b) and 12.2(c). 

  

	(l)	“Control” or “Controlled” means, with respect to any Know How, Patents, other Intellectual Property Rights, or any confidential,
proprietary or trade secret information, the legal authority or right (whether by ownership, license or otherwise) of a Party to grant a license or a sublicense of or under such Know How, Patents, or Intellectual Property Rights to another Person,
or to otherwise disclose such proprietary or trade secret information to another Person, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.

  

	(m)	“Effective Date” shall have the meaning set forth in the first paragraph of this Agreement. 

 

	(n)	“Feasibility Studies” shall have the meaning set forth in Section 4.1(b). 

 

	(o)	“Field” shall mean all uses and purposes for the development of human therapeutics. 

 

	(p)	“First Commercial Sale” means, with respect to a particular country, the first commercial sale of a PROTIVA Product in a country by
PROTIVA or its Affiliates to a Third Party or by a Sublicensee or its Affiliates to an unaffiliated Person, after all needed Regulatory Approvals for the Licensed Product have been granted in such country. 

 

	(q)	“Generic Product” means, with respect to a PROTIVA Product, a generic product in a formulation similar to and substitutable for such
PROTIVA Product. 

  

	(r)	“Indemnification Claim Notice” shall have the meaning set forth in Subsection 11.3(b). 

 

	(s)	“Indemnified Party” shall have the meaning set forth in Subsection 11.3(b). 

 

	(t)	“Indemnifying Party” shall have the meaning set forth in Subsection 11.3(b). 

 

	(u)	“Intellectual Property Rights” means all intellectual property rights subject to protection by intellectual property laws in any country of the world,
arising under statutory or common law, contract, or otherwise, and whether or not perfected, including without limitation: 

  

	 	(i)	all rights under Patents; 

  

	 	(ii)	all rights associated with works of authorship including without limitation, copyrights, moral rights, copyright applications, copyright registrations, synchronization
rights, mask work rights, mask work applications, mask work registrations; 

  

	 	(iii)	all rights relating to the protection of trade secrets, know-how (including Know-How) and confidential information (including Confidential Information); and

  

	 	(iv)	all rights analogous to those set forth in this subsection above and any and all other proprietary rights relating to intangible property 

 

	(v)	“Invention” means all discoveries, inventions, developments, improvements, Know-How, writings or rights conceived, discovered, invented, developed,
created, made or reduced to practice. 

  
 3 

	(w)	“Joint IP” shall have the meaning set forth in Subsection 6.1(b). 

 

	(x)	“Know-How” means all technical information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets,
specifications, instructions, processes, formulae, materials, expertise and other technology applicable to compounds, biologics, formulations, compositions, products or to their manufacture, development, registration, use or commercialization or
methods of assaying or testing them or processes for their manufacture, formulations containing them, compositions incorporating or comprising them and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical,
physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and information, regulatory filings and copies thereof, relevant to the development, manufacture, use or
commercialization of and/or which may be useful in studying, testing, development, production or formulation of products, or intermediates for the synthesis thereof. 

 

	(y)	“License Fee” shall have the meaning set forth at Section 4.1(c). 

 

	(z)	“MAA” (marketing authorizing application) means an application for the authorization to market a Product in any country or group of countries outside
the United States, as defined in the applicable laws and regulations and filed with the Regulatory Authority of a given country or group of countries. 

  

	(aa)	“Major Market” means [**]. For clarity, obtaining Regulatory Approval of PROTIVA Product from [**], which approval applies [**] (as then
constituted), shall be deemed to be obtaining a Regulatory Approval in a Major Market for purposes of the applicable provisions of this Agreement. 

  

	(bb)	“MARINA Indemnitees” shall have the meaning set forth in Section 11.2. 

 

	(cc)	“MARINA Inventions” shall have the meaning set forth in Subsection 6.1(a). 

 

	(dd)	 “MARINA Know-How” means the Know-How owned or Controlled by MARINA or its Affiliates on and after the
Effective Date relating to the UNA® Platform Technology. The MARINA Know-How shall also include
the UNA® Data. 

 

	(ee)	“MARINA Patents” means the Patents identified in Exhibit A and any other Patents owned or Controlled by MARINA or
its Affiliates on or after the Effective Date that have claims covering any aspect of the UNA Platform Technology, including Patents arising from MARINA Inventions. 

 

	(ff)	“MARINA Technology” means MARINA Patents and MARINA Know-How and MARINA Inventions.

  

	(gg)	“Milestone Event” shall have the meaning set forth in Section 4.2. 

 

	(hh)	“NDA” means a New Drug Application, as defined in 21 C.F.R. 314, and any other appropriate application or registration submitted to the appropriate
Regulatory Authority in a particular country in the Territory to seek Regulatory Approval for sale of Licensed Product in such country. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 4 

	(ii)	“Net Sales” means the gross invoice price of Product sold by PROTIVA or its Affiliates to the first Third Party (or by a Sublicensee or
its Affiliates to a non-affiliated Person in any arm’s length transaction) after deducting, if not previously deducted, from the amount invoiced or received: 

 

	 	(i)	trade and quantity discounts other than early pay cash discounts; 

  

	 	(ii)	returns, rebates, chargebacks and other allowances; 

  

	 	(iii)	retroactive price reductions that are actually allowed or granted; 

  

	 	(iv)	sales commissions paid to Third Party distributors and/or selling agents (which shall not be deemed to include contract sales organizations); and

  

	 	(v)	bad debt, sales or excise taxes, early payment cash discounts, transportation and insurance, custom duties, and other governmental charges. 

For clarity, Net Sales shall not include funds: 
  

	 	(vi)	derived from the transfer or sale of Product between any of PROTIVA and its Affiliates (or between any Sublicensee and its Affiliates);

  

	 	(vii)	derived from the transfer or sale of Product by PROTIVA or its Affiliates to a Third Party (or by a Sublicensee or its Affiliates to a non-affiliated
Person) for the development or analytical, preclinical or clinical testing of a Product; 

  

	 	(viii)	derived from the transfer or sale of reasonable quantities of Product by PROTIVA or its Affiliates to a Third Party (or by a Sublicensee or its
Affiliates to a non-affiliated Person) for samples, donations or compassionate use; and 

  

	 	(ix)	constituting Sublicensing Revenue. 

 Any Product sold in other than in an arm’s length transaction or for other property (e.g., barter) shall be deemed invoiced at its fair market value. The calculation of Net Sales of any Combination
Product shall, subject to the exclusions set forth above and be calculated using one of the following methods: 
  

	 	(x)	by multiplying the annual Net Sales of the Combination Product during the applicable royalty accounting period by a fraction, the numerator of which is the aggregate
gross selling price of the Product contained in the Combination Product if sold separately, and the denominator of which is the sum of the gross selling price of both the Product and the Other API(s) contained in the Combination Product if sold
separately; or 

  

	 	(xi)	if no such separate sales are made of any of the Product or the Other APIs during the applicable accounting period, or if any of the Product or the Other APIs have not
been sold separately for at least one (1) year, PROTIVA shall calculate Net Sales of such Combination Product by the fraction C/C+D, where C is a reasonable estimate of the fair market value of the Product portion of such
Combination Product, D is a reasonable estimate of the fair market value of the Other API(s) in such Combination Product, and the estimates of C and D are determined by mutual agreement of the Parties negotiating in good faith.

  
 5 

	(jj)	“Other API” means an active, proprietary pharmaceutical ingredient that is not an UNA and that, if administered independently, would have a clinical
effect. 

  

	(kk)	“Party” shall have the meaning set forth in the preamble. 

 

	(ll)	“Patents” means all patents and patent applications, author certificates, inventor certificates, utility certificates, improvement patents and models
and certificates of addition and all foreign counterparts of them and including all divisionals, continuations, substitutions, confirmations, continuations-in-part, re-registrations, re-examinations, reissues, additions, renewals, extensions,
registrations, and supplemental protection certificates and the like of any of the foregoing. 

  

	(mm)	“Person” means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other
entity. 

  

	(nn)	“Product” means any product or process covered by a claim in a MARINA Patent or otherwise utilizing or incorporating
MARINA Know-How. 

  

	(oo)	“PROTIVA Indemnitees” shall have the meaning set forth in Section 11.1. 

 

	(pp)	“PROTIVA Product” shall have the meaning set forth in Section 2.2. 

 

	(qq)	“Regulatory Approval” means all approvals (including supplements, amendments, pre- and post-approvals and price approvals), licenses, registrations or
authorizations necessary for the manufacture, distribution, use or sale of a Licensed Product in the applicable country or regulatory jurisdiction. 

  

	(rr)	“Regulatory Authority” means any governmental agency or authority responsible for granting Regulatory Approvals for Products, including the United
States Food and Drug Administration, the European Medicines Agency, or any successor entities thereto and any corresponding national or regional regulatory authorities. 

 

	(ss)	“Regulatory Filings” means any submission to a Regulatory Authority of any appropriate regulatory application, and shall include, without limitation,
any submission to a regulatory advisory board, MAA, and any supplement or amendment thereto. For the avoidance of doubt, Regulatory Filings shall include any Investigational New Drug (IND), New Drug Application (NDA) or the corresponding application
in any other country or group of countries. 

  

	(tt)	“Royalties Report” shall have the meaning set forth in Section 4.6. 

 

	(uu)	“Royalty Term” means, as to a particular PROTIVA Product sold in a country, the period from the date of First Commercial Sale of such
PROTIVA Product in such country until the later of: 

  

	 	(i)	the date of expiration of the last to expire issued Patent included in the MARINA Patents having a Valid Claim that claims the PROTIVA
Product in such country; or 

  
 6 

	 	(ii)	[**] after such First Commercial Sale of the Licensed Product in a Major Market. 

 

	(vv)	“Sublicensee” means a Person to whom PROTIVA or its Affiliate has granted a sublicense agreement under PROTIVA’s
rights pursuant to Section 2.2. 

  

	(ww)	“Sublicense Fees” shall have the meaning set forth in Section 4.5. 

 

	(xx)	“Sublicensing Revenue” means all consideration received by PROTIVA (or its Affiliates) from a Sublicensee in consideration of the grant
of a sublicense under the MARINA Patents to such Sublicensee (which may include upfront fees, milestone payments and other similar fees), but excluding: 

 

	 	(i)	royalties payable to PROTIVA (or its Affiliates) based on Net Sales by a Sublicensee or its Affiliates; 

 

	 	(ii)	any amounts paid as reimbursement of research or development costs and expenses incurred by PROTIVA or its Affiliates (including past and ongoing costs
and expenses) relating to PROTIVA Products; 

  

	 	(iii)	direct reimbursement of Patent prosecution or enforcement costs; 

  

	 	(iv)	payments of a share of amounts recovered in enforcing Patent or other Intellectual Property Rights (except to the extent such share is calculated or treated as
royalties under the terms of such sublicense); 

  

	 	(v)	transfer price payments for sale of compounds or products (such exclusion not to exceed [**] of actual fully-burdened cost of goods); 

 

	 	(vi)	bona fide loans on commercial terms; and 

  

	 	(vii)	any payments made to purchase equity in PROTIVA or a PROTIVA Affiliate at fair market value. 

 

	(yy)	“Term” means the term of this Agreement as set forth in Section 9.1. 

 

	(zz)	“Territory” means all countries of the world. 

  

	(aaa)	“Third Party” means any Person other than a Party or an Affiliate of a Party. 

 

	(bbb)	“Third Party Claim” means any claim, action, allegation, suit or legal proceeding brought by a Third Party against another entity or person.

  

	(ccc)	“UNA” means an unlocked nucleobase analog. 

  

	(ddd)	“UNA Data” means all data and information owned or Controlled by MARINA relating to the structure, activity and/or other characteristics
of the UNA Platform Technology. 

  

	(eee)	“UNA Platform Technology” means the technology for the development, production and use of UNAs and compounds containing one or more UNAs, including,
without limitation, Know-How relating to the manufacture, formulation, ingredients, preparation, presentation, means of delivery, dosage or packaging of such UNAs, all as in existence as of the Effective Date. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 7 

	(fff)	“United States” or “US” means the United States of America, its territories and possessions. 

 

	(ggg)	“Upfront Payment” shall have the meaning set forth in Subsection 4.1(a). 

 

	(hhh)	“USD” or “US$” means the lawful currency of the United States. 

 

	(iii)	“Valid Claim” means an unexpired claim of an issued Patent within the MARINA Patents that has not been ruled to be unpatentable, invalid
or unenforceable by a court or other authority in the country of the Patent with competent jurisdiction, from which decision no appeal is taken or can be taken. 

 

	1.2	Interpretation. 

 In this agreement unless
otherwise specified: 
  

	(a)	“includes” and “including” shall mean respectively includes and including without limitation; 

 

	(b)	a Party includes its permitted assignees and/or their respective permitted successors in title to substantially the whole of its undertaking; 

 

	(c)	a statute or statutory instrument or any of their provisions is to be construed as a reference to that statute or statutory instrument or such provision as the same may
have been or may from time to time hereafter be amended or re-enacted; 

  

	(d)	words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders; 

 

	(e)	the Exhibits and other attachments form part of the operative provision of this Agreement and references to this Agreement shall, unless the context otherwise requires,
include references to the Exhibits and attachments; 

  

	(f)	the headings in this Agreement are for information only and shall not be considered in the interpretation of this Agreement; 

 

	(g)	general words shall not be given a restrictive interpretation by reason of their being preceded or followed by words indicating a particular class of acts, matters or
things; and 

  

	(h)	the Parties agree that the terms and conditions of this Agreement are the result of negotiations between the Parties and that this Agreement shall not be construed in
favor of or against any Party by reason of the extent to which any Party participated in the preparation of this Agreement. 

 Article 2 LICENSES 
  

	2.1	License Grant. 

 Subject to the terms and
conditions of this Agreement, MARINA hereby grants to PROTIVA and its Affiliates a non-exclusive, irrevocable (subject to Subsection 9.2(c)), perpetual, worldwide license, with the right to grant sublicenses as
permitted in Section 2.2, under the MARINA Technology to research, develop, make, have made, use, import, offer for sale, sell, have sold, commercialize and otherwise exploit any Product in the Field in the Territory. 

  
 8 

	2.2	Sublicense Rights. 

PROTIVA may sublicense to a Third Party the rights granted to it by MARINA under Section 2.1 at any time at its sole
discretion, but only in connection with: 
  

	(a)	the continuing research, development and or commercialization of a PROTIVA Product or the manufacturing of a PROTIVA Product by such Third
Party or its Affiliates, either itself or as part of a collaboration with PROTIVA or any of its Affiliates, or 

  

	(b)	the sublicense of a technology platform consisting of the use of PROTIVA’s proprietary lipid nano-particle technology in combination with
MARINA Technology. 

 A “PROTIVA Product” means any Product with respect to which
PROTIVA or any of its Affiliates has conducted research, manufacturing, development activities that are related to such Product. For the avoidance of doubt, this Section 2.2 shall not include any right by PROTIVA
to grant a “naked” sublicense of MARINA Technology alone. 
 Article 3 DISCLOSURE AND TRANSFER OF
MARINA KNOW-HOW AND 
 COOPERATION 

 

	3.1	Disclosure and Transfer of MARINA Know-How. 

 As soon as reasonably possible after the Effective Date (and in any event within ten (10) days after the Effective Date), MARINA, without additional consideration, shall use good
faith, diligent efforts to disclose to PROTIVA or its designated Affiliate all MARINA Know-How in existence as of the Effective Date and shall provide such copies of any existing tangible embodiment thereof in written
or electronic form as may be reasonably requested by PROTIVA, including delivery of an electronic copy of the UNA Data in a commonly usable format (to the extent in existence on the date hereof). Such disclosures shall include all
MARINA Know-How and any other data, information and documents known to and Controlled by MARINA as of the Effective Date which may be necessary or useful to PROTIVA to practice the licenses granted
hereunder efficiently. 
  

	3.2	Cooperation. 

 Upon request by
PROTIVA within a reasonable period after disclosure by MARINA of the MARINA Know-How and other data, information and documents pursuant to Section 3.1, MARINA will provide reasonable
assistance to PROTIVA or its designated Affiliate in connection with understanding and using the MARINA Know-How for purposes consistent with licenses and rights granted to PROTIVA hereunder;
provided, that PROTIVA shall promptly pay or reimburse MARINA for any travel or other out-of-pocket expenses incurred by MARINA in connection with providing such assistance requested by
PROTIVA. 

  
 9 

 Article 4 FINANCIAL PROVISIONS 

 

	4.1	Upfront Payment. 

  

	(a)	In partial consideration of the rights granted by MARINA to PROTIVA under this Agreement, PROTIVA shall pay to
MARINA within [**] of the Effective Date a non-refundable, non-creditable upfront payment in the amount of [**] (the “Upfront Payment”). 

 

	(b)	[**] 

  

	(c)	[**] 

  

	4.2	Milestone Payments. 

  

	(a)	In partial consideration of the license rights granted by MARINA under this Agreement, PROTIVA shall pay to MARINA a
milestone payment upon first achievement by PROTIVA or an Affiliate (but not by any Sublicensee, as further set forth below in this Section 4.2) of the applicable milestone event set forth in the table below (each such event, a
“Milestone Event”), such payments to be in the listed amounts for the applicable Milestone Event: 

  

					
	 Milestone Event
	  	Milestone Payment	 
	 For each PROTIVA Product directed to a specific gene target:
	  			
	 (1) [**]
	  	 	[**]	  
	 (2) [**]
	  	 	[**]	  
	 (3) [**]
	  	 	[**]	  

  

	(b)	For clarity each of the above milestone payments shall be paid only once for a particular PROTIVA Product directed to a specific gene target, regardless
if any such Milestone Event is achieved more than once for that particular PROTIVA Product directed to a specific gene target. 

  

	(c)	For additional clarity, where PROTIVA has entered into a sublicense agreement with a Sublicensee who has been granted rights to commercialize a
PROTIVA Product directed to a specific gene target, PROTIVA shall not be liable to pay any milestone payments on account of the achievement by the Sublicensee (alone, or in collaboration with PROTIVA or
any of its Affiliates) of any of the foregoing Milestone Events; but instead, any payments received by PROTIVA on account of the Sublicensee’s milestone achievement shall be included in Sublicensing Revenue and
PROTIVA shall pay to MARINA the applicable Sublicense Fees pursuant to Section 4.5 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 10 

	(d)	PROTIVA shall promptly notify MARINA of the achievement of any Milestone Event for each PROTIVA Product directed to a
specific gene target. All milestone payments under Subsection 4.2(a) are non-refundable and non-creditable, and shall be due within [**] of achievement of the applicable Milestone Event. 

 

	4.3	Royalties. 

 In partial consideration of
the license rights granted by MARINA under this Agreement, PROTIVA shall pay to MARINA a royalty on Net Sales of PROTIVA Products by PROTIVA or any of its Affiliates during
the Royalty Term as follows: 
  

	(a)	For sales of a PROTIVA Product in any country in the Territory where such sale would infringe, absent the license granted in Section 2.1, a Valid
Claim of an issued MARINA Patent, PROTIVA shall pay to MARINA a royalty on Net Sales of such PROTIVA Product calculated using the royalty rate set opposite the amount of Net Sales in the
table below: 

  

					
	 Net Sales in a Calendar Year
	  	Royalty Rate	 
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  

  

	(b)	For sales of a PROTIVA Product in any country in the Territory where either (i) there are no Valid Claims covering the PROTIVA
Product that would be infringed, absent the license granted in Section 2.1, by a sale of such PROTIVA Product, or (ii) sales of Generic Products exist alongside sales of the PROTIVA Product,
PROTIVA shall pay to MARINA a reduced royalty on Net Sales of such PROTIVA Product calculated using the royalty rate set opposite the amount of Net Sales in the table below: 

 

					
	 Net Sales in a Calendar Year
	  	Royalty Rate	 
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  

 provided, however, that the royalty obligation under this Subsection 4.3(b) in respect
of such PROTIVA Product in all countries in the Territory shall cease upon the [**] anniversary of the First Commercial Sale of such PROTIVA Product in any Major Market country. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 11 

	4.4	Anti-Stacking Provisions. 

 If
PROTIVA or its Affiliate owes to one or more Third Parties, under license agreement(s) granting PROTIVA (or its Affiliate or Sublicensee) Intellectual Property Rights that are needed to make, use, sell or otherwise
commercialize the MARINA Technology as contained in the PROTIVA Product, royalties or similar payments on sales of such PROTIVA Products, then PROTIVA may reduce the royalties owed to
MARINA under Section 4.3 by [**] of the royalty or similar payments actually paid to such Third Parties, provided that PROTIVA shall not reduce any particular royalty payment to MARINA by more than
[**] of the amount otherwise owed under Section 4.3 for the applicable royalty period. 
  

	4.5	Sublicense Fees. 

 In partial
consideration of the license rights granted by MARINA under this Agreement, including specifically the right to sublicense such rights under Section 2.2, PROTIVA shall pay to MARINA an amount (the
“Sublicense Fees”) equal to a percentage of Sublicensing Revenue received by PROTIVA (or its Affiliate) from its Sublicensees pursuant to such sublicenses. The percentage of Sublicensing Revenue payable by
PROTIVA to MARINA shall be determined by the development stage of the PROTIVA Product that is the subject of the sublicense at the time PROTIVA or its Affiliate and the Sublicensee execute
such sublicense, as follows: 
  

					
	 Development Stage
 at Time of Sublicense Execution
	  	Percentage of
Sublicensing Revenue	 
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  

  

	4.6	Payment of Royalty and Sublicense Fee Obligations. 

 The royalty obligation under Section 4.3 shall accrue upon the sales of a PROTIVA Product in each particular country in the Territory, commencing upon First Commercial Sale after
Regulatory Approval of the PROTIVA Product in such country and, except as otherwise provided under Subsection 4.3(b), such obligation shall end upon the expiration of the Royalty Term applicable to such PROTIVA
Product in such country. All such royalty payments are non-refundable and non-creditable and shall be due within [**] after the end of each Calendar Quarter and are payable in immediately available funds. The Sublicense Fees owed under
Section 4.5 shall be paid, with respect to particular Sublicensing Revenue received by PROTIVA, within [**] after PROTIVA’s receipt of the applicable revenues, and are payable in immediately available funds.
PROTIVA shall notify MARINA in writing promptly upon the First Commercial Sale of each PROTIVA Product in each country and thereafter PROTIVA shall furnish MARINA with

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 12 

 
a written report (the “Royalties Report”) for each completed Calendar Quarter showing, on a country-by-country basis, according to the volume of units of PROTIVA
Products sold in each such country (by SKU) during the reporting period (whether PROTIVA Product is sold by PROTIVA or its Affiliates or Sublicensees): 

 

	(a)	the gross invoiced sales of the PROTIVA Product sold in each country during the reporting period, and the amounts deducted therefrom to determine Net
Sales from such gross invoiced sales; 

  

	(b)	the royalties payable in dollars, if any, which shall have accrued hereunder based upon such Net Sales; and 

 

	(c)	the withholding taxes, if any, required by Applicable Law to be deducted in respect of such sales (provided that, as to sales by Sublicensees, PROTIVA
shall report only the net sales numbers (using the definition for such term in the applicable Sublicense) as reported by the Sublicensee, if such Sublicensee does not report gross invoiced sales numbers). 

With respect to sales of PROTIVA Products invoiced in US dollars, the gross invoiced sales, Net Sales and royalties payable shall be
expressed in the Royalties Report in US Dollars. With respect to sales of PROTIVA Products invoiced in a currency other than US Dollars, the gross invoiced sales, Net Sales and royalties payable shall be expressed in the Royalties
Report in the domestic currency of the party making the sale as well as in the US Dollar equivalent of the royalties payable and the exchange rate used in determining the amount of US dollars. The US dollar equivalent shall be calculated on a
calendar-month basis using the average monthly interbank rate listed in The Wall Street Journal. 
  

	4.7	Currency Restrictions. 

 If at any time
legal restrictions in any country in the world prevent the prompt remittance of any payments with respect to sales in that country, PROTIVA shall have the right and option upon written notice to MARINA to make (or to
cause its Sublicensee to make) such payments by depositing the amount thereof in local currency to MARINA’s account (or such other designated nominee by MARINA) in a bank or depository in such country. 

 

	4.8	Taxes. 

 In the event that laws, rules or
regulations require PROTIVA to withhold taxes with respect to any payment to be made by PROTIVA to MARINA pursuant to this Agreement, PROTIVA will notify MARINA of such
withholding requirement prior to making the payment to MARINA. Any and all taxes levied by a proper taxing authority required to be withheld by PROTIVA or its Sublicensees on account of royalties accruing to
MARINA under this Agreement may be deducted from such royalty payment provided that (a) such amount is promptly paid for and on behalf of MARINA to the appropriate tax authorities, and
(b) PROTIVA furnishes MARINA with official tax receipts or other appropriate evidence of payment issued by the appropriate tax authorities. PROTIVA shall provide such assistance to
MARINA, including the provision of such documentation as may be required by a tax authority, as may be reasonably necessary in MARINA’s efforts to claim an exemption from or reduction of such taxes. 

  
 13 

	4.9	Late Payments. 

 All fees and royalties
not received by MARINA when due under this Agreement shall bear interest from the date they were due until the date they are paid at a rate equal to the then current 30-day United States dollar LIBOR rate plus two percent per annum or
the maximum rate permitted by law, whichever is less. Notwithstanding anything to the contrary in this Agreement, PROTIVA shall have no obligation to pay royalties to MARINA pursuant to Section 4.3 until
PROTIVA actually receives revenue from Net Sales. 
  

	4.10	Audit. 

 PROTIVA and its
Affiliates shall keep complete and accurate records of the underlying revenue and expense data relating to the calculations of Net Sales, Sublicensing Revenue and payments required under this Agreement. MARINA shall have the right, at
its own expense and no more than once per Calendar Year, to have an independent, certified public accountant, selected by MARINA and reasonably acceptable to PROTIVA, review all such records upon reasonable notice and
during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments required and made under this Agreement within the prior [**] period. No Calendar Quarter may be audited
more than one time. PROTIVA shall receive a copy of each audit report promptly from MARINA. Should the inspection lead to the discovery of a discrepancy to MARINA’s detriment, PROTIVA
shall pay the amount of the discrepancy in MARINA’s favor within [**] after being notified thereof. MARINA shall pay the full cost of the inspection unless the discrepancy is greater than [**], in which case
PROTIVA shall pay to MARINA the actual cost charged by such accountant for such inspection. If such audit shows a discrepancy in PROTIVA’s favor, then PROTIVA may credit the amount of
such discrepancy against subsequent amounts owed to MARINA, or if no further amounts are owed under this Agreement, then MARINA shall pay PROTIVA the amount of the discrepancy within [**] after being
notified thereof. 
 Article 5 PAYMENT TERMS 

 

	5.1	Payment Terms. 

 All payments from
PROTIVA to MARINA shall be made by wire transfer to the credit of such bank account as may be designated by MARINA in this Agreement or in writing to PROTIVA. Any payment which falls due on
a date which is not a Business Day may be made on the next succeeding Business Day. 
  

	5.2	Currency. 

 All payments under this
Agreement shall be paid in US dollars. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 14 

 Article 6 INTELLECTUAL PROPERTY 

 

	6.1	Ownership of Inventions. 

 Subject to
Section 6.2, as between PROTIVA and MARINA: 
  

	(a)	all Inventions of any kind whatsoever first conceived, reduced to practice, developed or created by MARINA or its Affiliates, alone or with any Third
Party, prior to or during the Term relating to UNA or the UNA Platform Technology (“MARINA Inventions”) shall be owned by MARINA; and 

 

	(b)	all Inventions of any kind whatsoever first conceived, reduced to practice, developed or created by one or more Persons acting on behalf of MARINA or its
Affiliates (or any Third Party acting under its direction) together with one or more Persons acting on behalf of PROTIVA or its Affiliates (or any Third Party acting under its direction) during the Term relating to UNA or the UNA
Platform Technology (“Joint IP”), shall be jointly owned by the Parties. Neither Party shall assign its rights to Joint IP without the prior written consent of the other Party. 

Inventorship and authorship will be determined under the applicable rules and precedents prevailing in the United States. 

 

	6.2	Disclosure of Inventions During the Term. 

If, within [**] after the Effective Date and during the Term, MARINA becomes the owner, solely or jointly, of any additional Intellectual
Property Rights that constitute MARINA Inventions, whether developed in the performance of this Agreement or (unless prohibited by the terms of any agreement between MARINA and a Third Party) outside the framework of
this Agreement, and whether or not patentable, MARINA will notify PROTIVA in writing within [**] of becoming aware of any such disclosable MARINA Inventions. MARINA shall, throughout the Term, provide
status updates on any additional Intellectual Property Rights that constitute disclosable MARINA Inventions at such times and in such manner as may be mutually agreed by the Parties, provided that during the first two (2) years
during the Term, the Parties shall meet no less frequently than on a Calendar Quarterly basis. 
  

	6.3	Perfection of Ownership Rights. 

 Each
Party will ensure that its employees and contractors who perform any obligations under this Agreement have entered into written agreements with such Party under which its employees and contractors assign to such Party all ownership rights in any
Intellectual Property Rights made or developed by its employees and contractors in the course of work for such Party. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 15 

 Article 7 PATENT PROSECUTION 

 

	7.1	Prosecution and Maintenance. 

  

	(a)	All Patent applications included in the MARINA Patents and, upon issuance, all resulting issued Patents therefrom, shall be filed, prosecuted and
maintained by MARINA, at its sole cost and expense and in its discretion, which shall be exercised in good faith, in accordance with this Article 7. 

 

	(b)	All Patent applications arising from Joint IP and, upon issuance, all resulting issued Patents therefrom, shall be filed, prosecuted and maintained by
PROTIVA, at its sole cost and expense and in its discretion, which shall be exercised in good faith, in accordance with this Article 7. 

  

	(c)	Without limiting the generality of the foregoing, MARINA and PROTIVA shall in the performance of their respective obligations under
Subsections 7.1(a) and 7.1(b), be responsible for: 

  

	 	(i)	the continued prosecution of any pending Patent applications; 

  

	 	(ii)	the maintenance of all such issued Patents; and 

  

	 	(iii)	the filing and prosecution of additional Patent applications (and maintenance of Patents thereon) in any jurisdiction world-wide, on a commercially reasonable basis,
including, without limitation, any continuations, continuations-in-part, divisionals, Patents of addition, reissues, re-examinations, supplemental protection certificates, renewals and extensions or substitutes therefore. 

 

	7.2	Updating of Patent Tables. 

  

	(a)	The table of licensed Patents in Exhibit A (“Table of Licensed Patents”) will be deemed to be a living document continually updated by notice
from MARINA to PROTIVA of Patent filing, prosecution, maintenance and discontinuation of any MARINA Patents. 

  

	(b)	PROTIVA shall create and maintain a table of Patents arising from Joint IP (“Table of Jointly Owned Patents”), which table will be
deemed to be a living document continually updated by notice from PROTIVA to MARINA of Patent filing, prosecution, maintenance and discontinuation of any Patents arising from Joint IP. 

 

	(c)	By way of non-limiting example, a Patent application shall be deemed to have been added to the Table of Licensed Patents or to the Table of Jointly Owned Patents, as
applicable, on the date that such Patent application is submitted to the US Patent and Trademarks Office or any foreign equivalent. 

  

	7.3	Consultation and Reporting. 

  

	(a)	On a timely basis, MARINA will consult with PROTIVA on all material actions to be taken with respect to the filing, prosecution and
maintenance of the MARINA Patents, including claims and any proposed amendments thereto. PROTIVA will have the right to comment on MARINA’s proposed actions and to identify any process, uses or
Products arising out of the MARINA Technology that may be patentable and MARINA will reasonably consider such comments. 

  
 16 

	(b)	On a timely basis, PROTIVA will consult with MARINA on all material actions to be taken with respect to the filing, prosecution and
maintenance of any Patents arising from Joint IP, including claims and any proposed amendments thereto. MARINA will have the right to comment on PROTIVA ’s proposed actions and to identify any process, uses or
Products arising out of the Joint IP that may be patentable and PROTIVA will reasonably consider such comments. 

  

	(c)	In the performance of their respective obligations under Section 7.1, MARINA will disclose to PROTIVA in respect of the
MARINA Patents, and PROTIVA will disclose to MARINA in respect of the Patents arising from Joint IP, on a timely basis: 

 

	 	(i)	the complete text of each Patent application and issued Patent within the MARINA Patents or Patents arising from Joint IP, as applicable; and

  

	 	(ii)	all material communications to and from the patent office, including communications concerning the institution or possible institution of any interference, opposition,
re-examination, reissue, revocation, nullification or any official proceeding involving any of the MARINA Patents or Patents arising from Joint IP, as applicable. 

 

	(d)	If MARINA desires additional claims to be filed, prosecuted and maintained under any Patents arising from Joint IP for MARINA or its
sublicensees’ uses outside the Field, MARINA will: 

  

	 	(i)	notify PROTIVA in writing setting forth the specific claims, jurisdiction and nature of Patent protection required by MARINA; and

  

	 	(ii)	request that PROTIVA file a divisional application with such additional claims and either (A) oversee the prosecution of such divisional
application, at its cost and expense, in which case MARINA will keep PROTIVA informed of the progress thereof, or (B) have PROTIVA oversee the prosecution of such divisional application, and
reimburse PROTIVA for all costs and expenses (including PROTIVA’s external patent counsel costs) incurred by PROTIVA in pursuing such additional claims (“Patent Prosecution Fees”).

 All Patent Prosecution Fees shall be due and payable to PROTIVA within [**] of
MARINA’S receipt of each invoice from PROTIVA, with interest on late payment calculated in accordance with Section 4.9. Notwithstanding anything to the contrary in this Agreement,
PROTIVA reserves the right to offset any unpaid Patent Prosecution Fees and accrued interest against any payments due by PROTIVA to MARINA hereunder. 

 

	(e)	Notwithstanding Section 7.4, MARINA shall instruct its patent counsel retained from time to time in the Territory for the filing, prosecution and
maintenance of the MARINA Patents to forthwith notify PROTIVA in writing in the event of any of the following: 

  

	 	(i)	MARINA fails to pay when due any statement of account or invoice issued by such patent counsel in respect of the MARINA Patents;

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 17 

	 	(ii)	MARINA fails to provide to its patent counsel instructions relating to the filing, prosecution or maintenance of any of the Marina Patents, or any other
proceeding relating thereto, that could reasonably, if left unattended, compromise the continued prosecution of any patent application, the issuance of any patent, the validity of any issued patent, the outcome of any proceeding relating to the
MARINA Patents or otherwise impair any Patent rights under the MARINA Patents; or 

  

	 	(iii)	if such patent counsel reasonably believes that a state of facts exists (including, without limitation, delay or lack of funds) that could reasonably, if left
unattended, compromise the continued prosecution of any patent application, the issuance of any patent, the validity of any issued patent, the outcome of any proceeding relating to the MARINA Patents or otherwise impair any Patent
rights under the MARINA Patents. 

  

	7.4	Abandonment, Withdrawal and Discontinuance. 

  

	(a)	If either Party elects to: 

  

	 	(i)	discontinue pursuing one or more Patent applications, Patent protection or Patent maintenance pertaining to any of the MARINA Patents or Patents arising
from Joint IP or any continuation, continuation-in-part, divisional, reissue, re-examination or extension thereof for any reason; or 

  

	 	(ii)	not pursue Patent protection in relation to any of the MARINA Patents or Patents arising from Joint IP in any specific jurisdiction for any reason;

 the Party electing to discontinue Patent filing, prosecution or maintenance will give the other Party prior
written notice of such decision (each, a “Notice of Abandonment”), and together with sufficient detail in sufficient time, such time not to be less than [**] prior to any deadline imposed by a patent office, to enable the other
Party to assume and continue the filing, prosecution or maintenance of the Patents identified in the Notice of Abandonment (the “Abandoned Patents”). 
  

	(b)	The Notice of Abandonment will clearly identify the Patents that are being abandoned, the actions required to assume and continue the filing, prosecution or maintenance
of the Patents and the deadlines by which action must be taken to avoid abandonment. The Party in receipt of such notice at its sole cost and expense, and in its sole discretion, may assume and continue the prosecution and/or maintenance of any
particular Abandoned Patent identified in such notice (the “Non-Abandoning Party”). 

  

	(c)	In addition, if within [**] of receiving an Invention disclosure from the Non-Abandoning Party, the Abandoning Party does not file a Patent application for the
Invention described therein that the Non-Abandoning Party believes could become a Patent: 

  

	 	(i)	the Non-Abandoning Party may prepare and file a Patent application for the Invention; 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 18 

	 	(ii)	a Notice of Abandonment will be deemed to have been given upon the Abandoning Party’s receipt of the Invention disclosure and the Patent application for the
Invention, when filed by the Non-Abandoning Party, will be deemed an Abandoned Patent, including all rights under Patents related thereto, including foreign counterparts. 

 

	(d)	Both Parties agree that, effective upon [**] after the Notice of Abandonment, the Abandoning Party will have no further obligations to assume and continue the filing,
prosecution, maintenance, protection and related costs for the Abandoned Patents, provided that if the Non-Abandoning Party assumes and continues the prosecution and/or maintenance of any particular Abandoned Patent, the Abandoning Party will
provide the Non-Abandoning Party with all reasonable assistance required for the prosecution, maintenance, defense and/or enforcement of the Abandoned Patent, at the Non-Abandoning Party’s cost and expense. 

 

	7.5	Prosecuting Infringement Proceedings. 

During the Term each Party shall promptly report in writing to the other Party any known or suspected infringement in the Field of any
MARINA Patents or Patents arising from Joint IP of which it becomes aware, and shall provide the other Party with all available evidence supporting such infringement, or unauthorized use or misappropriation. In the event of such
alleged infringement by a Third Party, the following shall apply: 
  

	(a)	MARINA shall have the first right, in its sole discretion and sole expense and using counsel of its choice and reasonably acceptable to
PROTIVA, to initiate an infringement or other appropriate suit against any Third Party anywhere in the Territory who at any time has infringed, or is suspected of infringing, any such Patent in the Field; 

 

	(b)	if MARINA does not take steps to prosecute such claim or litigation within [**] after receipt of notice thereof, PROTIVA may take such
legally permissible action as it deems necessary or appropriate to prosecute such claim or litigation (or defend such litigation in the event of a counterclaim) at its own expense, using counsel of its choice, but shall not be obligated to do so;

  

	(c)	the Party prosecuting such litigation (in this Article, the “Litigating Party”) shall have the right to control such litigation and shall bear all
legal expenses (including court costs and legal fees), including settlement thereof; provided, however, that no settlement or consent judgment or other voluntary final disposition of any suit or action brought by a Party pursuant to this Section may
be entered into without the consent of the other Party if such settlement would require the other Party to be subject to an injunction or to make a monetary payment or would restrict the claims in or admit any invalidity of any such Patent or
significantly adversely affect the rights of the other Party to this Agreement (the “Non-litigating Party”). By way of example and not by way of limitation, there shall be no right of the Litigating Party to stipulate or admit to
the invalidity or unenforceability of any such Patents. Before any action is taken by the Litigating Party, the Parties agree to, in good faith, consult with a goal of adopting a mutually satisfactory position; 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 19 

	(d)	the Non-litigating Party agrees to co-operate reasonably in any such litigation to the extent of executing all necessary documents, supplying essential documentary
evidence and making essential witnesses then in its employment available and to vest in the Litigating Party the right to institute any such suits, so long as all the direct or indirect costs and expenses of bringing and conducting any such
litigation or settlement shall be borne by the Litigating Party, provided that the Parties shall recover their respective actual out-of-pocket expenses, or equitable proportions thereof, associated with any litigation or settlement thereof from any
recovery made by any Party. Any excess amount remaining after satisfaction of the Parties’ recovery of their respective actual out-of-pocket expenses (the “Excess Amount”) shall be shared as follows: (i) [**] to the
Litigating Party and (ii) [**] to the Non-litigating Party; 

  

	(e)	the Litigating Party shall keep the Non-litigating Party fully informed of the actions and positions taken or proposed to be taken by the Litigating Party on behalf of
itself or a sublicense (if applicable) and actions and positions taken by all other parties to such litigation; and 

  

	(f)	at any time during the litigation, the Non-litigating Party may elect to participate formally in the litigation to the extent that the court may permit, at its expense
(subject to the possibility of recovery of some or all of such additional expenses as described in Subsection 7.5(d) or from such other parties to the litigation). 

 

	7.6	Breach of Confidence Proceedings. 

 In the
event of an alleged breach of confidentiality respecting Confidential Information or any Third Party use of Confidential Information, if each Party agrees in its sole discretion that the interests of the Parties are aligned in connection with such
breach or use, each Party shall reasonably cooperate with the other to enjoin such Third Party’s use of such Confidential Information. 
  

	7.7	Defense of Infringement Proceedings. 

 In
the event that a Third Party at any time provides written notice of a claim, or brings an action, suit or proceeding, against any Party or any of their respective Affiliates or Sublicensees, claiming infringement of its Patents or unauthorized use
or misappropriation of its know-how, due to the use of the Intellectual Property Rights in and to the MARINA Technology or the making, using or selling of Products covered by the MARINA Patents the Party in receipt of
such written notice or claim shall promptly notify the other Party of same, enclosing a copy of the claim and all papers served. In the event of such alleged infringement, the Parties will assist one another and cooperate in any such litigation and,
if applicable, be subject to the indemnification obligations of Article 12. 
  

	7.8	Procedures. 

 If required under applicable
law in order for the Litigating Party to initiate and/or maintain such suit, or if the Litigating Party is unable to initiate or prosecute such suit solely in its own name or it is otherwise advisable to obtain an effective legal remedy, in each
case, the Non-Litigating Party shall join as a party to the suit and will execute and cause its Affiliates to execute all document necessary for the Litigating Party to initiate litigation to prosecute and maintain such action. In addition, at the
Litigating Party’s request, the Non-Litigating Party shall provide 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 20 

 
reasonable assistance to the Litigating Party in connection with an infringement suit at no charge to the Litigating Party except for reimbursement by the Litigating Party of reasonable
out-of-pocket expenses incurred by the Non-Litigating Party in rendering such assistance. 
  

	7.9	Product Trademarks. 

PROTIVA shall own the trademarks for any PROTIVA Product and shall be solely responsible for filing and maintaining such
trademarks in the Territory (including payment of costs associated therewith). PROTIVA shall also assume full responsibility, at its sole cost and expense, for taking legal action against any infringement by a Third Party of any
PROTIVA Product trademark, and for claims of infringement of the rights of a Third Party by the use of a PROTIVA Product’s trademark. 
 Article 8 CONFIDENTIALITY 
  

	8.1	Duty of Confidence. 

 Subject to the other
provisions of this Article 8, all Confidential Information disclosed by a Party or its Affiliates under this Agreement will be maintained in confidence and otherwise safeguarded by the recipient Party. The recipient Party may only use the
Confidential Information for the purposes of this Agreement and pursuant to the rights granted to the recipient Party under this Agreement. Subject to the other provisions of this Article 8, each Party shall hold as confidential such Confidential
Information of the other Party or its Affiliates in the same manner and with the same protection as such recipient Party maintains its own confidential information. Subject to the other provisions of this Article 8, a recipient Party may only
disclose Confidential Information of the other Party to employees, agents, contractors, consultants and advisers of the Party and its Affiliates and to Third Parties (including, in the case of PROTIVA, Sublicensees and their
Affiliates) but in each case only to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement and only if such Persons are bound to maintain the confidentiality of the Confidential Information
in a manner consistent with the confidentiality provisions of this Agreement. 
  

	8.2	Exceptions. 

 The obligations under this
Article 8 shall not apply to any information to the extent the recipient Party can demonstrate by competent evidence that such information: 
  

	(a)	is (at the time of disclosure) or becomes (after the time of disclosure) generally known to the public or part of the public domain through no breach of this Agreement
by the recipient Party or its Affiliates; 

  

	(b)	was known to, or was otherwise in the possession of, the recipient Party or its Affiliates prior to the time of disclosure by the disclosing Party or any of its
Affiliates; 

  

	(c)	is disclosed to the recipient Party or an Affiliate on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality
obligation to the disclosing Party or any of its Affiliates; or 

  

	(d)	is independently developed by or on behalf of the recipient Party or its Affiliates, as evidenced by its written records, without reference to the Confidential
Information disclosed by the disclosing Party or its Affiliates under this Agreement. 

  
 21 

	(e)	Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the recipient Party merely because
the Confidential Information is embraced by more general information in the public domain or in the possession of the recipient Party. Further, any combination of Confidential Information shall not be considered in the public domain or in the
possession of the recipient Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the recipient Party unless the combination and its principles are in the public domain or in the
possession of the recipient Party. 

  

	8.3	Authorized Disclosures. 

  

	(a)	In addition to disclosures allowed under Section 8.2, PROTIVA may disclose Confidential Information belonging to MARINA or its
Affiliates to the extent such disclosure is necessary in the following instances: 

  

	 	(i)	filing or prosecuting Patents as permitted by this Agreement; and 

  

	 	(ii)	in connection with Regulatory Filings for Products. 

  

	(b)	In addition, PROTIVA may disclose Confidential Information belonging to MARINA or its Affiliates to the extent such disclosure is
necessary in connection with prosecuting or defending litigation as permitted by this Agreement; provided, that PROTIVA (i) informs MARINA as soon as reasonably practicable of the proposed disclosure; and
(ii) shall use commercially reasonable efforts (but in no event less than the efforts used by PROTIVA with respect to confidential information derived from its other drug development and commercialization efforts) to limit the
disclosure for the required purpose and to obtain protections to maintain the confidentiality of such MARINA Confidential Information. 

  

	(c)	In addition, PROTIVA and its Affiliates and Sublicensees may disclose Confidential Information of MARINA to Third Parties (including
Sublicensees and their Affiliates) as may be necessary or useful in connection with the development, manufacture or commercialization of Products; provided, that such Third Parties are bound in writing to maintain the confidentiality of such
Confidential Information in a manner consistent with the confidentiality provisions of this Agreement. 

  

	(d)	In the event the recipient Party is required to disclose Confidential Information of the disclosing Party by law or in connection with bona fide legal process, such
disclosure shall not be a breach of this Agreement; provided, that the recipient Party (i) informs the disclosing Party as soon as reasonably practicable of the required disclosure; (ii) limits the disclosure to the required
purpose; and (iii) at the disclosing Party’s request and expense, assists in the disclosing Party’s attempt to object to or limit the required disclosure. 

 

	(e)	Notwithstanding anything to the contrary contained in this Article 8 or Article 11, MARINA shall be permitted to disclose a copy of this Agreement to:

  

	 	(i)	MARINA’s current or prospective banks, financial institutions, investors or other Third Parties for the purpose of raising capital or borrowing
money or maintaining compliance with agreements, arrangements and understandings relating thereto; and 

  
 22 

	 	(ii)	to any Person who proposes to be an assignee or to purchase or otherwise succeed (by merger, operation of law or otherwise) to all of MARINA’s
right, title and interest in, to and under this Agreement, if (A) such Person agrees to maintain the confidentiality of this Agreement pursuant to a written agreement at least as protective as the terms set forth in this Article 8 (with the
exception of the term of the obligation of confidentiality, which may be for a specified term of years) and (B) any such assignment, purchase or succession would be permitted under Section 13.1. 

Article 9 TERM AND TERMINATION 
  

	9.1	Term. 

 The term of this Agreement, as to
a particular PROTIVA Product in a particular country, shall expire (on a country-by-country basis) upon the earlier of: 
  

	(a)	the expiration of the Royalty Term for such PROTIVA Product in such country; or 

 

	(b)	the end of calendar quarter in which sales in such country of Generic Products exceed [**] (on a “per unit” basis) of the sales of the PROTIVA
Product in such country. 

 Upon expiration of the Royalty Term with respect to a PROTIVA Product in a particular
country, then the licenses granted in Section 2.1 for such PROTIVA Product in such country shall become fully paid up and irrevocable, and shall survive any expiration or termination of this Agreement. This Agreement shall expire
in its entirety upon the expiration of the last Royalty Term for any MARINA Patent with respect to which PROTIVA has a license under this Agreement, unless earlier terminated pursuant to this Article 9. 

 

	9.2	Termination. 

  

	(a)	Termination for Convenience. PROTIVA shall have the right to terminate this Agreement for convenience in its entirety, or in respect of any
particular country or countries in the Territory, by giving ninety (90) days prior written notice to MARINA, provided that no such termination shall be effective sooner than the date that is nine (9) months after the
Effective Date. 

  

	(b)	Termination for Bankruptcy/Insolvency. 

  

	 	(i)	A Party may immediately terminate this Agreement in its entirety, or in respect of any particular country or countries in the Territory, on written notice in the event
(each, a “Financial Event”) any of the following occurs with respect to the other Party (the “Bankrupt Party”): 

  

	 	(A)	such Bankrupt Party files a petition in bankruptcy or makes a general assignment for the benefit of creditors or otherwise acknowledges in writing insolvency, or is
adjudged bankrupt, and such Bankrupt Party (1) fails to assume this Agreement in any such bankruptcy proceeding within thirty (30) days after filing or (2) assumes and assigns this Agreement to a Third Party; 

 

	 	(B)	such Bankrupt Party goes into or is placed in a process of complete liquidation; 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 23 

	 	(C)	a trustee or receiver is appointed for any substantial portion of such Bankrupt Party’s business and such trustee or receiver is not discharged within sixty
(60) days after appointment; 

  

	 	(D)	any case or proceeding shall have been commenced or other action taken against such Bankrupt Party in bankruptcy or seeking liquidation, reorganization, dissolution, a
winding-up arrangement, composition or readjustment of its debts or any other relief under any bankruptcy, insolvency, reorganization or similar act or law of any jurisdiction now or hereafter in effect and is not dismissed or converted into a
voluntary proceeding governed by Subparagraph 9.2(b)(i)(A) within sixty (60) days after filing; or 

  

	 	(E)	there shall have been issued a warrant of attachment, execution, distraint or similar process against any substantial part of the property of such Bankrupt Party and
such event shall have continued for a period of sixty (60) days and none of the following has occurred: (1) it is dismissed, (2) it is bonded in a manner reasonably satisfactory to the other Party, or (3) it is discharged.

  

	 	(ii)	In the event MARINA: 

  

	 	(A)	makes an assignment for the benefit of creditors, or petition or applies to any tribunal for the appointment of a custodian, receiver, or trustee for all or a
substantial part of its assets; 

  

	 	(B)	commences any proceeding under any bankruptcy, dissolution, or liquidation law or statute of any jurisdiction whether now or hereafter in effect;

  

	 	(C)	has any such petition or application filed or any such proceeding commenced against it in which an order for relief is entered or an adjudication or appointment is
made, and which remains undismissed for a period of one hundred twenty (120) calendar days or more; 

  

	 	(D)	takes any corporate action indicating its consent to, approval of, or acquiescence in any such petition, application, proceeding, or order for relief or the appointment
of a custodian receiver, or trustee for all or substantial part of its assets; or 

  

	 	(E)	permits any such custodianship, receivership, or trusteeship to continue undischarged for a period of one hundred twenty (120) calendar days or more;

 (each, a “Bankruptcy Action”) and the occurrence of any of the foregoing causes the applicable
Party or any Third Party, including, without limitation, a trustee in bankruptcy, to be empowered under state or federal law to reject this Agreement or any Agreement supplementary hereto, then PROTIVA shall have the following rights:

  

	 	(F)	 in the event of a rejection of this Agreement or any agreement supplementary hereto, PROTIVA shall be permitted to receive and use any

  
 24 

	 	
MARINA Technology within the scope of its license hereunder for the purpose of enabling it to mitigate damages caused to PROTIVA because of the rejection of this
Agreement; 

  

	 	(G)	in the event of a rejection of this Agreement or any Agreement supplementary hereto, PROTIVA may elect to retain its rights under this Agreement or any
agreement supplementary hereto as provided in Section 365(n) of the United States Bankruptcy Code or comparable provision of the laws of any other country in the Territory. Upon PROTIVA’s written request to
MARINA or the bankruptcy trustee or receiver, MARINA or such bankruptcy trustee or receiver shall not interfere with the rights of PROTIVA as provided in this Agreement or in any agreement supplementary
thereto; 

  

	 	(H)	in the event of a rejection of this Agreement or any Agreement supplementary hereto, PROTIVA may elect to retain its rights under this Agreement or any
agreement supplementary hereto as provided in Section 365(n) of the United States Bankruptcy Code or comparable provision of the laws of any other country in the Territory without prejudice to any of its rights of setoff and/or recoupment with
respect to this Agreement under the Bankruptcy Code or applicable non-bankruptcy law; and 

  

	 	(I)	in the event of a rejection of this Agreement or any Agreement supplementary hereto, PROTIVA may retain its rights under this Agreement or any agreement
supplementary hereto as provided in Section 365(n) of the United States Bankruptcy Code or comparable provision of the laws of any other country in the Territory without prejudice to any of its rights under Section 503(b) of the United
States Bankruptcy Code or comparable provision of the laws of any other country. 

  

	 	(iii)	Notwithstanding anything to the contrary in this Subsection 9.2(b): 

  

	 	(A)	any reorganization or arrangement involving MARINA, its Affiliates and/or its wholly owned subsidiaries which does not prejudice the rights of
PROTIVA shall not constitute a Bankruptcy Action for the purposes of this Subsection 9.2(b) and shall not give rise to the remedies set forth in this Subsection 9.2(b); and 

 

	 	(B)	if PROTIVA asserts any rights under Subparagraphs 9.2(b)(ii)(F), 9.2(b)(ii)(G), 9.2(b)(ii)(H) or 9.2(b)(ii)(I), PROTIVA shall
continue to be bound by all liabilities and obligations imposed upon PROTIVA and its Affiliates and Sublicensees, and any remedies available to MARINA under this Agreement. 

 

	(c)	 Termination for PROTIVA Material Breach. Upon any material breach by PROTIVA under this Agreement,
MARINA may notify PROTIVA in writing of such breach and require that PROTIVA cure such breach within a cure period not shorter than sixty (60) days after receipt of MARINA’s
notice for any default of a payment obligation under this Agreement, or one hundred and twenty (120) days after receipt of MARINA’s notice for any other

  
 25 

	 	
material breach. In the event PROTIVA shall not have cured such breach by the end of the applicable cure period, MARINA may terminate this Agreement immediately upon
written notice to PROTIVA. Notwithstanding the foregoing cure periods, non-payment of the Upfront Payment in accordance with Section 4.1 shall automatically and immediately terminate this Agreement. 

 

	(d)	Termination for MARINA Material Breach. Upon any material breach by MARINA under this Agreement, PROTIVA may notify
MARINA in writing of such breach and require that MARINA cure such breach within a cure period of one hundred and twenty (120) days after receipt of PROTIVA’s notice. In the event
MARINA shall not have cured such breach by the end of the cure period, then, at PROTIVA’s sole option: 

  

	 	(i)	the license granted by MARINA to PROTIVA shall automatically convert into a worldwide, royalty-free, fully paid-up, perpetual license; or

  

	 	(ii)	PROTIVA may terminate this Agreement in its entirety, or in respect of any particular country or countries in the Territory, immediately upon written
notice to MARINA. 

  

	9.3	Effect of Termination. 

  

	(a)	Upon termination of this Agreement in its entirety pursuant to this Article 9: 

 

	 	(i)	all licenses granted hereunder to PROTIVA shall revert to MARINA; 

 

	 	(ii)	all sublicenses granted by PROTIVA under the rights or licenses granted to PROTIVA under this Agreement shall survive such termination,
provided that the applicable Sublicensees are not in material breach of such sublicense agreements, and shall become direct licenses with MARINA except that MARINA shall not have any obligations under any
such sublicense agreements that are greater than the obligations of MARINA under this Agreement; and 

  

	 	(iii)	PROTIVA (and its Affiliates) shall immediately cease all development and Commercialization of any PROTIVA Products that contain
MARINA Know-How and/or are claimed by a Valid Claim, and shall return to MARINA all physical manifestations of the MARINA Technology and MARINA Confidential Information.

  

	(b)	Upon termination of this Agreement in any particular country in the Territory pursuant to this Article 9, this Agreement shall be amended so as to delete from the
Territory, the country that is the subject of the termination. 

  

	9.4	Survival. 

  

	(a)	Notwithstanding any expiration or termination of this Agreement, the provisions of Article 1; Sections 4.8, 4.9 and 4.10; Sections 6.1 and 6.3; Sections 7.1, 7.7,
7.8 and 7.9 and (as to Joint IP only) Sections 7.3, 7.4 and 7.5; Article 8; Article 9; Sections 10.1 and 10.2 (solely for purposes of indemnification from third party claims); Sections 10.3, 10.4(c), 10.5; Article 11; Article 12; Article 13, and any
other provisions which by their nature are intended to survive any such expiration or termination shall survive any expiration or termination of this Agreement. Termination of this Agreement shall not relieve the Parties of any liability which
accrued hereunder prior to the effective date of such termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach or default of this Agreement nor prejudice
either Party’s right to obtain performance of any obligation. 

  
 26 

	(b)	Any sublicense contemplated in Section 2.2 shall survive termination of the licenses or other rights granted to PROTIVA under this Agreement and be
assumed by MARINA as long as: 

  

	 	(i)	the Sublicensee is not then in breach of its license and/or sublicense agreement; 

 

	 	(ii)	the Sublicensee agrees in writing to be bound to MARINA as a licensor under the terms and conditions of the license and/or sublicense agreement; and

  

	 	(iii)	the Sublicensee agrees in writing that in no event shall MARINA assume any obligations or liabilities, or be under any obligation or requirement of
performance, under any such license and/or sublicense extending beyond MARINA’s obligations and liabilities under this Agreement. 

 Article 10 REPRESENTATIONS, WARRANTIES AND COVENANTS 
  

	10.1	Representations and Warranties by Each Party. 

 Each Party represents and warrants to the other as of the Effective Date that: 
  

	(a)	it is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation; 

 

	(b)	it has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken all corporate action required by law and its organizational
documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement; 

  

	(c)	this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms; 

 

	(d)	all consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party in connection with the
execution, delivery and performance of this Agreement have been obtained; and 

  

	(e)	the execution and delivery of this Agreement and all other instruments and documents required to be executed pursuant to this Agreement, and the consummation of the
transactions contemplated hereby do not (i) conflict with or result in a breach of any provision of its organizational documents, (ii) result in a breach of any agreement to which it is a party; or (iii) violate any law.

  

	10.2	Representations and Warranties by MARINA. 

 MARINA represents and warrants to PROTIVA as of the Effective Date that: 
  

	(a)	Exhibit A sets forth a complete and accurate list of all MARINA Patents; 

 

	(b)	MARINA has obtained from all individuals who participated in any respect in the invention or authorship of any MARINA Technology effective
assignments of all ownership rights of such individuals in such MARINA Technology, either pursuant to written agreement or by operation of law; 

  
 27 

	(c)	All of MARINA’S employees, officers, and consultants have executed agreements or have existing obligations under applicable laws
requiring assignment to MARINA of all inventions made during the course of and as the result of their association with MARINA and obligating the individual to maintain as confidential MARINA’s
Confidential Information as well as confidential information of other parties (including PROTIVA and its Affiliates, although they may not be specifically referenced by name) which such individual may receive, to the extent required
to support MARINA’s obligations under this Agreement; 

  

	(d)	MARINA has all necessary legal rights and authority to grant the licenses and rights granted under this Agreement and has not assigned, transferred,
conveyed or licensed its right, title and interest in the MARINA Technology in any manner inconsistent with such license grant or the other terms of this Agreement; 

 

	(e)	MARINA has all necessary legal rights and authority to use and disclose and to enable PROTIVA to use and disclose (in each case under
appropriate conditions of confidentiality) the MARINA Know-How; 

  

	(f)	To MARINA’S knowledge, the issued Patents in the MARINA Patents are valid and enforceable without any claims,
challenges, oppositions, interference or other proceedings pending or, to MARINA’s knowledge, threatened and MARINA has filed and prosecuted Patent applications within the MARINA Patents in good
faith and, to MARINA’s knowledge, complied with all duties of disclosure with respect thereto; 

  

	(g)	To MARINA’s knowledge, MARINA has not committed any act, or omitted to commit any act, that may cause the MARINA
Patents to expire prematurely or be declared invalid or unenforceable; 

  

	(h)	All application, registration, maintenance and renewal fees in respect of the MARINA Patents as of the Effective Date have been paid and all necessary
documents and certificates have been filed with the relevant agencies for the purpose of maintaining the MARINA Patents; 

  

	(i)	To MARINA’s knowledge, the practice of the MARINA Technology does not infringe Patents or misappropriate Know-How of any Third Party,
nor has MARINA received any written notice alleging such infringement or misappropriation; 

  

	(j)	MARINA has not initiated or been involved in any proceedings or claims in which it alleges that any Third Party is or was infringing the
MARINA Patents or misappropriating any MARINA Know-How, nor have any such proceedings been threatened by MARINA, nor does MARINA know of any valid basis for any such proceedings;

  

	(k)	MARINA has taken all reasonable precautions to preserve the confidentiality of the MARINA Know-How; 

 

	(l)	MARINA has not entered into a government funding relationship that would result in rights to any Products residing in the US Government, National
Institutes of Health, National Institute for Drug Abuse or other agency, and the licenses granted hereunder are not subject to overriding obligations to the US Government as set forth in Public Law 96-517 (35 U.S.C. 200-204), as amended, or any
similar obligations under the laws of any other country; 

  
 28 

	(m)	Subject to Subsection 0, MARINA has not granted any Third Party rights that would otherwise interfere or be inconsistent with
PROTIVA’s rights hereunder, and there are no agreements or arrangements to which MARINA or any of its Affiliates is a party relating to the Products, MARINA Patents, MARINA Know-How or
that would limit the rights granted to PROTIVA under this Agreement or that restrict or will result in a restriction on PROTIVA’ ability to develop, manufacture, register, use or commercialize the Products in the
Territory; and 

  

	(n)	MARINA has not failed to disclose to PROTIVA any fact or circumstance known to MARINA and relating to any of the
MARINA Technology that would be reasonably material to PROTIVA in determining to enter into this Agreement or the transactions contemplated herein. 

 

	10.3	Acknowledgements of PROTIVA. 

 PROTIVA acknowledges that MARINA has granted rights to practice certain MARINA Patents: 

 

	(a)	to [**] solely in connection with the development and commercialization of a limited number of specified proprietary compounds belonging to [**]; and

  

	(b)	to [**] in connection with DNAi human therapeutic use. 

 DNAi does not include RNAi, antisense and microRNA oligonucleotides that base pair with mRNAs, microRNAs or pre-mRNAs to affect expression of a gene, directly or indirectly. The Parties agree that the
foregoing grants do not interfere with, are not otherwise inconsistent with, and do not limit the rights granted to PROTIVA in Section 2.1. 
  

	10.4	Covenants of MARINA. 

MARINA covenants and agrees that: 
  

	(a)	it will not grant any interest in the MARINA Technology which is inconsistent with the terms and conditions of this Agreement; 

 

	(b)	if, at any time after execution of this Agreement, it becomes aware that it or any employee, agent or subcontractor of MARINA who participated, or is
participating, in the development of the MARINA Technology is on, or is being added to the FDA Debarment List, it will provide written notice of this to PROTIVA within two (2) Business Days of its becoming aware of
this fact; and 

  

	(c)	it shall maintain insurance with respect to its indemnification obligations under this Agreement in such amounts as are commercially reasonable in the industry for
companies conducting similar business and shall require any of its Affiliates undertaking activities under this Agreement to do the same. 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 29 

	10.5	No Other Warranties. 

 EXCEPT AS EXPRESSLY
STATED IN THIS Article 10: 
  

	(a)	NO OTHER REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF PROTIVA OR MARINA; AND

  

	(b)	ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 

 Article 11 INDEMNIFICATION; LIABILITY

  

	11.1	Indemnification by MARINA. 

MARINA shall defend, indemnify, and hold PROTIVA, its Affiliates, and their respective officers, directors, employees and
agents, and all successors and assigns of any of the foregoing (“PROTIVA Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 

 

	(a)	the gross negligence or willful misconduct of MARINA or any of its Affiliates; or 

 

	(b)	the breach of any of the covenants, representations or warranties made by MARINA to PROTIVA under this Agreement;

 provided, however, that MARINA shall not be obliged to so indemnify, defend and hold harmless the
PROTIVA Indemnitees for any Claims to the extent that PROTIVA has an obligation to indemnify MARINA Indemnitees pursuant to Section 11.2 or to the extent that such Claims arise from the breach, gross
negligence or willful misconduct of PROTIVA or a PROTIVA Indemnitee. 
  

	11.2	Indemnification by PROTIVA. 

PROTIVA shall defend, indemnify, and hold MARINA, its Affiliates, and their respective officers, directors, employees and
agents, and all successors and assigns of any of the foregoing (“MARINA Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 

 

	(a)	the gross negligence or willful misconduct of PROTIVA or any of its Affiliates or Sublicensees; 

 

	(b)	the breach of any of the covenants, representations or warranties made by PROTIVA to MARINA under this Agreement;

  

	(c)	the exercise or practice by PROTIVA, its Affiliates or Sublicensees of the license granted to PROTIVA under Section 2.1 (excluding
any such Claim that alleges that the exercise or practice of the MARINA Technology infringes a Patent or misappropriates other Intellectual Property Rights of a Third Party); or 

 

	(d)	the development, manufacture or commercialization of any PROTIVA Product by or for PROTIVA, its Affiliates or Sublicensees;

 provided, however, that PROTIVA shall not be obliged to so indemnify, defend and hold harmless the
MARINA Indemnitees for any Claims to the extent that MARINA has an obligation to indemnify PROTIVA Indemnitees pursuant to Section 11.1 or to the extent that such Claims arise from the breach, gross
negligence or willful misconduct of MARINA or a MARINA Indemnitee. 

  
 30 

	11.3	Indemnification Procedure. 

  

	(a)	For the avoidance of doubt, all indemnification claims in respect of a PROTIVA Indemnitee or MARINA Indemnitee shall be made solely by
PROTIVA or MARINA, respectively, on behalf of the PROTIVA Indemnitee or MARINA Indemnitee, as the case may be. 

 

	(b)	A Party seeking indemnification hereunder (“Indemnified Party”) shall notify the other Party (“Indemnifying Party”) in writing
reasonably promptly after the assertion against the Indemnified Party of any Claim or fact in respect of which the Indemnified Party intends to base a claim for indemnification hereunder (“Indemnification Claim Notice”), but the
failure or delay to so notify the Indemnifying Party shall not relieve the Indemnifying Party of any obligation or liability that it may have to the Indemnified Party, except to the extent that the Indemnifying Party demonstrates that its ability to
defend or resolve such Claim is adversely affected thereby. The Indemnification Claim Notice shall contain a description of the claim and the nature and amount of the Claim (to the extent that the nature and amount of such Claim is known at such
time). Upon the request of the Indemnifying Party, the Indemnified Party shall furnish promptly to the Indemnifying Party copies of all correspondence, communications and official documents (including court documents) received or sent in respect of
such Claim. 

  

	(c)	Subject to the provisions of Subsection 11.3(d), the Indemnifying Party shall, within [**] after receipt of the Indemnification Claim Notice, advise the
Indemnified Party whether it is assuming the defense and handling of such Claim, at the Indemnifying Party’s sole expense. The assumption of the defense of a Claim by the Indemnifying Party shall not be construed as acknowledgement that the
Indemnifying Party is liable to indemnify any indemnitee in respect of the Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party’s claim for indemnification. In the event
that it is ultimately decided that the Indemnifying Party is not obligated to indemnify or hold an indemnitee harmless from and against the Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all reasonable costs and
expenses (including attorneys’ fees and costs of suit) incurred by the Indemnifying Party in its defense of the Claim. 

  

	(d)	Upon assumption of the defense of a Claim by the Indemnifying Party: 

  

	 	(i)	the Indemnifying Party shall have the right to and shall assume sole control and responsibility for dealing with the Claim; 

 

	 	(ii)	the Indemnifying Party may, at its own cost, appoint as counsel in connection with conducting the defense and handling of such Claim any law firm or counsel reasonably
selected by the Indemnifying Party and reasonably satisfactory to the Indemnified Party (such consent not to be unreasonably withheld or delayed); 

  

	 	(iii)	the Indemnifying Party shall keep the Indemnified Party informed of the status of such Claim; and 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 31 

	 	(iv)	the Indemnifying Party shall have the right to settle the Claim on any terms the Indemnifying Party chooses; 

provided, however, that it shall not, without the prior written consent of the Indemnified Party, agree to a settlement of any
Claim which could lead to liability for or create any financial or other obligation or restriction on the Indemnified Party (or abrogate the license rights granted under this Agreement) for which the Indemnified Party is not entitled to
indemnification hereunder or which admits any wrongdoing or responsibility for the Claim on behalf of the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party at the Indemnifying Party’s expense. In particular,
the Indemnified Party shall furnish such records, information and testimony, provide witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith; subject to the
right of the Indemnified Party to obtain confidentiality protection in connection therewith consistent with the confidentiality provisions of this Agreement. Such cooperation shall include access during normal business hours by the Indemnifying
Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Claim, and making the Indemnified Party, the PROTIVA Indemnitees or MARINA Indemnitees, as the
case may be, and its and their employees and agents available on a mutually convenient basis to provide additional information and explanation of any records or information provided. The Indemnified Party shall be entitled to participate in, but not
control, the defense of such Claim with its own counsel and at its own expense; provided, however, that if the litigants in any such action include both the Indemnified Party and the Indemnifying Party and legal counsel for the Indemnified
Party shall have reasonably concluded in a written legal opinion delivered to the Indemnifying Party that, by reason of certain bona fide defenses available to the Indemnified Party which are different from or additional to those available to the
Indemnifying Party, the interests of the Indemnified Party materially conflict with the interests of the Indemnifying Party such that it would be unethical under applicable rules relating to attorney conflicts of interest for the Indemnifying Party
and such Indemnified Party to be represented by the same counsel with respect to such defense, the Indemnified Party shall have the right to select one separate counsel and to assert such legal defenses, with the reasonable expenses and fees of such
separate counsel to be reimbursed by the Indemnifying Party as and when incurred. 
  

	(e)	 If the Indemnifying Party fails to assume or conduct the defense and handling of any Claim in good faith as provided Subsections 11.3(c) and
11.3(d), the Indemnified Party may, at the Indemnifying Party’s expense, select counsel reasonably acceptable to the Indemnifying Party (such consent not to be unreasonably withheld or delayed) in connection with conducting the defense and
handling of such Claim and defend or handle such Claim in such manner as it may deem appropriate; provided, that the foregoing shall not be construed as a limitation on the Indemnified Party’s right to claim that the Indemnifying Party
has breached its obligations pursuant to this Article 11. In such event, the Indemnified Party shall keep the Indemnifying Party timely apprised of the status of such Claim and the Indemnified Party shall have the right to settle the Claim on any
terms the Indemnified Party chooses; provided, however, that the Indemnified Party shall not, without the prior written consent of the Indemnifying Party, agree to a settlement of any Claim which could lead to liability or create any
financial or other 

  
 32 

 
obligation on the part of the Indemnifying Party, other than its liability for indemnification of the Indemnified Party as provided in this Article 11, or which admits any wrongdoing or
responsibility for the claim on behalf of the Indemnifying Party. 
  

	11.4	Mitigation of Loss. 

 Each Indemnified
Party will take and will procure that its Affiliates take all such reasonable steps and action as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Article
11. Nothing in this Agreement shall or shall be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. 
  

	11.5	Insurance. 

 PROTIVA shall,
at its own expense, procure and maintain during the Term and for a period of [**] thereafter, insurance policy/policies, including product liability insurance, adequate to cover its obligations hereunder and which are consistent with normal business
practices of prudent companies similarly situated. 
  

	11.6	Special, Indirect and Other Losses. 

NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT,
INCIDENTAL OR PUNITIVE DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION
UNDER THIS Article 11. 
  

	11.7	No Exclusion. 

 Neither Party excludes any
liability for death or personal bodily injury caused by its negligence or the negligence of its Affiliates or, in the case of PROTIVA, its Sublicensees, or their respective employees, agents or sub-contractors. 

Article 12 PUBLICATIONS AND PUBLICITY 
  

	12.1	Publications. 

 For avoidance of doubt,
PROTIVA or any of its Affiliates may, without any required consents from MARINA but subject to its confidentiality obligations under Article 8 with respect to the Confidential Information of MARINA:

  

	(a)	issue press releases and other public statements as it deems appropriate in connection with the development and commercialization of the Products under this Agreement;
and 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
 33 

	(b)	publish or have published information about clinical trials related to the Products, including the results of such clinical trials 

 

	12.2	Publicity 

  

	(a)	Neither Party shall use the name, symbol, trademark, trade name or logo of the other Party or its Affiliates in any press release, publication or other form of public
disclosure without the prior written consent of the other Party in each instance (such consent not to be unreasonably withheld or delayed), except for those disclosures for which consent has already been obtained. Notwithstanding the foregoing,
PROTIVA shall be entitled, upon reasonable prior notice to MARINA, to use the name of MARINA to identify its licensor to the extent necessary or useful in connection with the development or
commercialization of the Products, including in connection with sublicensing and subcontracting transactions. 

  

	(b)	Subject to Subsection 12.2(c), each Party agrees not to issue any press release or other public statement, whether oral or written, disclosing the existence of
this Agreement, the terms hereof or any information relating to this Agreement without the prior written consent of the other Party, which approval shall not be unreasonably withheld, conditioned or delayed; provided, however, that
PROTIVA may issue press releases and other public statements as it deems appropriate in connection with the development and commercialization of Products under this Agreement and provided further, that the Parties approve the
text of the press releases annexed as Exhibit B to this Agreement. 

  

	(c)	Notwithstanding the foregoing, each Party may, without the prior approval of the other Party, make any disclosures required of it to comply with any duty of disclosure
it may have pursuant to law or governmental regulation or pursuant to the rules of any recognized stock exchange. The Parties shall nevertheless use good faith efforts to coordinate with each other with respect to the timing, form and content of
such required disclosure. If so requested by the other Party, the Party subject to such obligation shall use commercially reasonable efforts to obtain an order, agreement or other governmental or Third Party action protecting to the maximum extent
possible the confidentiality of such provisions of this Agreement as reasonably requested by the other Party. Unless the Parties otherwise agree, such disclosure shall be limited to the minimum required as determined by the disclosing Party in
consultation with its legal counsel. Without limiting the foregoing, each Party shall consult with the other Party on the provisions of this Agreement, together with exhibits or other attachments attached hereto, to be redacted in any filings made
by MARINA or PROTIVA with the Securities and Exchange Commission (or other regulatory body) or as otherwise required by law. 

 Article 13 GENERAL PROVISIONS 
  

	13.1	Assignment. 

 Neither Party may assign its
rights and obligations under this Agreement without the other Party’s prior written consent, except that: 
  

	(a)	a Party may assign its rights and obligations under this Agreement or any part hereof to one or more of its Affiliates without the consent of the other Party; and

  
 34 

	(b)	either Party may assign this Agreement in its entirety to a successor to all or substantially all of its business or assets to which this Agreement relates.

 The assigning Party shall provide the other Party with prompt written notice of any such assignment pursuant to
Subsection 13.1(b). Any permitted assignee shall assume all obligations of its assignor under this Agreement (or related to the assigned portion in case of a partial assignment to an Affiliate), and no permitted assignment shall relieve the
assignor of liability hereunder. Any attempted assignment in contravention of the foregoing shall be void. Subject to the terms of this Agreement, this Agreement shall be binding upon and inure to the benefit of the Parties hereto and their
respective successors and permitted assigns. 
  

	13.2	Extension to Affiliates; Subcontractors. 

PROTIVA shall have the right to extend the rights, immunities and obligations granted in this Agreement to one or more of its Affiliates.
All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to PROTIVA. PROTIVA shall remain
primarily liable for any acts or omissions of its Affiliates. In addition, PROTIVA may subcontract to Third Parties the performance of any tasks and obligations relating to its exercise of the license and other rights under this
Agreement as PROTIVA deems appropriate, subject to its confidentiality obligations pursuant to Article 8. 
  

	13.3	Severability. 

 Should one or more of the
provisions of this Agreement become void or unenforceable as a matter of law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the
Parties will use their commercially reasonable efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties. 

 

	13.4	Governing Law and Jurisdiction. 

 This
Agreement shall be governed by and construed under the laws of New York, without giving effect to the conflicts of laws provision thereof. Any disputes between the Parties relating to this Agreement shall be subject to the exclusive jurisdiction and
venue of the federal courts located in the Southern District of New York (without restricting any right of appeal), and the Parties hereby waive any objection which they may have now or hereafter to the laying of venue of any proceedings in such
courts and to any claim that such proceedings have been brought in an inconvenient forum, and further agree that a judgment or order in any such proceedings shall be binding upon each of them and may be enforced in the courts of any other
jurisdiction. 
  

	13.5	Force Majeure. 

 Neither Party shall be
responsible to the other for any failure or delay in performing any of its obligations under this Agreement or for other nonperformance hereunder if such delay or nonperformance is caused by strike, stoppage of labor, lockout or other labor trouble,
fire, flood, accident, war, act of terrorism, act of God or of the government of any country or of any local government, or by other cause unavoidable or beyond the reasonable control of any Party hereto. 

  
 35 

	13.6	Waivers and Amendments. 

 The failure of
any Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other
Party. No waiver shall be effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of
each Party. 
  

	13.7	Relationship of the Parties. 

 Nothing
contained in this Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of any type between MARINA and PROTIVA, or to constitute one as the agent of the other. Moreover, each Party agrees
not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for any tax purposes. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the
power or authority to act for, bind, or commit the other. 
  

	13.8	Notices. 

 All notices, consents, waivers,
and other communications under this Agreement must be in writing and will be deemed to have been duly given when: (a) delivered by hand (with written confirmation of receipt); (b) sent by fax (with written confirmation of receipt),
provided, that a copy is immediately sent by an internationally recognized overnight delivery service (receipt requested); or (c) when received by the addressee, if sent by an internationally recognized overnight delivery service
(receipt requested), in each case to the appropriate addresses and fax numbers set forth below (or to such other addresses and fax numbers as a Party may designate by notice): 

 

			
	 If to MARINA:
  

MARINA Biotech, Inc.
 PO Box
1599
 Bothell, Washington
 USA
98041
  

Attn:    Mr. J. Michael French

   President and CEO
  

Fax:     (206) 830-9424
	 	 If to PROTIVA:
  

PROTIVA Biotherapeutics Inc.
 100
- 8900 Glenlyon Parkway
 Burnaby, British Columbia
 Canada V5J 5J8
  
 Attn:    Dr. Mark Murray
    President &
CEO
  
 Fax:      (604)
419-3201

  

	13.9	Further Assurances. 

PROTIVA and MARINA hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge and
deliver any and all such other documents and take any such other action as may be reasonably necessary to carry out the intent and purposes of this Agreement. 
  

	13.10	Compliance with Law. 

 Each Party shall
perform its obligations under this Agreement in accordance with all applicable laws. No Party shall, or shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may
violate, any applicable law. 

  
 36 

	13.11	No Third Party Beneficiary Rights. 

 The
provisions of this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights to any Third Party (including any third party beneficiary rights). 

 

	13.12	English Language. 

 This Agreement is
written and executed in the English language. Any translation into any other language shall not be an official version of this Agreement and in the event of any conflict in interpretation between the English version and such translation, the English
version shall prevail. 
  

	13.13	Expenses. 

 Except as otherwise expressly
provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this
Agreement. 
  

	13.14	Entire Agreement. 

 This Agreement,
together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties, with respect to such
subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail. 

 

	13.15	Cumulative Remedies. 

 No remedy referred
to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 

  
 37 

	13.16	Counterparts. 

 This Agreement may be
executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by the Parties and transmitted by facsimile or other form of electronic
transmission and if so executed and transmitted shall be for all purposes as effective as if the Parties had delivered an executed original agreement. 
 IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives. 

 

									
	PROTIVA BIOTHERAPEUTICS INC.	 		 	MARINA BIOTECH, INC.
					
	By:	 	 “signed”
	 		 	By:	 	 “signed”

	Name:	 	 Paul Brennan
	 		 	Name:	 	 J. Michael French 

	Title:	 	 SVP Business Development
	 		 	Title:	 	 President & CEO

  
 38 

 EXHIBIT A 

LIST OF CERTAIN MARINA PATENTS 

CONFIDENTIAL 
 [**] 

  
  

	[**]	 Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT B 

PRESS RELEASES 
 Tekmira Acquires Worldwide License to Novel RNAi Technology 
 Tekmira and
Marina Biotech Enter into License Agreement for UNA Technology 
 November 28, 2012 

 
 Vancouver, BC — Tekmira Pharmaceuticals
Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it will obtain a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (UNA) from
Marina Biotech, Inc. (OTCQX:MRNA) for the development of RNAi therapeutics. 
 UNA technology can be used in the development of RNAi
therapeutics, which treat disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects. 

“Our license to Marina’s UNA technology expands and diversifies our foundation of technologies that enable us to develop RNAi therapeutics.
With Tekmira’s leading LNP delivery technology, a strong balance sheet, and access to multiple RNAi payload technologies, we are well positioned to aggressively advance multiple products into human clinical trials,” said
Dr. Mark J. Murray, Tekmira’s President and CEO. 
 “We intend to leverage our expertise in LNP delivery and our broad
understanding of therapeutic RNA payload design to optimize the use of UNA in our development pipeline, as well as provide pharmaceutical partners the opportunity to license UNAs combined with our LNP delivery technology to develop RNAi
therapeutics,” added Dr. Murray. 
 Under the license agreement, Tekmira will receive a worldwide, non-exclusive rights to MARINA
Biotech’s UNA technology for the development of RNAi therapeutic products, and MARINA will receive an upfront payment plus milestone and royalty payments on products developed by Tekmira that use UNA technology. Financial terms of the license
agreement were not disclosed. 
 Unlocked Nucleobase Analogs (UNA) are acyclic ribonucleoside analogs in which the bond between C2’ and
C3’ atoms is broken. This change in sugar structure renders this nucleoside analog very flexible. This characteristic is in contrast to the widely used locked nucleosides that lock the sugar conformation by a bridged bond between C2’ and
C4’ atoms. The flexible nature of UNA reduces the binding affinity between two strands of an RNAi drug and gives unique characteristics to its genes silencing abilities. MARINA Biotech has demonstrated that UNA has the potential to improve RNAi
therapeutics by increasing stability and reducing sense and antisense mediated off-target effects while retaining potency. 
 About RNAi and
Tekmira’s LNP 
 RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing
genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically.
Tekmira believes its LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Tekmira’s LNP platform is being utilized in multiple clinical trials by both Tekmira and its partners.
Tekmira’s LNP technology (formerly referred to as stable nucleic acid-lipid particles or SNALP) encapsulates siRNAs with high 

 
efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models. Tekmira’s LNP formulations are manufactured by a
proprietary method which is robust, scalable and highly reproducible, and LNP-based products have been reviewed by multiple FDA divisions for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the
specific application. 
 About Tekmira 
 Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners.
Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

 Forward-Looking Statements and Information 
 This news release contains “forward-looking statements” or “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking
statements”). Forward-looking statements are generally identifiable by use of the words “believes,” “may,” “plans,” “will,” “anticipates,” “intends,” “budgets,”
“could,” “estimates,” “expects,” “forecasts,” “projects,” and similar expressions, and the negative of such expressions. Forward-looking statements in this news release include statements about a
worldwide non-exclusive license to UNA technology from Marina Biotech, Inc.; the potential of UNA technology to improve siRNA; the use of UNA technology by Tekmira; the use of UNA technology to lead to future development of RNAi (ribonucleic acid
interference) therapeutic products; providing pharmaceutical partners the opportunity to license UNAs combined with Tekmira’s LNP delivery technology to develop RNAi therapeutics; delivery of upfront payment plus milestone and royalty payments
on products developed by Tekmira that use UNA technology; UNAs potential to improve siRNA therapeutics; Tekmira’s aggressive advancement of multiple products into human clinical trials; Tekmira’s strategy, future operations, clinical
trials, prospects and the plans of management; RNAi product development programs; and expectations regarding the expansion of Tekmira’s product pipeline. 
 With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: LNP’s status as a leading RNAi delivery technology;
Tekmira’s research and development capabilities and resources; UNA’s compatibility with Tekmira’s existing LNP technology platform and other technologies; the potential for UNA technology to lower the potential for off-target effects
and increase the specificity of the guide strand; and the opportunity to develop product candidates using UNA technology. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business,
economic, competitive, market and social uncertainties and contingencies. 
 Additionally, there are known and unknown risk factors which could
cause Tekmira’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include,
among others: the possibility that UNA technology does not improve siRNA; the possibility that UNA is not compatible with Tekmira’s LNP technology and does not result in additional product candidates being developed by Tekmira; the possibility
that pharmaceutical companies will not license UNAs combined with Tekmira’s LNP delivery technology to develop RNAi therapeutics; the possibility that other organizations have made advancements in RNAi delivery and payload technology that
Tekmira is not aware of; and the possibility that Tekmira may not advance any further product candidates or expand its product pipeline. 

  
 B -2

 A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira’s annual
report on Form 20-F for the year ended December 31, 2011 (Annual Report), which is available at www.sedar.com or at www.sec.gov/edgar.shtml. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and
Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments,
except as required by law. 
 Contact Information 
 Investors 
 Jodi Regts 
 Director, Investor Relations 
 Phone: 604-419-3234 

Email: jregts@tekmirapharm.com 
 Media

 David Ryan 
 Longview
Communications Inc. 
 Phone: 416-669-7906 
 Email: dryan@longviewcomms.ca 

  
 B -3

 Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement 

for Nucleic Acid Chemistry to Tekmira Pharmaceuticals 
 Bothell, WA, November 28, 2012 – Marina Biotech, Inc. (OTCQX:MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that it has entered into a
license agreement with Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), where Marina will provide Tekmira a worldwide, non-exclusive license to Marina Biotech’s Unlocked Nucleobase Analog (UNA) technology for the development of RNA
interference therapeutics. Tekmira will have full responsibility for the development and commercialization of any products arising under the Agreement. Under terms of the Agreement, Marina Biotech will receive an upfront payment plus milestone and
royalty payments on products developed by Tekmira that use UNA technology. Further terms of the Agreement were not disclosed. 
 “We are
pleased to enter into this agreement with Tekmira, a leader in the development of RNAi-based therapeutics,” stated J. Michael French, President and Chief Executive Officer of Marina Biotech. “Marina Biotech’s UNA technology is quite
novel. Besides providing drug-like properties to an RNAi drug, UNAs also eliminate passenger strand activity as well as reduce guide strand mediated microRNA-like off-target activity. The result is that UNAs are able to significantly increase target
specificity of an RNAi compound to its gene target. We look forward to a continued relationship with the great team at Tekmira.” 

About Unlocked Nucleobase Analogs 

Unlocked Nucleobase Analogs (UNA) are acyclic ribonucleoside analogs in which the bond between C2’ and C3’ atoms is broken. This change in sugar
structure renders this nucleoside analog very flexible. This characteristic is in sharp contrast to the widely used locked nucleosides that lock the sugar conformation by a bridged bond between C2’ and C4’ atoms. The flexible nature of UNA
reduces the binding affinity between two strands of an RNAi drug and gives unique characteristics to its genes silencing abilities. Marina Biotech has demonstrated that UNA has the potential to improve RNAi therapeutics by increasing stability and
reducing sense and antisense mediated off-target effects while retaining potency. 
 About Marina Biotech, Inc. 

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics
utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two
preclinical programs — in bladder cancer and myotonic dystrophy. Marina Biotech has entered into an agreement with both Mirna Therapeutics and ProNAi Therapeutics to license Marina Biotech’s SMARTICLES® technology for the delivery of microRNA mimics and DNAi, respectively. In addition, Marina Biotech announced
exclusive licensing agreements with Monsanto Company for Marina Biotech’s delivery and chemistry technologies and with Girindus America for the supply of CRN-based oligonucleotides. Marina Biotech recently entered into a non-exclusive
agreement with Novartis Institutes for Biomedical Research to license Marina Biotech’s CRN technology for development of nucleic acid-based therapeutics. Marina Biotech’s goal is to improve human health through the development of
RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com. 

  
 B -4

 Forward-Looking Statements 
 Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause
actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to
obtain additional and substantial funding in the immediate future; (ii) the ability of Marina Biotech to attract and/or maintain research, development, commercialization and manufacturing partners; (iii) the ability of Marina Biotech
and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and
(v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those
projected or suggested in any forward-looking statements are contained in Marina Biotech’s most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation
to update and supplement forward-looking statements because of subsequent events. 
 Contact: 

Michael French 
 Chief Executive Officer

 (425) 892-4322 

admin@marinabio.com 

  
 B -5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]